var title_f14_48_15104="Palpation trochanteric bursa";
var content_f14_48_15104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the trochanteric bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The trochanteric bursae are palpated to assess for tenderness. The trochanter can be palpated either in the sitting or the lateral decubitus position. In either case, the hip must be flexed to 90&ordm; to be able to adequately identify the superior aspect of the trochanteric process. The trochanteric process is the most prominent portion of the femur. Firm pressure must be applied to determine local tenderness in the obese patient. Bursitis is the most common cause of local tenderness; other causes include occult fracture, stress fracture, and metastatic disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15104=[""].join("\n");
var outline_f14_48_15104=null;
var title_f14_48_15105="Med bronchogen cyst CT II";
var content_f14_48_15105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan with soft tissue and lung window settings shows a gas containing cyst, surrounded by ground-glass opacity and consolidation in the right lower lobe, which represents a pneumonia that caused infection of the adjacent bronchogenic cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15105=[""].join("\n");
var outline_f14_48_15105=null;
var title_f14_48_15106="Gallbladder anatomy";
var content_f14_48_15106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Gallbladder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15106=[""].join("\n");
var outline_f14_48_15106=null;
var title_f14_48_15107="Patient information: Chronic bronchitis (The Basics)";
var content_f14_48_15107=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17195\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43186\">",
"         Patient information: Breathing tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/59/5043\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/47/9970\">",
"         Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/34/41506\">",
"         Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/11/24755\">",
"         Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/52/14148\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/13/1236\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/12/39105\">",
"         Patient information: Influenza prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14225\">",
"         Patient information: Pneumonia prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/22/33122\">",
"         Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic bronchitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-bronchitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2058721\">",
"      <span class=\"h1\">",
"       What is chronic bronchitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic bronchitis is an irritation in the airways that lead to the lungs, often due to smoking (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ) . It causes a cough that brings up mucus (phlegm) every day for 3 months or longer.",
"     </p>",
"     <p>",
"      Chronic bronchitis is 1 of the 2 main types of a serious lung disease called &ldquo;COPD.&rdquo; The other main form of COPD is called &ldquo;emphysema.&rdquo; COPD can make it hard to breathe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058736\">",
"      <span class=\"h1\">",
"       Why did I get chronic bronchitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of chronic bronchitis is smoking, which can damage the lungs forever. People can also get chronic bronchitis from breathing in toxic fumes or gases.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058751\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic bronchitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having a cough on most days for at least 3 months, for 2 years in a row",
"       </li>",
"       <li>",
"        Coughing or spitting up clear or white mucus",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Feeling short of breath",
"       </li>",
"       <li>",
"        Chest discomfort or tightness",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058766\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor might do several tests, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A chest X-ray &ndash; This can show other conditions that might be causing your cough, such as pneumonia.",
"       </li>",
"       <li>",
"        Spirometry &ndash; During this test, you take a deep breath and then blow out as fast and hard as you can into a tube. A machine connected to the tube measures how much air you can blow out of your lungs and how fast you can blow.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the results of your spirometry are NOT normal, your doctor or nurse will give you medicine in an inhaler. Then he or she will test you again. This will help the doctor or nurse find out if your problem is caused by chronic bronchitis or another lung problem, such as asthma. People with asthma usually get normal results after they use an inhaler. People with chronic bronchitis do not.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058781\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes.&nbsp;If you smoke, stop. This is the most important thing you can do for your chronic bronchitis. It does not matter how long you have smoked or how much you smoke. Quitting will slow your disease and help you feel better.",
"     </p>",
"     <p>",
"      You should also get the flu shot every fall and the pneumonia vaccine at least once.&nbsp;Infections like the flu and pneumonia can hurt your lungs. It's important to try to prevent them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058796\">",
"      <span class=\"h1\">",
"       How is chronic bronchitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 3 main types of treatment for chronic bronchitis:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines&nbsp;&ndash; There are a lot of prescription medicines to treat chronic bronchitis. Most people use inhalers that help open up their airways or that reduce swelling in the airways. Often people need more than one inhaler at a time. Sometimes, people need a medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        that comes in pills when their symptoms get worse than normal.",
"       </li>",
"       <li>",
"        Oxygen&nbsp;&ndash; If the disease gets worse, some people need to use oxygen for breathing.",
"       </li>",
"       <li>",
"        Pulmonary rehab&nbsp;&ndash; In pulmonary rehab, people learn things they can do to improve their symptoms. They learn exercises and ways to breathe that can help ease symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2058811\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=see_link\">",
"       Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       Patient information: Breathing tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=see_link\">",
"       Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"       Patient information: Influenza prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"       Patient information: Pneumonia prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"       Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/48/15107?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17195 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15107=[""].join("\n");
var outline_f14_48_15107=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058721\">",
"      What is chronic bronchitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058736\">",
"      Why did I get chronic bronchitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058751\">",
"      What are the symptoms of chronic bronchitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058766\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058781\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058796\">",
"      How is chronic bronchitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058811\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=related_link\">",
"      Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=related_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_48_15108="Linear IgA bullous dermatosis of childhood close view";
var content_f14_48_15108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis of childhood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0ZwWUZ5+lOWMtnAwPerKQtwemKl+zEnJJ/oa4LXPoXUSIY42UfIQfrVmGHYMknB71Yt4lAyVqyqKBtYc+lVFWOadS+gyMgJgfpTTk8k+1TEZ2nGOxoZVCDaOncUzG+pEis3fgUix5bdjjpzSgOu4ngY4pVcqADy2OgoHcHUkDDd6QrgHZxT1PfI+lPJHfA+lAXGRZ2YPWk2leM9eMUwysGwevbHpT1JLbm5HTNGgCICxw/U9zUgxuxxx6U8ntgjA60secnjrTExu0qoPaqtwu4ZB6nnmrwXOcmq00XG452g9KTKg9TFmAiRgmGJ4oiMgBY8ZNWpLb5ggJ2k5p4UJG6MpIXrk8YqLHbzq1iuFaQEkjP1qyqlVwWUsaieYHaqRqAOpB5NOjiuJlLIhPrzT9CfUcIwWzwWB6U8qGGGXHPUUwJJbqhk/nSJKGckgFT6mi4t9geMBgMttP41GZEhB2lmJ7ZqfeCNijBH61XYKz/vABj0FJsa8xyOrg8bSBnmoirNklPmHTmn+VtlzHlgfUcUkjLCDgkE9M+tOxS8hMGNDtAzTBJIMfLwRnpT4yQ6kyKX9Ksqu5lw/GOhpBtuQQw+btzESAcnnFWSiB9o2+1SGNmA2gqoHaiKNI8A/Mc5zTMnMqmIjgoD3xT1QhSBj6GrgZWbGzoO5qFypJKfezQCnfQrBXBbPy5oFuVjZmI9+KsNIAvz/eqNZWCjPzZ/Si5SZWEZYqDyOv0p7W7B8gEY7jjNSea28og+c/jTozIZSXY7h2IoHdkaF42HJA9TU6zO3IBK+g6UHD5+Rj+NMKYx5m8Efwg07ktJ9CVpsj096kR1wcrUQCgZjjJI6bjxUYJB3ndknpnincj2aZbXPpx7U2NR1yAOnPeoFk3MRk885U/d+tRKJGmJYgr7dKfMHIzQMcQDFnUCm+VEVyDuPXrTEeMp8wGaljCLnpkjmnchpoja3jIGQcUgtEJO3j39anBWQ4A46c05g6rggYPHFInmZAIR25Pt2pkiMQeuKtKVX+LHtSE+/FFwUigsUmRtOOe9PaHcQMdasFkZjjJ7VIHP8AzzUkd8000NzZUNscjgfn1phiKk/KPwq8cdyc+gFRmBX+bkE9KLgpdzPkQnkAjtSXUTwsoYqcjPFXRGAdm0gGmvABkFcHPWjmLUlcypH8t8KSPoafDdSxy/u5pE9Tuqe5ti43ZwfbvVU27hiCCfcUvaNGvLTmrMu/2reA7UuCB6nnNWk1u8jx+9jbHXisYq0YKyKf6012KEEZwav2pLw0H0Omj8SOPvwqR14NS23iOCRwLlGQnoe1cshU5ycMelI6MehxT9qzJ4KDO8TU7RmCiZOenrVlZVL/ACkMvXOa89jVl/1q9sAg09GmQALI4OegNWq3c55YHsz0hWG4E8ccUVwNvrF9Ap2uzgADa/NFP2sTF4Od9C1gDAIGRzilUblyxxzRtVQccn1pfLAUd81znVcXkfdPy+lPDEntz1piAZPGO1LweB+lAmPJ5ySOegoxknB49aUjKjB4A60mM4yWxQIV4y21WI45+tIACTgdKfkY5PSmRhdxDDIFIY4Y57Cl2YPY4FByoJ60yPHmEEYpiF8tWK5ABHNSfKoIGKYSFJKjI9+tAZDkk9Op9aBgCH5PBp8bjJIOQByajG5jk9COgFP3IqkbT15oCw53AXPP1xSsB2+bioxhhzxxnGe1LG3mhSMbe1AWI9jM2cAsP4fSqksWZW+UAd+9aW0DPzED1A5NRfZ9zcqSCealq5pCdjKRNsn3eOuasPdtvACsExzg43Gp5oF+6QCT0GOKjYFZEGOAOR2pLQ2509yCSXfhQoZj7nikSFUPzjnPFX4YSWU5G0HscVKsOc5Ixnr1JotcTqJaIzt0SEsE3t7jpTo1cuW2KqngDGeKvyQxR7QSCx5ptz5hZQvp0HNFhc/YhMRVTuIz1GBVWa2juFYkMr8YPY1fSCUkH5guKi+YSsSMAdR61QRnbZlJbIo2Tgc4ABz+NPWMKu49M8YHWlu5ZWC79x/3R0FIjP8Au9oyfTrip0NdWrsmjCjozn2fpUiOxJLBdh4wOTTW3BV3MmOvAqJFfd8j7gf0obsRa5NI/ljbjLH2qLzGJYqQSe4HSp1hE2C4KjuSeKUMsakKAc84xj9aF5k6FH70nKsVPJapAzRjMe0jPRh2qZTI3C8e1OPyj5gS350inIgVm38xg5H3yOlSkyIVIYEnoD3qBrjCkFCSOlM+2gHbuCuex9KZXLJ7FiYyMSOxG75BimeT8vcOPWoUu+TyD6Y7VOlx53ABJHHWnbuLlkhDERjIzu6EGneWmGJ2sQAOe1SId6bV/h7Gmy2zuAUIAPqcUl5Cv3K4JJGwDbznFPIUpwcEdBnFSeXJCflzyvNV5IiOWB2479qLstWYqeTIcMSCOfarsSqwAzgds1Rx5pKg7FUZUsOp9KSG6ZJMSHjuBVJkyptrQ1fkQ+h9RUfnK5OAMj1qrHMrMMdferibSMAD3NG+xi4WF80bcHZ7nHSkDBTnGVx3GaZlS3YH0pju6hlHze3ajUSjfYexhIJ24OM4FODRlPlPNVfNQIy7NofGGyRj3FRhdropIbnPXnFK5XIXeT0zn0pyMV4I+maWMAKTyBimtsAG4tQZtCsASRJw1Rs6hwCRn3p7IjsMFzmjyVJGQcnjBouLQYYwDkEEZ7UkiBiVC8npUpRQ21eAByDTVARuSQD0NAJtFKa0LHLFl9CeaVbLs54PT3q82cctxTRGyFcDhqVkX7WS0KDWYB6BWz1pzWjEZJUqOKvmM8HqfQ0jrwdoP0FO1g9rJlIQIAUkz9fSkkjjRMnkAYB6GrHJQgqDjvTAuB8wznseadw5mVkhBwCCRjIP+NFXSgUBgBg80UC5h6oV2nqMdKcE5BxjjP0oAYHjgA45pr7nGAxGetMz1BgSoAWhF+UDuaUZ8wAHrQ5VVP8Ae+nWkMNny7QuF74pchic87fwpnlh9rMMup3L7H2pQUO1s4z1x/Wi47CkHPyjPbnvSux52rn1qZCoHI+YdhUDA+ZjacHvmhiEGerMCD2FNwwz1xnjFSomEOOnUmmsVZT0GKWox6bixDEbu1MRBvJJz7dqcoDc5IA46UuSpPI29ADTAATyQDk4/CkKtvYknnnOKPMK4BAOeRk04yE8EAZ6UAMl+biJie54xUyLhVVUBI6ZqNGYswwNucdKlDsGPzYGOlFxO7FddvO3JoUbsnBHbrimLnAZsYx3NKzoiZxliccUABQbjzwO1MP3vlDBeBnOKSWVUYKzHceMVXnuAFIQYYnoT0pNotRbLZH8KYIBzg0BwzhdwU+wxVFLnIHzAPjkt1qWN1b52cE9eGzj8KVyvZstBOm4BjStKGB9R2pgcsmBkA8n3ogCoWwinnuT6VW2hFu4yWWRXb94OB07CqRleRWBJIOcAHFXZ1Do67APpVCePaoYKS/95uMUm2bUrEMiO2N7lduMAtU8L4jG1Rt6cHkGq8BaRgJPmzyCO1aCWJ8h3HReeKlXZpOSWjIpYo2ZWUsQe6/1qeKMJycqMcDFRqAqYUZPTg5qRIB1m6+pbmqsZtku5fLCg59BimoYxuJ3Pjt2qQLGBkN8w6KCMCnBU5yoJxk5bqKbRCdiBlmZsrhFPB5HFV5AUL7QSCOc96mn8tgAjFX9MZFV7iGR5eHYORkcdPpQjWLMXUNSuIbwWlrGplcZMjnCr/8AW964nWNRul1CQXLySSg/wDGDXf6nALhhErCBmQRtI3JOPf61z95p01jO8UbgNOCxZsEOwP3s9a4sVQqT66HqYSpTjutTJt9W1OKVY5I2wDhgT19q9B0txqGmR3CJ5DMSu1u+K57SbBRYGG6iV0WTzEYjDM/94+1dVp6ytEY2JSJV3KMYANa4WnOC956GOOnGXwq1h1taMzKUZcjgjkVZa3dUw3Xr0qOKPOAZSMdRVxHkC5JBUcfNzXTypHmyk76FBWkXhjuHoe1NMe53beNxGOavAqoAkVcseMDoKgmBDt5Y4J+uam1hqRTUJGzoz7APXkGqr2gLh4mDZPStG5j6Mq5xSHMeEXHT8fwp9TWM7aoprbykEod314wKsQggMOcADB5waeswjYdPQ571OJAwzkAkcg9gOlFk9iJyZEUkCqQQWPATvTc5ba7ZAPOMipSjby5IBPfPJoKjCkgnt8tOxNwMhSBNmOvHGQKbHbKzeYo6cHAzVlI0yFAODzinxbUGYzsIOPagzcrbAvmHI3cYwMjjFRLGplbJ6cDPSptrCTPQfoaJVGwhc4Pvk0mkTciMW0fK4JPYUqSbQd2c04JkDBA+nWlKqeH9MZzzQkIjZBKygLk0KpVNrKCPepFjG5WVjgdqeUBYnJ5GRRYV7EAGSR0x1zS7NuRuz9KSXKdOo79aVgcKc8n9aQEZbacsW54+tIGHVTj60+TewwQOOhpFQFjxzQMj5YFsjb3GKMAHg/h61IUXcQMgighdwDZxTAi2lx8oPvRT9oTOCcepopDuNJG0ZJAH3RTpHG3HHIx1qIgnqQCaULxljk1Qh8SjbuPyio5yGZsEhQOo9ae8g8s7Qdo7eppUjGwZBLUgEjfMfzggj1qIEbSduSDg+1TTDumBion4h3HIycmhlLUUhnlGM7Rz9acedwVtx6mmxZAwc5x0pVRi/TnqT2FJhaw/cPL3MB6U5iAhBXuDxRt3uAm3BGBzSSkDORgdAcd6Yh7Kz/NGScE8npUAic5zyByD61ZYFUG11IHHXGaUEKPUAcjOadhJlcRn7q4x2JojRmfll2+xqYyIc/KAT3qK4m2bQq7g3XA4pFK7J4Xwg+6M5bimlu4TOTxgUQMNu7BKZxjFTsAxOOR27U9yXuM3E4U7ff2pBjBZh3zgDk0oQ7sll9wBT9pDfMw2rzQBlTfPL9wbRy2aryo0j7VA2j17mtVo9yM2N2TnFUhFtB5UseuOwqHE6YTViVbdlUnCggY+XFNjDliqxhSfQU+OFXkUqDwMn/Gr6rjhjgHpVJESnYbFG7Iee3fmpVgALENyTg4HSpdyxxkkg5NNYCM8FuuauyRhzNkYiUJhcZJ6nrVC5hzksy5PtWk4DKDkjI6VAFThioPPNJq5UJWMpoAqB4Ac9SWPOPpU8LzIqvtUrzlRwfxqyxK7lAJqlcBw52nA4/Go0RunzbksbM2QBgMehIxTyuWz0UDAXOM1SVsyc847r2NXFKEACRScdCMn8BQOSsxmTjbMNvfAqZIwcbVzjoT2qLy9oBQbs9A3GKUbSoBnAcfwqc/rQkS/IkRCisHZeTlsj+tIuSxKnr0p8JZlBk+Zc49TTJmKfNyy9AtMlMrgbblXKAyY6sf1FJcgXXAGx84bI4P0qwqo6limCelO8pQwyG3djnNVfSxanZ3KUVvFEwMoaTA+YY4q27STL+8bK/wr6CnbWJGwqxHXByae28Y3YJxkYFDbFKV9WRqwiUxmIc9z1o85V6nK9fpRHG+4Ecr1+lK0JM4wpKY6dqjVi0F3pIxOWHoDSqArrk45PU1KYo1XKknjHA6GqtycBEJ6nnI7U2JWYkk0WckHJ4Ht702OIS4PIbPHtT0gDEg7MdcZ5Ap5JRcqVVeynqKSvfUu6WxCUlVgrhGI6nGajMDkq+7Azj2NTAMq5J/EHGaQycHeMdSKaHqLuWJnR5M7edvepLWfcN+RzyufSqKOhLIzcEZyTypp1mdoVgdykYPI60uYUoaGmFJxjg5z1pyZ2nI5JqvHIxkAIOR/D149avBtygFeD0B71SOeV0MACjBwRUb4Iyh5FPeJEdmy3z4BGehHoO1OTgEEKcdT3oYiFR8+dwx6etLt2t6/ypzKC3yqTu/SlUb4zn+8cDoaAuNxtBIY4PrzTQ7eZgLjjPPepwNyA/geahVGJJUNgcZNBOnUV92GDDpTVPy8jIH6U8RtnDcY/I0LEcHB59D1oKIiG2tg5yKjVmZRxu47VZZMEAfKO4J6U0EKDng9PSkCK7gpMhweRjHqamJ3cqvPpRNjK7WzjninISQcdR6U0F2QP8xxt+uaKmlZCfmGWoqeW47mepAVeTxU3y+uCax45SxU5+929BV+NwSVHRec+lFzWULEzEbkRfXJNWNxUHk5P6VEuAw5zkAn2qSQjIOM8ZFUZMQdz8ucYprDeqrtHy9felDhUJHbqR/KlVsJg4+bk5pAQoGdQcAnPPNSkKnQZYjnmlhCx267yuMk8d6a7boHPKA8Ciw0RqfLdW7YxxyM1M+Ay8cAZJ9Kau1CFzhsZBP86QKftLN/CB07GgbHfNvBYDaeRxTvv888HtxS+YoRgMD04okHyjA5PNNIB3ATJCjbzk+lQRsr8uep4B9KimJkdUIxnk546VJC20hSvT1PagtRsizzj5VHtz2pIZGl254+tVzIGBAbap7DrUkC7QQWB5yaCLdy2vXPQH3pJyTHt5w3pQqCNDkncTjgfpTiAFB9uMmm9iLjD8iYYHJHynsBUPlqrgovPqD1qUE7ywAOeBSkfMoyo9fekx3sJCoIYhiOxOOtWOcHt7YpsaKqnHQnPTvTyCu3kFj3x2polyIyOVz6dDSkkIc9e/0pZVUHP3uPSmspJDFePTFADyC2eMj6ikkUbcKMA4ApFGMg5PbAocbgOTnsKYEE653DgnjmqU7HlPmYgcYHFWbuXajYyoxnJ5qijbW++qnGTnNZy3sdEFpchSMxEB2BP3sEd6slY2IXBEp6ccZqCA5mZ1TzBntzmtK0mRJAtxDlMkqHGD+FEUaTZWgcyblKlGzyQOv40912gmPjHTbj9auyQRmQPAQGfJMZOMVGF4zj24HX3p2MufsQLK4ALKWUDkgYp0U6MMEBmIxt6YFSOu7rGSrEKM9qijQRsVlUMCeGPBAo1QXTJDKVj+XH581XM8pZm3DA+X3qQIcAxyMuDyc54pkY2yMQpJPQ56mi41YY3nsV2odp4J6Gpore48vesiAZ5BbmplYuCzZ83jOOlRTclRww9Oho2Dm6IcXKnc4PuMj+lNMkby/JkDkEYzSxw/KAwIVuQvQ1JiPziA20/wB3b0osRotRpiYLlOFHY09lik2s7OMKRkLn8KCR5gK4JP8AECRmmzKSwWMPjvj09KOgXIHjIAIk285BIxSS4wFc/MRlXH9asFTKnz9D6dqYWEQZgB024PJ/KlYakyMF4yMsGU9SRkCggSQkKuTnPsatRMskIZEVB3Ab+lVDKdxJP4YxT2KTbIZIo4z++VVHQuf5UyJokxGgWQDhW5HFTSRrK0cco3K3cnoajez8psRzCRf+eYPzLS9DS6ejLVozbFU7lz3HeroGADwc9fUVQt/kIyC2OnPSr0DbiGALLnCnoD701qc1TRj2XKk5+YHpTIx8oOchuQR1qd0VTggsT3H+FMbaFyufc4xiqMkxhbsyDHXINIq4XnqDmnuQAM9M/gaZkOMjIx0GaGNDtpZvl6Eckd/alABxg9sU6PcsezGR6ntUb568An0oEMKFVyDg+mc4oBLDjax6mmLuOUUgMD1PY0jnOMDDdzSNLD+NwGGYtkhh0GPeopmA+8cjGfelCksc9e4pJIyrcjAI4wOtLUcVqZ7TOkmQcAnoPSmNebH+UEt9etR3YcMcdO2eOareQ4G5mB57HkGoszsjCLWpaS+IK9uep9aKgCGRwsYPHQEd/SijXoP2cSkrbgWwQBgdev41PHOTJjPP17U0zhoY4lhUMRnr+oqFfkAZwQo6ccmn0uirJm3DJlo1YkgHJPvU25Tk5LHqo9Kz4gBsQFs53fjV2IgRBiDuZvX0qkcc42Jk2n3B6/40jkFS7H12jp0pCP3bPzlu3fFIFB2qBkAHmmRYWMBoozjHPANIzlpAufuqcYoToxbhhnHPakXnAz0HJ/pQMeykghgMjqSMnpTsAALgkgdKIE3SMecFh/KlclJt4J9NtArgImJVQp/3qVn2kE8kjuOlPEm5C2RgnHXmk2piQn8Md6YrkMiqx3nqABiluIWUbAf3mO/pUwKjBwMjA9vrTXx94kkjn3p7lKVmV4IQvJYAAglh1+lTqCwZ+Fwe/fFOYIqZXiR+fansP3Y3HJxnApNIJSuSqvyDGcY3MajY7zkKd2cUxpTtjQAqDyeadE25yxbBzjpxSJSZYjjMajI46nPNKQCF4TjvjrUCKwjIz0PfrT8tsAIbjk0+grEobCtgAAc9KYSFIO7AxnjnmmMuQ3zHHtTAhAA5IJyc9qVwSLEZckcZ5/KnP8jKxHJ460xGQA9QOoJ4oOH2kgA4yOaYC5XkgketErCOME8duOlNfbuLcbRwOazbqbcRGhP5cUXsVGPMQ3dwZDlQpVeAo61U3Ey4XIDfKR61buYXaPbFGeDww4ot7V8bnXB3YzuHPrU2OyLjGJLahIIt6EpsPcd6WRmlOHZjuPBI6AVbePy0AjdCv8Snqfaq3lGQRmLPDHOP5U9tDBST1JIVG0KPlboxP881OcZKrIHXruP8qVhIgBAxlemev+TToZHEaZPznocdRQiJO+qGXCFWjIXavQkn2ppRePmDA46mpJEU5Eb8nqaRYRIGUkM4wSQ3607CvoSiFY03YAYHr2PtUEiqAW2kux7d6lLFI8SM5CttYLzikQ5iYr8+SRjGNtGglclikV4cCNc8DB6/WofLInVyucc8GnOQqq3KkjnYM5p0cn99tnPGORRuJaDJZhK5MiHCAjDHmohIp/eCMBSMDJz+NSzPJJmMGNwCAOOv40LCD800RKZydpztNDVytEhkhQAfuwAO4fn8qXsBOSjnkjbzTZ9jxqjBgWP3gOCKllhYKm8MVJG1t2T+FKxN0QyqBt27lycD0/GkeUshV0jYtxkfeWrUyFYgjjKnksOTioZbdSEd2HOMHHJ5osUmupGIgF4wGHORx+FISCyb1zg8MDwB6VLKzAf6tGyegFV4o2O/y03jHY9PwpbOyKWpHc+XHlsFGHGc5H4U7ytpMgwEIAJPUc9jT7ezbCMpzJ1wx4Pt7U5EDqYcnbnOTzjn/IpobkSIm5CQwLjpv4bHse9Wbb5VBJwc4HoRTvJwFUoQqjJB7fSp4igbaWUA8q3+NUkc8pkUqsrjcMN1IzyB60nyBweh7qeM/j3p7YGBn5icf/XBpzsy5Dfe6Zp2IRAAm5socZwFp3k5yAFBzkZOCfakDHHzZAPfrjFSGUFiT07kDI+uKNGGowPtPzYYZxz1FVZO+PuntnpU77ByGI5xiiWPeiOVGMfeHQfWk0WtCu+No7k/dPcfWkixuG8nI9MDNK6OYcksGVhnHSpDFmPdsO8H5jmi2pVxy5IZsbsNjd6VVu3dUynz54xjirDqVjBYFARyR0qCWTbEQD8hOCex96ZUNzElaWZyoQbj2PNFqDIwJcuq8FWHzLU0satdYiJz1XB5oKyxq+UIOOXHB/H1FRY7rq1hXXynJCsUB+YHkr9PWinQ3E1t8ow4JGQwyCPY0UGbujFDkAyMAQgCrkYGaRXY7lflidx7/gKj2s9psA3HuAORU1inljDEMclckfyqEmbu1jQtiSULKB82Dir4iY/wgnpgelUSwV1CDHT61oFDGq7G5z1FWlocdTcSRhEGHIULxx3pXcBGwRgDBPb6U1wMSBvu4/yKbxsKsp8vHI6k0GTEmBYg84wD+FKspHY5Iy2PSpJgZnOD8uOPWo1Ty5TkhiT6cUhp6FmHKqAAc9h609/kQKfmOcADuarSuTMwTPJ3E+ufSnk7txYH0zjpTIcepIxCMwIXK9jSsoKKVI4GQPemBNmAq5LA4Hp9am2f3WVi2B9T3poBu9ooM9SDyPb1pnzFDk5YqCOe1SM5kcogBwNmAKh24UHHXjHrRYaGhhtJIPT5R7U9i+SRgHgnHfiopWXLAH5lx24qUuzO2VOAoJ9CPWixdrjrdNqAsxJwTyc1GI2V1AJDMecnvTreTzFG0BuuBjpzR5sQkSOVsO5wPwoErlhwyzMQF44H9aInyyqMcg53HgVC8yEj58ANnJGBikEqlwSg2k5I65FK4uUsrkAngE9AKewXHLehOD2qOIrnDqdx+bjqoqMg5ZgODxjHNUTbUm3qGb5Pl6gZ6+1OD7UAAIPrjoKYoBclQSOw9acVYMdhzxzjt7UWAinLLtCk/MCM+tURIhG3JXac57k1ZmJJ+bCj35xWe8e6Qhgf3Y4K8df8alm8F3GfadoYtucqNvPQVd0yCNfmZWYMOVHNUpiYpE3NGOcLnnFaVncmJnjito5YwQm5j1b0BojuXU20C6QFO4C846mo7MST4EUwh5GQOgxTL7fECNmw7dzANnBHUU+K3lRIpo5VEUgHzgZA+tPdkbR1JZzKzZLZckqMHpVl4mjRVIzuHBzk5/pVNCJ5Tv42nOB3Ht7VosokSIszIwz8vrjj600kZydrIjTLORhQ445psiPFuChTIx2t/PikeVGjP7ogZwcdjTBKMlw+CBjLLjmi5NmWGPly5OCAQRhcZPvTGjUzHcCVZSw2dTRIHWNcSocAZbqfrVuNVd08kI0qnPynhhjmny3JcralKBl2ood8jlSelKokLsGTcQfnxwR7/SrVxZpbwgyYkbf5jL6A9qref5U7SKmISu09+DS5bDUubYRLmNZipjKqwxg1aUBWPys8Yx8o6jjr71Yhti9opJRo+oVhk4PbNEtrGpE1uHCICuxe/vVKLRm5puxXkRW3SIWdAvyID+fFVA0aygsJNuep4OKkyRJs2ukhGRj1q1FE5ZnkVXKEoc56UnG5V7LUr4jWN1icPn5uR0/+tUW1BGpDt13FG7f7tWRCFb5E2J0dmJ5/KoZIuTHG4TByoPRh3FDQ0yJpT/AF5O4KD1PemFN2XAY7uARnIxUqJFksseGHO3OQT3INXg0S42xZjb7wJziklcHOxTtyItoYEqRuBIyfpV6M+YVyi7x/CRzj61GxOxdkw2KcKrD5hSSLtVBKVUg4JA5UfSnsQ3fUmUFZD27EH09aQKA7bB0G4DPSlEqPbxqx2MnfGcimXBMcw2ALgA46ZFVe5As65KlSMMAQR0Ipgyx2BhlO/cD/AApDEGDGAkoCSQfSkuYkkTaWxuG5cdAf8Kmw7isrxuFbG0ckE9c9KEVYzvAbyR8p2n5gaey7Y3WZt4HAdTio0LqVaNslfkZcdc96LANlVMhwF579qe6hhuiDDfzjt71XQkMyquM8MD2+lTxJGu+OQnyyCYpAO/pQtxtkiICoIDlejAjGBUckpQHyyu09/WrCo8cQbBaNxn5TnPtULuF3bEIjbovvV2CLuRO65DfMgYYb+79TUMaJIHjJGWJKuTxxV9FB8p8hreTOQw/i96osBHCxh3HDHdH/AHh2wexpNFwlczL6FoI1eNdrg7jkY/H8ajSYSxqJCcscgAfMM9vcVqyzGS2LSgSRsRhlHI+vvVPUbCSMwXNudsIOVGc7T7fWpceqOmFRNWkMG9FMUqAxsAEZV/KitCK4i+zyGSFvLcbZQDjB9aKfKTzvscZbFhG7KW3A/LjvVqHfJHtVAvzZHt9KoQTyAqFGI3Uj6k1cswQUI4I+bBPK1imdkla7LVqoLKFBCDIYnvitCNiVAGAVYsT68dKoxynzmRQu3JC++asybQzKW+Xgdf1quhyz1YAEbkB3YIIq2pP2jnAzkE47VQWdCfm3E5ABHTHvVpH2rNtbP8K5/WhGck0OMqgZJ5xz7VBLiOUbcMeuKidt7hkPoCxHH4etWFYOGRN2xmAL92PtQLVCxy7pggXgH5iP6VMmGfIXPt61AHUvkj51Gz0wc4p/zCUcAHOF560IGSqzFDktnqT3NKm3a7fxDAUA9PeoW8sBCuePT9aVtqrjo2MnPf2p7CaHyEJlkfAUjv1NQxu0kiFy5J6D0p4YviQoqxAj5T/EBUu0KmUB6g8UFLQclthWHyrlu/UVCxw33t8YPTGPxp5kzgo24Hp6Uit5ikuCqg4GBxntTbBX6kcQkSJAoA2AkkDFMllEMjSMU3KMcYz+FF4Y41ZQQHD4+vvWbc3KiaXfH8pwvPUGpbN4Q5tSeW4Ztm8bRn5Q3c1cs5xJGTJKPkOdmKzUxLGiggFDkcdyOc0kNy6yBYowQO2PvVKdmW4JqxqeeW5zuwc9eMVM92fOGwr028+lZSXITnGCT0xx9KtPNGFXzfn5DbTxzimmZun5F+G4MuAnKnjNK85LBcbDj5uaz5ryMRqYyrZO7aBgqaXY/mMSw3lcpg/pVX6EezW5I7BZlDSE5wSPQGqgZVQ4ZmXft27sAip7fBkzu5K/PkcUkEMcknly5dYxuTavc/zpGitHcpMiSyFAAEwdmetS28jxQiNScqNxxwPx96SS2McrMrFmJO7B459KgmkkktgUIk8n7+erewx/Opfu6mtlLRFu3uow0i3DbgRycHd9as283m7IoWbAb5NtZWlXCuWeZSBu2AtyeP610BjIEbwRKsYO7zcDOe1VB8yujKouV2ZTvEaIKXLIc9MYwfX2q1Z3IbG+QhmHyleSSO/0p9usskkkF3GX808rj9c9qxrmO4024O0jy2P3h2FN+7qRGKn7r3NXzCZY2jdWkU4IIyDTpJITFuDSLJuzz091rLimmli3xOpYDj5cEVHZSQ/agb/zgMHopOWpJj9j1NtZ3luwsTDnqoH3R0rZtk8yZHgm2jG1sgAjHY1y/nqlzK1xbO0RUHcpwwHY1ft4zhXt5XIOGAY4Ye/vxVpmFSn20NG5I86eJnLFVyTng0rw/uGeKPLbQMNwuc1UmMkAdpAZo1GdyjGM1OLiBbdFjJViAfY/X3p3MrNWsQQTbCYCWY5wFLY2N/WrjyiHakMhZSdrh26epqG7dMAyIreYDiXoM1c08RLZRGURM/ILMOtOLtoEtr2GXJeQCSGMsVOMIcEf/Wqrb6ntnfziY2kAzx39SKdef6I4lgb91IwDKDjaT7VnNMEmVGHzHIbcMlf89qbZUYqSLv26MocS/MzHccfdxVIM6uksnmCJW5z157g0B2gmTChxyQw5I+o71Zm1PzZVgnxGgHVRx04BB6VLfcvl5dkSAqrb2Vo5d+cjALL/ACp0kysXKsevPGCT61XijeWBUbJXO7kH6YzVhoGRjtXaFbaVHO0+1CM5JE7C0uIQS5EoxtJHP/6qd5n2hAWUK0YwcD5j+HpUZZktiSAVzgnHKn/CmWo482TdsJ2lvTPSnuZW6gHEbr52TG3I2jpnqD7VPM4KgSE5j+XB7g9AKa8Uf2jYw3ZPy46c+tVmX948Uu4uhwHPp6UbD0JikluVdBt45XsRUc5Lzb0yI8blYcYPpT2lufOjUlNy8LkZ3D3pxUNCywo6uBlkyMKPT3FFw2JvLeVMEAMw+YN0K1ThAjd/MJUcAsD098elWI4pYsG0yQV3hT6egPeop54ZZIg6DH3XjxhhRcENliVSkp/enOW2D5Sv4VcKZbbAyPG/Kq3+eKqpbiKPzrSR0ZTwvYj0I9ahe48plETFcnKex6/lRtuO19i+SyokYZ4pUzhcZxn09qhWJgr78gE4KZ+YVZ0u6hLnznBuCeW7fnVu+CQxtLjcWIx6Ve5nzcrsZFsCHcZYjIOzGN34Vb8tJrd5EKlD1ZeMeoqu24zYzINjcjOMH1Bp5ZbQ74W3Ix+ZMggk0epo7t6EMe+3kOFBjZQQP74H9aYrxwrtiX5FJdA38LegqwqJLAYj5iFclMtwPamWdu1xEy7lFxF8p4zSHddTNeaNrrBDW4lXDKFyint9KKdqX3CiOjHJikwPzP1oqTqjDmV0zjC+5pHVPvfKBn7p/wD1VpQoiqpBH3cH1NZsRY72cDduHI9qmjkUlYdvzsex71gjrqbF6O3CqhIy+eDmp3PLHgsowBmmt8spLNjgnjsaR9rkbyRu5DHj602ct2yS2Qx7GZCOoJ6gika4DRyIf9WxHsS3tUCu7lUOfKGRweWzRLEWCjqFbAPFAeo/cZSMsAEwoH9KWSfAVIx93q3r64qtO5WMgHcFfJx39xSCRjCZE+ZQpJXPKnpU3NVBPU0IXLO0iv8AMDuwOeOlWVxtQsANxNY8TIkkWzOWXDnuT/hWmH3QxgvnIzkc8+tUmROFiQjEYOCyZ3gUMAsbknOOR3/CmowRJd2eMd+elMkkCKQDlnOMkdRTM0iZmDyAhVO8chj0qGa7Mav5R5Jx1yB2qlNOfKGNysP3ZP4/4VXeRVtmU/fZ+G7cUr2N40epq2l04R1hXlkKA9SDTYHkhKyAkktuKluo6dKzElkGZIcfOcjae/8A9etGz2TrKr/ui2ACTnB70K7HOCjqS6qm9Iwqk7AB16Z559ao6qrGaNjgpMR83vwCa0rhFeJlJO7J5LcHtVJbciNBKnHzAHuDn0pvUVOVijPAyy7sFQxI9uKktp3tHDCNSucZxwfWrgkTqgClCdytyAO9LazRXEvlyAbEPmIM4/L69ahrXQ0c21qhialEWxcWyvj7wHXmmahNFLDG8KuUU7SGPGPSrMkaxSZuVVwxwsi4Bz71XuIxbLMAm5HbK+gwe9N3tZkx5b3RLZzLNLFEWFszZVGdQVP1Nauo2UlmkTM0bZBGVPB96xvKjSFQ+1to8wK3Vl9M+1Nkm2HERcoCSuWyNp7inGVlqKUW5XiyZhM2EEmSejE8FfQ1ZncQWqRuoxu2My/xD+8KpWsm67iWQqh4K7j8pz2rYUvIGVFh5bywx5BGO3tVx1RNRtNXMmS2JjWSOTa/cFeo7GpEjkdAWCwyqeOOGB9DTblPs+Y3IZUP7thkqPY+1RvesVCsvOMhDxt+lIpXa0JLy3QuEYrGkn93gKabH50FoYEnLRqM/Mcbee3rS25IlY3crCRQWjjPI+n0xT2dWtudrRH5lToyD0z3FTyrcLvYSOdWjVpIJJGQH5lY8+mRVyUq9kIym3A/eEnnJ6daowz4Y288MazN9xnPDDt9frWg8aqA6ygzIFeSJujDOD+VUlpYiejuVDYzRRKNr+QW3AqoJHqc/wBKtxvGY0gukR0HSTBHHsatXMU8alLRi8eclVb7vsKrNMXCwyxsFXJPHIHoarYjmch8iND5jQ7to/dhG5x3yPUUxVQ7DztP3VTny/8AEVHM0USiITErncjHI/CmmUNICUTciEbo+DkHODUsEm0aElxIsMyOFKooD4OOP7wqlfGOTYUdpVYAqw4K4qfykmDXUflNGwwUY8575FRqd/mBYQwiA3Jjlh1yKHdkxSV2OkndYlB/fxHK89cHp9CDS2t63mqWZFaJc7W/jx3qoZ1SMyWgBVeWG4kOCehHaoJbvb8picIScBxnbn0Pai9i1TTNrUJzeQtgKA7D5lPQ9hmq0Ug3o28mRDiUkcg9sj6VlkyPbEIWwrcBW6k1YhWSRSWB85Rjep+Yj196fNcXs1FWLl8N0SSW3yOvJkXt9fWmC4mu4hDLHCXf5WcLhsf1qtEJ0jK+YRGevGA/vmtSzDtIvmIQTgE5wQfahasiVoqwtjG0UBGGYKcBWJGVHUfjViJjIxUqUAPzAnBP5+lDRNgrceZtYc87j14IprTNGcMAZAMb9vUVRzyfM7ltlV88N5nR1xgn3HvTUlihSUf6wtwY9uCff0pkjq3lOh8skZGw/KfX6VT/AHud/JzwORlfp/8AXo2JUblmBpZCnz7pQSASOtOfDSgSgxkj7pzjOexqnBm3uNkgbj5gGGDipZZzOWVpNy9FxwwPvmi47aly6jUHEShH4JU8bvpVaa4RrhHVTG4GG7Y/GhppMI0u4svyiQdQfpUVwfOk2kh3HJCHBYe3vQNLoW7OZ4yyRRszp93ccHHp9KdqEkdxbR3McYy3yllPKn0xVSxm8kuzgsnQ5OCAfUUT7bXzPL3+RI24d8UxcuugwmX5ZCTIF+YkcZH09atqYJ5IBjcnATJ6juDT1RG05VfIDrwy/eB96xFun0m52NEXQ/OzL1wepFJtR3LjF1NFuWryIi/aC2BQhsqjH79Ek11GdjyFdr7o9x3KR3z9KpjU0G7eN7k7oZ06kdwfSr091GQs0UkTxsm04PXPB/Gi66Gji1ZNFuHUhqdmVVFWTcBIhbHPYj2rPvZy8L24U280T7lyAQ5FZ16/2ZFBwjKwVZB/EPf3qWW9nvVaWOKOQJgSK3XA9u/1o5uhSo8uq2Niy1eP5oXTFyvqMb8DOAfWqz3zretPD8rPhZwRjArCVh9sjmCsUJyA38Ldjn1q5dSFbgeZhmIxOVH3h6Y9R60uZsp0Yp+pp3BWUTtEwGQHG5eMe/1oqpBbDfn7QxEi5HOdwA6+1FPcl8sdDluCGEZJCtuaoY4me93HcqxjLH6mpmuFijcnA7lRxv8Aao7cmKNC55PzkdqxaOrmZoTbVMbBsID1zyfwoQGTZ5pZUYkZPWmRL91jmRVAdSfepJyi4IztIBK96oy20JJ0Kgx+nJJ7Cn7lZWQD5x0x2qujnPzvntuHr6VNEqOysAVbHTGCaRHmNuof9HEbnOCSQOuPUVmnehAY8HuP4h6VrXLBo4+AT93K/wBaqKFdB6KMn3+lDRrTnZalZ3lEu6M/KBxzjArZgZmjQTKo4A3Af4VRlIVGITAwGYEdPpUyXC5LRk4DDDDpk0oqwVJcxYLhgwzyyleO5qvPPH9lAUklEG4DrmmXMvDllHyMTyazjcP5ci5+UJn6+1OTQ6dPmJzPIfmJVkbpnpn/ABqqrGcrAG+VDliRyaiWUsQj5Chcf4/jVu0sXuMvFtyAAAahe8ddlBak8J2blVQ7J0YcYHY1ZtyZGIDKhx5i/MPmaqbIwBjKFJgOCP4vaq2yRJGMY+YDdjOSMdfpVGbjzI1oJd8r7pDHkbtpGeRVnzWkWFcLu5DdiB9KoCS3niSVVVZiB8hXIPqwNSQAgOwCuJFyCCcofX6UzKSuyQqzq6MVD7sZIO3/ACagCEyASRrE4+RtvAz2NP8AOmCu0ytJG+NxHqKtw3sN1F9nJVZm+YM2DyOg+tFkwu4kCmVokDSg7TyuM5HrSy75MROyZH3HORu9vrTyysq4QZVuo4I9jUKTI0m1mUoWJKnp/n6UCTIHl2v5UkY8sg7jnPzAdR6VJo6pLNtklVQR8rN0z2//AFVcisIdweKYOF3E7RuKj/A1jXNqVQ+W21hlsYwCOxBqWmnc0UozTSNTUbXezxlGSRCMkHIz7j3qHSbiWK6EaM+egToQR6VDp1w4OLkCbcOVlfGR6Zpt7DNBILuLeSBu3D5h9OKe3vIFHTkkX0lkkunVWaYAkyoUwRnrxWfezwysqoTuTjPQ/Q1e0y5h1IYDBLpe3ILfQ1V1iCQMjzQ7Ac7JiMF6ctVdBCylysv226bTisznah+UqRuAx2qpeqtvGBBJ5kOARvHzD61cikgfSFEO6OSPBfvn39qdqLPcWocIhdcDzIiCCDxgiqa00M07SKS3Bu0je5TzFiOzCH51H+FWry7kinhuvIZWTK7jghwexx3qlE8drNCSoAB2idR972IrTvrRo7USRSK8UmcqgJ6dCalJtDnyqSuirLcyF4mhlBRmBAIP5Vom6jldcsfM5O7OWHsfWsGRJUO5kLS9sZKuvsKc93FIdrQss2BwOOfampDdJPY17kslvIpUyqvUEZBX2PUEVHElsMCQ4LAYZiVIHviqwmYyALOcEdJOWXPY+o96ldw0gTCCdeXjB4ZfY0GfK1oSWsU4m863eGdomKYzgt9R39jTpbkLNHcQb4pRkMFHH41nKP3BkVCFfJzvBJ5qzAsryrKgK8bQVPP4+1HoNxW7IRMCWJjCBj1TOR9R3Bq9HJJ5CKpyjH5Hx0Pv3pnlptaQZSXoMHhvXjtUsEKlCowC5yuT0/D+tNJoiU1YSBiWI2fMTjHp74PWtNJEWXLqI5Qu3cAR+gquyxqcYYHPfnFSjkbZCGZeNucEjrxTuYTdwhceY+18YYgEDI9wRUzZicNDtzgkgNlSPQZqjAd68jdzllJ2k8+tSPMhnAgJ+UchuPzouRJak8LASAncBwwwc06S4LzBWbcMEk4qCFh5zh98aDBJXrnHXHpRIXc7htdTwvqT6GncmxOjYCIxxGTuBHUfX2qu8gGUfIOdu4DgjNSGQOMLKSFUZVxyh9PpVZxxguArMBtbow9MigcUTzTEHb57F1bdHgdu/wBKlimLMJCvmMP4TxmqWGhKheQOMk1KshByMJu+6D0PrihDaLJuFFwJEYqudrqT0PY+tQ3KhJT5i5Q45Q5+p9qrs+47iAdvVTwfpmnHOBkttUYXvsz6+tAJEkT7JCwIfaMFT/Gv+NBlLvEiAZClQOmR3zUEgAAIkw6DquSrD09jUHJRjFIDu5JY4wR2pXZpGN2PtNRktN8CqchiFz3HpzUl3ex38tuFVY5FbBLDAU/4Vkyy8/vkfzfvjj7x7fhUk80UkbXDII3OBk55buDjtS5n1N1TS1tqI8Oy9uI5UVkYnds6L6NTXuRGY4zGhlVt3y8Z46Z71W8zbOxZo3UjjBzikmIT/j6RmbHyyJ0HoTU+hqovqaDOb8fMmCuW2nktVYXEsc+2BsQ5+6ByP/rVVluJI4IWim8xB8/HBX2zUHml3LD5ZMbw27IHtScilBrQ1zMv7+K4GCeCQM/iParMY85C09nKZFXIYNgPWFaXUk8m2Tar469QT61o3SQzztKNQRGOCc5wp9Kak2rmco62GXM88VwS+Y2bGU7DjjH4UVXuJkh2pFIjPxu29G9/rRS5vMuMbrYoAtK5aQY4xt6gfjVwqrQrwOOCOtVIiFRAT04JqUPhs5B6UzNkqMQnlI2zjgn+VDMxlUchFPY9T3qtPIFLKd2PVR0p8TBEDKD1ABB6GgLFoFjKHVcxnkrno1XVYKThQNo5Hpn0qlDNGVwR82eXA/nT55OSobDkc4HQU0ZNaiSTFpVEWSOT0+97GhJAflAAY8+pBqrnypwE54OMGnIrcFhhs855zSuactiadSyo8zs7s4AY9CPpU0aokTbTyT0AqtC2SGXny85FMd8ZKnA6D1U+lNhZt2GXUwEZiILq/wB09CKqSbVAcZaQjBHYikklYkFtx2kn8KrTEMuEJz1BzWUn1OynGySL9ksUsgWUlATyW7e9XGumgiVZEUqPlDLwG+tY1nLJt3bwGU8Bu9W4Jw0gVpcZPIYfLiiMrIJwu9S48pl+dQTIpy2OCPwomkcqZ0mVZW+VmXg46cio+BIBuLR8jcvJA96dOiG3D7180sFBXAz9feq3Rm7InUphQ6opOMMvUGpG3RR/vVDkZIAODVNCssTAlw+7nA/pUguDGygSZx0LjnilsS0XorvzIGKSMjrgbezgdPxFRm3VgJSnly8MV2/e9SPeqrIJdzKqI2M5DfrU8HnR+WkrOWT5k5yB9TVLXch6bE80yyys+cqRuUMPTqM1BEkUirKR8o4KntnoacZoZbtGwtnKpw2Put7kVBcAxwIiZEueSBwR6gjtQ2xRLkuII/Mt5JIgw2HbypqS3lN4gULHI4UhwFzkeoHrVOB42jaNl2O3BweCe340wuBcI1uBHIo2kDjB6HBp36j5ehHesscokAUL3XBx+VXtMWZ4Z5rYuY48bjGRuXPqp61U1J5fLRbhGGfmODlfr7fSobcS28i3NnIy5HODg4/DtU3szW3NHQSCNJL8QvLhGcbpOhGehp2rCWESRyXXnQq+I3J4P4etVbqbzZ98ZG5Thiw5FdBFZW1/b2y3EwgjdGLZYEjHcf8A16EuZNIqclBqUjnbS6kRsoxBJx0/n6iugntFR7dopFSN0ALKN2xvTHpWCbfY8gQq0a8Ao3XnrzW7ol6kkAsJCqMSCrynA+n1op9mTXe04lO7tZLSdlnRipHVlIzUtlqbaac+WSjggoX+9x1rW1O7urOJIpntrgDBMZ6+3PrWdeqty7QvDHC0oBwVwAR3Bq2mvhMoyU17y0LUdzZTWahpGMud3HBUfX1pJYPmkMixXSsQUkDbXI9R71SaxmiVA+FhznkDeCen4VUWPYrvKNkyucFScZ7ZFJvuhqC+yzReBGbEMoDjhRMMY+hqK5M0QkWa12PxtMZyV9CPUUxA8lt8zr5bcjcSQv0qSTKmL7UhwgI4bKnPcH1p+g7WdmOtwwlICggcswHDe/4VfidOZAQGbADAYwff61n2nmbi8DncuCA3+ea00dkjxPGrIf4dvHvtI6U0jGpfoPiZDIWuBiYcDnGeex7/AEprTnz3ZFJjQBeWGcmopr1PIeOF90bHIVh9yo87YlAKMQM7l6n6j+tNsx5e5rrMCoLZDlfmdjkN9aoy/MfmiAQjscg1HDdNMwDrgIckjkZ/wp08gijMnLI3JVMfmPShu+pPJZ2ZNNMFA2DY2OB/ntS2eCriJyZCMkMAd1Z0Ej7PPjm2sTjPUH2IqZplEeNpVz1YHOfcVI3GxM0yl5FyRwOD1H0NTBy20u23j7wI/kaprIEBZsSM3O7HNRTMJgQu456nGdvuPencFEuzzNIfmZMpgF1OCR2pk05WReMDpyByPWq8bCM8OTgY3AcEe4NLIpeSNkQhckABsjPtSCyLhIeIbkJGc4VsEj+RpUIERXc6pnBGMke+DVJW8sEEqM/eXP8AL0oOXvCXZtqfMOcEfiOtMViWSUbRGpDITkkc4/z6U91BG5DuX/Y4P1NVW3n5Q3BOSR29xUTNNEw8khMdw3JouUkWPtC7WKMWHRieNp9CO/1qjdXKwx5wsgByreh9D/jT5SzggKfNHO5fvH15HUVlXg3xs4Krng4P8xUtvodFOCe5LPf723JuXjH3s4+lV0vJwrgfNHnLD+tZybm3BlYAn5R0qVCDuR9wU+lZpts7PZxSNMXgDs21TEQPvAEZ9PanB0jlCw3BQ54WQZGDzxVFf3ap5bLJtySuMED+tOMiNvJCqgGNoGMH2qr9yHHsWXXZIWSPa3XHUN/hUazortsTBIIZW5qibrynjUMyvnqTwRUw5BMi/vBzlTSUkHLbcuWd4yCQSxRueoLL0A9qmOqI8ZxZWolA7qeRWRJO6BtrBlbrnrUUku8MFyDgZBPajnF7JMuzOJz5pWNHwAUQYC0VXlMS7Ggm8wjqNmP84oqXJFpWRM2Q4yx+hFOkkCqdo9sd6iMq5BwQp4B9KFbezEYLL1A6EVqchLFGroXbHPvUoU7skfMOSemR2qudqoEyAM53f0xTXEjS7eqdMZzkUh6k8chfcIsnJzvPIU+3rUjEtETuIYHk0K67FRcYHTAwQaiedQ+1vlOeTjvQTuwjnVrlTtI42E54I71bfK4XPAOB7f8A1qp2wU4JCtkkkevNTM4ckR9c8An9Kaeg2tSZQA8me/FRFmfdgjcOORwR/jTR88XyyAY4LdvpUYOMjAGRjnvQxrcruCwlUElhzt6Ef41SRyUMTnarc57bu1F3I0VwpUnf97jnFJNdLcyFzgFuTsXgnvkVjJnbTuWtPZpLdw0Il2nO1fvD6UrxqSdueeeeCKp6ZdPbTlkf1UnFXp7oOVZpQ5x/cxu9qd00D5lItQFWZozIYyBkqTz+FMkaWESBQJIwcZ4yOKjEgk2EY3jkOBz9Kkk3Iodmw5HKt/GPaq6GT3LIKSEOuF+XcQp6e9DhjF8zJJg/e6VXgdwnyrtAOcEelToQVZldUPXac07X3MXdEkAbyD5bHAO7bnIqa2ujCRlnC5wwHcfQ8VAFELBo2cKw+cNyAaguYnLkrggnvzRdoElLcsybHD7hsdMHkdKktJG2ZjdQ33SjDGV74qh+8V1UllVuN38JPofanESu+YyN2MbQ2OlClcbiWZ5GG1PN+VeVqGZmuF42M6jI5ALD0pZp/MgCMUSXOCW9R2psOUZN4ibGG/eD5SPrS3KWiuOgnYEo7tDMf4nHy/QjvUaB4pChVCzZwVb5SDReyJMZJDGLcE5AVdyfgaZZyFULHDID2PT6jvQnqaLa6M+7lZL4ZyO3XOK0LTUGe2NpcIvlM2446kA1lzOWncKdoByA3YexPap7RfPyS+4uflBHI+hrOLaldGs4prU6uSXS5ViMZZVPEikYOD3H0rJvY2guXiYieHtswQw7GsqRfJJEjZYjKj0pqXPlHC/KcdO3PWtJVLmMaNtnctzXcgBHmBl5AL8kCoIp3LoNzKDwCzcVXYm4fdFscrgkVbEscSCOa3YEE9eGA9RWabfU25VFWsXLrUb6NI0um8yNh8jdR+BplvP5h/cSJbNjdscHBNQNNEUIiJ2H+CRf1zQt5CgePymC9duAcH271afmTy6aLUnuZGe4AkaJJCMqYzhT/wDXp0F1JBIhufmCn7voP61Qe6hT5X3NnAGRkj6VNDPCFTzB5i5OQeQw7DHahPUbhpqjVGoQtNtdWAJ/dsBjb7+1XDewbxD9qDDOVflee9c+Uty6gNJCW5GfnX6eoqGSFkG6V2KseGAyPbJ7VXM0ZOjCXWx1mpRBHcAxzQvg74x91sdTjpTCwjMa3ZUN1UqOCMdcjv7VyylrVSZZJY8nACHqPepYdRuIrdvIHmIezHJX3o51u0S6Dtvc2TKihHjJBbJyGz+BPpUxkRgsYO6V/wCMn+tZAv0nlWKYNCqnPB7+1STLIj7kDyKADuAGQfXjtTTW6JdLuXzvAKqjI4PIXnNWlc4VNwwBu+YY21k20m0kOevfOPxFSxSTCLDFmxnae4FMylBmjJI3l84L52qyng01VPaQvt/i7fjiq8Tkgu6EyqMKVOD9af5pA2EgN1LAfzpmLTRM/wA4CgEtn+FuKbJJ5KBQW39TnrUbbl4cALj7ynn86bvRv3YXK49cf5NAl5jhtkhJdmabqHU8D6impI0cZEQX6Z/WoWZoivysFB7jn86bJJuYsFJU846EGky1EsLMrRhcrhuobpn2NEc3lsQxUjngjOKqmQGTheCMYNMIYnBUhQeq8/nRdlKKLhMRU4wuOQR6/TrWTeFVdyp3E8cjJqWYiL5tyuOuDzVDUJ42jYwAqpHKjPB9qUmbUo6j4LlFjUTkMf4eentTgMyA+YvPIU1leaHiClhkcbvumpkuCyBJApYDG5eCfxrNS7nW4di2syB2JceYv8DDtTHZpySgAIIIIPFU42jaHDx5O4ncp+YUPPFGNpLGEj7xHeh67hy66D7ogr8wG4cEdc1YUsCPMAdSM8nn6VXiIZC0bLtP8DGltp1JKMw2qSOR09xSFLsW1wy7ZCM9D7VrXFslo89wluCYwsNsGXcHJ/iI71iksTjCPk4rUu0htLZyHuGe0dFc7zt55IA/rWkUc83qrFTU4VS/IjAjbAZlHRWI5H50Uahaubz90GMbbZEfpkMMjPvRUuLvsOMlZakG8ABm+WPrkcke1Mt5cBDF8zYz06VRyXbYGMYJyC3ce1XoioBCHknkDv7iqMmiVCWP3lEo67uMe1SI4jYl8qODgVXlkXaSATITyB0I96Xzg23ZllHyjpkH0NV1EW45FMzOclSeT2x/jVe8JzkHlhw2eD9aj81lJfZsXsRz+neoGMgmPndHXHy8YqW+hUY6mna+X9lQbjuAHJ7GnynZGRyGxuU56Gq0brwvyZUcFuMioCzPKQ4IDEbf9mm9BWuX7ZlAO9C6nqVPNR3T4lC5EiHox9KMOv7zHByPlPU96Yrxsu2Tknow4Io6WDS5WukVp9yNk7ehHQ/WqOdiqQ+wZwQOhq+QA8jB84OOnWqVwi8j5WB71nJanVSfQAjKQWLBXbg9iPr61Yt3SKQx3Ejqg5AI/pWck727EAtsJwyEfKR61dhnWZdjBCuflk4yPY+1THU2kifZC037yQrH2ZfT/GrrI7IBGVuYASP8+hrMulaCYhkwpHA9aktkDvuafYH6nt+NUtNDNpPUtmVYl/eLIAeD3Kn0qUzOY3+bcuAA6rwB71VKSKzLHMr5GCFb7w/rVOyuJ45i0TMnzF2UHsKOblepnycy0NmB5I3z5kZT+LDdRUk0yxopBGG5GR/I1WSbepuIdu9eWHl/rgdaqtJHKNn3S3IB4xj09Kd7LQjluzRhldQxtpSQx5WQDimzyics6xRQyRnloztB/CqIkeGQKOCeAc8CnxTyP96NGYjlxgY+tLm6MOWzuWYibhgHljEzseW+7+PpRNIbUbUaRXTggjIP0PeqUrYK4jOc5GKnWRVJdGcx9QA2GH0/woKSHG4S6Q8gFhkgHHSo4XMKGS2l3bW+ZCOoqjJKXlYxAN3AYD/OapofmwCUbod1S5a6m8KasS3kw8yRNhAfHyEkbT7VMjlAA4zGCOc4K/lVKbc8kZeRXQgkEnnjsaREaRSUVmHOcVm20a2TNGMmb5iP3Q4X5jzTWASbELoI2ONrAnHsfWs+OU4IJKMo4B6VagkY4DASRH0OcH+Yq4u4nFrUtQrnPlGIBjguAcfT2qYSbnQTKSmcAg8DjsarSMIyVMWwHhmVtwYVNa5iuEZf9X9SBg1a00M5PqW0EMcr+XLKq+hGSD7jv+FDPBLhJPLaUsCjAEbx6Me1LJh0DMylM4CE/MPcGqx8kLhZfNH91gRT20Mr3J5IIoi/m27L22h9wX6ZqrPGpMRWRA/RVdSP1oWSKYxxrI0bk8l+VH9RUc++GQtJIQudo2AMpqXYuLZN9sdLUxtHGcHPXDA1JbakywtFcIz2743KrYzURaOchdkJYj6f/qpr2v8Az1SSNOmSDjPbmj3ug7we6JGvESNtiLKh+6u7oPTBqPy7YOAWeJDyxPr/AIVHc2YgTIniYk/wtn86oiRRI25ShPAA5FJt9S4pNaM0BAzx7s/NjjBpbK8nSaSIOykHaVPWqSK/mE8yIADujPIz61E5lE7PEHkVectyRRe2pVr6M2WuVMhWRAG65BxmrENwwTessg7bmPaseGU3DoY84xjaRzmlczRT+XKMr1Of8avmMnBPQ3WuXK4dhu6jd6exqwkshAfcQSMEkDGaxYbmPaBtIHTHXvV+OYOAVOFPBB/zzVRZyVIW0saMbu67dgGOfrTGLKoZRyD35FVGkUSDZ+RpXkyCQ+32qk0zBRHtNIzFS5x2Bb5aRJSBt3AqDn6VUEi7/mCn3pH4JGV2n8cUi0uhpIyv8yDOOox+tRSEJht20N15qjHM5bG/OOAQakMoYBnB3DgdiKL3RPK0xX2yPgkqqjOV6/j61lzqCWRSfm53VcLZcHPz9qhd1aUoQODhsdzUNdTeLcSpNbkx8H5hyQRwRVVnMWPl3p3Uj9c1fkBV9ysGI9eapz4UFiXVuwFS0lsdMJ9GRyXCMuNvfII+8KI5V8z97tJHUHvUKzyiUGTbjrnAz9KrO+c5GRn8qhs3SNSB0kZEztB4HpmpIUU5JI3g8471ngoIlwwY/wB30p1rNgqcsMZwQOlNO5lKPVGvDIWbEbRgjrG2Ofz71v8AmXsa5fSYZXnAZy84XcV6EjvXJS5DAsofHb+8KvXxtru5kuIdVt4Y5Mbopgd8Qx0AH9K1jJo55QTa/wCD+hJql7q8TGS+iQIz4yMbUPYcHjiiq1xqFnt1OViXW5CRJGeGbbjMh7CimpeZpGK2cQMo2LkJyeOeBQ8oXBYbQ3QjufSqMeWHLEZ/hzkf/WqSJtgZfNdR+lDOaxYdDn98CvHAx0qeBlDHZkZHIHIrPZ3ZOZSU7CrMZ8tABIWB6EHrQkN7EySkKA4B9Pp7U8zL5bEt8vQBuoPpWfJMfNBZvlBwW/xqWNdzJJ5iuV+6AMAD6UBYtF2ZcNwzceWTwP8A69OlZlZF37By3PK/pUCyoWby3257HoPpSo7LK5cEjGNoxginpYCdXZlO4tGRx8v3X96aJQyjLKGXqcfzqGSYLsV1JjI529aRed5gVZI8YbPb3I6ikOxaEyrGYn2lSc7M42k91NUrtN67WyCv50SxB1GHIIH3c8D6HuKrRyMWUsXLfd57ih67mkNNSF3RkZTJh+ACRwwqICWImQ4aPjJU5FXJ44mwhDLu5U46f/WrPndosKm0duOPzrKStqdVOfNodNYXcF5Yy29ywBTlD1qjNCIJg0EvuGAwDjsa56KQhgUyCD/DWzpt9aXMqpfjau3AkQ4P/wBeqU+bR7kypunqth1xqLxyiRAFl4U5HB/A1ZWeFiGlVtxG3d/Sm6vaQLiS2u2nhXlWYDP4+9ZqyyQum4ttPdhkfUUO8HqCUZr3TRuSsbqY2eJTghs8Y9Qacl5kyCeJJWH3ZVOG/wDr1QnvA8ZSUJuz8rgfzFKJ1jiGwqf9huQfpSXkJx7l4TqMSJslBOdv3WX8KUSKowMSAZOTwarxqwQLIsYJG4uejD2ParGYHhYQTIkgOCrNkH8+RTsyXFXKpuR5jBJHEZHAPUH8KuJLuIEEu5uqkgKwPv61n3ckayLvjCv3VTj8fSnwyxhHiYrIv8LBeQf55pJdzRq60JXvZg370A8knK9SaBNE8gYwBJMZ3KSB+IqrNmXJBYEEDDZ+amlmglO4Kcc8Hp9aTuh2VtNy28kIg2mMSKeueufrVTyPkBjOA54DcVLLcJIQ5jVUfqFHAPrQNjjLR7lB4ljYkfiKGrsE2gt2idGWaIBh91wTj6Gnjy1k+4UyvB3cUblYMscxx79KdHGkhwSoK9g2BTsS5akEcjo/O4qec9Rirn2p4Y0Rm3dkPr9PSoGtyTiPeVHIOMEVWkSSUoyfN2GKSutg0kXo7vzX3ZcMDyBzUqnHzFSf9oDpWfLqlvZ+WxxvHDgrj9ada+IYp3aKS3YQsMMVkKj2NVZdWJxk1dLQtIyB3cjczcLg4pxnheNw6SLIB09aqo80c8rsCQf4XGeD05puVKbxgEcDmltoTy9WXFVghYDcrDnAzxUkU0wgKpM3lE4xnI/Kq8Ug2mMkqT3BqKY7GEfyk9SR2pWS1Fe5ZwYZAjOjL3x2/CmNEHRpBymePaoY0EgYJKAYxnDdTUcbyRJwRlsDGafqUn2HK235onw55HtQLuJpWWRCuQMsp5JpZUBQFVww7djVRgGn2424Xke9JXRorMleWFZC6yPC+D0Xg1bjmcIBLISx6tncCDWXM/llOmDwWJ5p0NwZAUU4TPpn/wDVTTtoU43RpGWOOWPDbkzjI9PerolZWwWUx54OOK53z3ido3BKnnGf1q9bzEIMswJPXH86E0zKrT0N1XUgA4bPQ5pssnlvub5lHHuKopPIQuWzngGlLliRgFVPLVp02OLl1LYZccn5z19qHuDtEeM+/tUEbDOcDHuahSYLK7NnA4C9jRsBOM8Meo6YqSSTAHyjB4IFUVn3RHa2D6Z4pPOJQLgjHcc0vQdrlyOXd0wQOxOKaGLB22gqWPviqrvtgL7tw6A1XinPlgEgDrzxmn6jsXGBjAP8JHPaqgLSsxJIOOmM0NMw+VgSp68ZzSoyofMDMCOlTYpOwnlL0Ygn9DSPCm3IXA/SmyOoX5W4PpUcku1Bt6Zo0KUmITGGZRgEjA9KhD7AYyj7hycHp71WnkMnzA9/wqEymMEZKhuCahs6YxVtTTM2GXGOcZbPIrq7qVrc6gkFnb7rZUaJDCCXQ8E5759a4Qlx5Y/iZwM9q6SZ7Gy1AxNfai17ABGzowXHfAz25q4MwqrVWKniXd/asmSEDpG2zAGwFQduPaiqWpvDPdSSqZdpIO+UguT3ziiod7hGTSSJhKojBx2wSOM01ZAUBY7WHAB54quACxbIk9MdvqKC4Kbm4AOM5raxkmWzKVk3K3B4OKc04j3cBj7dKqlUJzGxbPPHBFOX7hQjKr1zzil0HoTLOrgY6dgRmrEd0CcAbWI79Pw96z4vusevPBB4NODMH3KMEc/SkgaRel3bWK4JHPJ/nSwDKDexU9T7H/CqUt052xMqnJyT/e9qlEikAfMgHRuopokvMrcL5YZ8YBU/epPmXkF1YcbupFUtz4YJKCCex4/Ckt5QrZZsSKeCP4vrTdgV0i+pyG4QkHkL8u739qTzHjQrhjEx/i55qOO7juQokTy51JPmryGHuKjkZnmIiwAeu09fzqXtoCYs8rL95tyY4Xrj6VTnTO1kcHI+8Rx+JqxKm0Ekjf3xVZAFJZfyz1pPsawlYp/cY/OFY+h4/OmsWXYzIQw43dc5qa4KSsQyKjn+JeM/UdKglDiZS+U3EYweDxWdjpVS5dsNS+yyZH8JyQQDn8Kvfb7a6dzK5hifkoq5TP0/wrBeNXLAkn3BwRSSFQAQ2ccCqUpA4xbuaYZJJCIAgVT64Gf8Kla38lVYlGDfe2Pn9KyrdJETzETcP4sc4NSJdujMSoI6MGFK6e6F6MtySHYdpYY6DFRGWJV/eIWc9x/hTGuI1Ksiqo6FMcYp0U6SSO+1VPYKMYot5jvZbDw7OggL4OSR5nQcevanIjB8E4Kjr1B+lQTzRuAZFyM8MBUP2qSMlE/eAjADD+VLTqNSutC/I1zEiu4LxZBVwcj/AOtU9y26NJdu3cNpcL1/xrDlu5I/l3EA/eA6GtKx1m4t4/KDDyiQdrDI/wDrU7q1rkO97pBGCGA3Eehp8U0kQ2odjHhjnrT7u+juiDwrLyMjpVfb8vylMjrlwaGuxSlfc0I5hHy6gSDoydCPenG4ByNsbD/Z4qGGQCHCTKjY+4wyPzqFmdWBMYC9RIvSqtYyHC42SAIWCscbfQd6sn5ixhlULt6YwCPSq/mL80qxAk9STnmqcs8TuA8aoc8suelNNofoZOoTGedwqsIgfu9RVaK8EcxWRWK9Rk8ZrYubSBJlliuCpHI3qCp/LmsK9hCFpB5rKecIec/jXPOMou5206kWrM6W1ukcbTJJtXDAYzg1fS4iJURyIzk5ww2j8QeK5TRw/l+a7yOrHJ3sCUA9a17eVQWYxpKpbKsDjitk3JXfU56iSdjX/eeWzPCjfw/I2Me9ETBCzBjuJ+Zj/L6VXinVFQQKUI6AkEVISWjL4AJ55H9Kto5723LI27iYmRz/AHO9Vt6vNhk2uvAwMVAk53HymIwOhPehBIjiRs7h8zFuanyGhXchiykhgOOcZo+0o8YDhvMGeQP0pJ5YpeS20nnGOKrCIOxO5sLwO2T6mlqtjWNnuMnkZJVLYJHNFrOdhVSAwJ5bg0zyyTIhQbSp79KjEICq2/Lbec8496Vpbmiktiw88gYE4GD3qwkzs3zFvbNZKsPNVTJvUnng1o2oOT5Z3L7HqKauyJtI0baXZIuSRkcjdn8asPId4Ccp2xxkVnxASFcKAFB/H3p4feSG4I6ZOK0s7HDLVl5ZdpO9iEPtzTWZNnALDPfg1UMxUDnPbJ5qITfeVguOoYcmjTYlE1ocFuR94jDVYU7GKo6r6ZPH4Gsu2nYI25s5boRVl3DBSQAPrxQhtj5i2GL4JUc4PNRIzbVYtgrzkjpVV23yZBIXoPSmrOcbDjKng9qQy088mcqxCn0PGaXz/kVTjdnn1qsjn5gxOD+Waazso+XjjoRSQ20WHcbhnjHUUk8nONwK9sd/rVWSYTcHGP50gG4gbjgdSKaBMZMSmSOUPaoPPRR86h19OmKsXPy5UjA9azZiV3FhuTGAfeoas9DopzT3J1uAs4CMxQnoeoHp9a7PU5tQjvSLfRYprZFUQyPbl2K47nOc1w2kwWVzM/26+NoFAKkRl9x/DpW4zWQGf+Eouyo5yI3/AMaI3JqKMn/w5Hq1zIbuVrm1+zy7V3RKmzbxxwfWisvUJ40vJTFdG9QqMTSAgtx0wfTpRVoShoaBn+X92CcnnK8fnS+ZyTwyEcrjP41XsXSYyRM22RQTGOn4fWnCUgDGGB7dCKu3U5blxMODtAyehzyRUcblXIjdxkY+Ycg+/rUDuxhIUblHIz1U0RyOcbTkL3zkigaZdi+YbZHRD67eD/hSKVWf53bHquMVXD5BJYKp9RwTSKgXDE7snj/9VDDmLBCpDuSRuDyG9aUSb23gFtwx6VCJOATgknbjrQJgkwVgCD2B5zSsPmJGclh/s8e9NeUZLICPY08BF7lcnqwpJo2X5tmEbphganlKUhsYkIDKRtPOd2GH0qxPK4UMdzKP4jwTVEkHO87c9M1IsrRgqsjOM9V5B/Okht3LSzFmjwpdMZ64JqMiJgTI7KM4xn9M1UDdwxBPTHalm8zzDl18zrk8ZFVYSZO7xqGZFLj0JyQPrUSbJmjyuCpOTnoO1Ijq6qX5DHn1oIBcZ3470rWHcm8lArl23ehPBAp0cRQBkCFG78HP196rtcRbSJAQo/iHB/EU8MseAQrqwyCODT80HM7EoYBz8oyf7vGagWIiQkkhffmpRIhA3AcDgNxml3+YG2fOuD8meQfahxuOM2iokZd/mdDEOxODk1ZEexCjx5B+6+OR+VRxqY1G8YIOSCM063klZmMLBNozg8Z/DvSStoN1GyeJoSmyQsPRlOePoagFsrSZt5UlC/8AAT+Rpz/vMFSFYHPIA5qMMc7yn5dKdkJTa1Ce2DjDjywT2HAqvJAYV2+YNp5znNWJUldkdWBQg/LyTmqcmxGJlX8s5BqJJMuFSQ2C4G5o2ZQc/eNXDdBv7kmPQf1rFYtu5CgA+nNPjWVwRGCQOoHUVF2tjpVnqbkNxEisBGcY5J659qc1xC2Au5M9fmxWLFIUGOCOhzwaVScksw49Tmq53YnlRtLcFQSAOOM9/rTYpBLHI5UFicADow9xWYblVj3NktggkfyqWBCkSlWDkDJx2/CnczemhPII2bbhkJ9sioGj8xSjgMvTK80jSJMcAZAOCQcYpSwLDAbPQHpmkPmKF5YL5hcEhsdM4rQiRlgCZyVA5qOSaRpB5nzgHPNSNJEGBBYj0NJRSdxuo3oy3GpUZJBB6GrcMsvRWbABPJzismG8Me8AdTwT29qsLqTtB5CIFDn5pP6VonEyd2Pdgz7iN2/qcYoZ2U7jkIfzqE7oo/3soU564OKheeXBJIKHoetGiKiWpJcMdpAkGOw6U1p34D7dxPWsu7Gxt0THaRkZNM85lwGIC9ahs2Suac8yjerlxjgYORUM0jKoZWOB1OKzbiV2LbyWI6H1qWOcsuCSy9xS5r6INtS5bsksgz8p78frWhCFZgisMdz0zWdG0b8gbWx0qTzCQAmQB3FWlbc56kubY0S5QyDcR0Api5Lgtkj1B6VWEpcYYZ9SKiLBCHG5scUMyRos+XyCOnpioyyqrFjtOODVQXJJyRwB1pkk/mAK2OfzNPqSXNwSMKR0HWkE+F2KQQTlqpyTbVyGyOmD3pFcGLIOHzzxTEWpbgHhMZPbuBTY39OSemO1Utyxudv3qPtBxtI4HpQMvtKG+U5Ujpg/zpskrj5TJkdD6/Ss+W5DMDyDjHFJ5qpt8zJJ6Z7UWuTctmRAoAYlwehHalNwduAAAPSqcjeWM5Iz3xTWuIuBls98DilZlJluSc7Q3UGqqEq+5j+AqIyL5gXdgD7uKYZhk7uSPWiwKVi7ZaVc6g0psEEjLywLBcA/U1OfC+tGPY1uqjOf9an+NZat5h2EAE8K3pk4rqLmw8P2aaiklreTvp5jWZ/PwX3cFh9DTUEwdaUdjj9TsLuyuzBcp5cq4JUMCACMjkUVoeI4IrTVJIbWIraFEaIbi25WUENk9z6dqKl04lrESauOkYhgWOwqN2R/OgXWxxuwQw5OOnvWfJcmMhgd23nGeKHukIztIB/u9M1d10MUayS7nwufwpGm8uQsg2568cZrLhuhCMHlSOQOtStN56NIsq+UCBszgg+pFMLml9pQLgdevHP6USShl+QtnufU1nxTtIm0kAr6jFTblPQ4A4+b1/CjcDQSRSVOdko/v0jH94TId69yh6VSWRJEw5II6YPX8aGYeaQjuB3GKdrgaVvKpLcuB0HfNNSQROMMB7N3qolwqqUlHtuQ4NRvKhYAMxA6butKwF6d0JxgI2elILjy5MqigDrg/wBapRNukLIxPse9PXCqUkQ5HPXBpWbKuXlmhPBfbu9RmmuX8rlkdB3znFVSgeISRHOOuTyPwqBU2z787iPXg03cVyyJwijYMkngnpTgwmk4XB67QagZ38sKMFc9GGab5ioAzmQADtyKVhXLjqjrvXzFOcEsMgUifIrANuIORxUDyuY1dWGxuN4JGfrSu6EJhscc+hosPmHPduFCw8nvkZFPRzgMXxnk9s+1M86Dy8IkglBzkEbfyqJZmmZ2bac/hkUraj5rltpXCfIuT32n+dIs0jN821iBjntVUglfNiyEB5weVqNZiWxwVz3/AMaGhp6GirE7h5ign14FIswZiWJGePl5FVTMsbYGMnseRimrKqyAGUY6gA0CsWXlEZBLZU980zeGYGQttI+UdcfWog37sjI2MOeM1DFIoyGY8HriixaHtII0c7UyzHg9BUe4ptLLkHr2/WoGdOTKm6Ns45wQakibMZQOWDdj2NTa7sbx0RNLOVVVGNoP3WH9afJ5UnOFQ+oORVCVG+Zu44B7GmecQArjBI4qb20Zas9i4gAWQDawYU6O4MOVdTgfdNUlkDKDyDT5MmFQpGQcjmheQmXI3EYDh1+bqvWnzTAoFKAMfQ1mrcrJD93GOOO9BfOHVhnuCecU09BGjHJywycDpnmp45/KT5EQMerL1rJjlGFO7jvmnmUCM4PTpQQ0So7sWRzlXJOe4NTrM5iClgo759ao2s7PGylssFyMUqyF2bDblI5UnkU0GjLm8yAAuTIexqm8u19qn2NK85jZWjJ3DoCKjiaGUsrg7z2zxRJXLi7Di7eW2zBA6gjNIZItn3G59zwaqOrxg7cg/wAxREZJRtVgG/2uBUcr2LckiyZDJ3OAeMCrNqNrMT8zN2x0qnb7kyuRjrzzVlWZSrbsN1GO1XGNjnnVvoTu4HCAh88jPFOyMABtpPBqF5gQwMSmQjBJGT+FRlipG4MDnNXboY85ahO08sWDcAihnAJXJBA+tQSMpI6YPbNRSthd2PunPWhqxKkXVmy+3c20DnFLIRliqj86ows7LkMOvzVG8vz7S2V74PSn0FcuKxkcbmAQHj3pzKUkYZPXr6iqTyuqbowGB4zjpUDTMhK/eqbJDuaTFlP+z2yM1HLLsGA2WI4qpNc7AMHnuabHlg0hI49TTC9iwjsg5bPfNIZWYEk47+9RedwVcAe/rSLPkELtp2J5iUXDsoUsCB2PFRNINxBHPtxxUJbDbjx7gU1pgznYOnqelKwcxYlIZcrlRTTID85PzdCai83ux+WmSMh6EgnvTsTzE5bLcEkH9a6aa+urLXIo9VewaS4t0hug4JQL1Hm4/iHHIrkIxJlniEjLHgsQuQpzxn8a6q7i0/Vbh7y+sNbt7mUAzRQ2+5XbHJUnpmmiJSM3xNPcrrE4v1jE4CgLEf3YTHy7fbGKKo+Ir03erNI9vJahEWOOBwQyIq4XOe+O9FJgpaFJlaVSchT6EdqZFCN+0Fjg53DtQ0xVvn3DPc+tTL8g4bdkZwaXKrlcxKE3KQvXuCOtSxmNMMFIcDkg9frUKHCdfLPTjkGldtpI6nHrVWDmLKyxsvLMpz1PQ1PKrqoUqrZ+6ynI/Ssl2Al2s3ykdcZwfSnxO8RyAUX+Fh0pFXNOKVjhVXlcn3pqzneeQGbvjpVKW6m4EuC3Tcev50ya53NuEeABjj1p3GixI29Cykkj7w70+N98YYZDe/OarW84J3CVc9Ch4yPrT55I+Qp2Y525pN6XNC95ka+WRjceHB7GnvM67gjcN2ByPrVAyoVBTk9WBpv7thgfXOeBR6EM1llxhXAJ/vLwTS/aiBx8wzjJ6rWSjlX2St9D1we1OWY7iJFKN0OOaaJuaJdZZSFUBvc4pmCQyu2CP73YVRaQbcqyt244NR/bTvxn5R2IzRddQTvsaDkpMFDbVPBPY1A84yUUjAOMiqzai4hKGBWU5G5x0+lVEuCOWjBA/A1DaRtCN9zRS6UE5lUMDgYHUd6c5US7YnBXqpJxkVnfa42lzJA2PVWwanMkKbUYyLwMFhkfpRuU0kW0kInHmDI6ehqXdGG384HGG7VSmckCQSRS9sqcH8jQbvzFCO46YyaeiIsXZtgUsnBP8JNQIQwYLnIHJ9qgd4jMv7148LzjoTTy3TlwCMA5ByaOVML2LUVykaMJAQT91uw/+tTLi8WRP3gbIHY9fwqpNO8i+W+GA6E44/GoJLkvlXwMDAGOtFhqRIs0TPs/edeCehqdZ4klZZVLArhGR8YPb6is8OqDOMjGMdKovKApIxnse4rNqxrzXR0MVwY4t2VYDjBHWrESJOuU2ox5IPSuWgvJ1+8gce3UVch1CJmG4sPXIxQpJ6MHpqjZaznSRVAwW+7g5BqjdSTRSlSASvUGp/t0TLweMZwTmq8l+XO2OVMjkArtFVKMVsEZt7ixXBBwVJ74x+dTGZGGcbT2IOKzJj8xO5mBI5zSCQAlf++fUHtU7PUOc1xIApBA9sVHIwKjbz3IqjHOxPKM2eM+lBmyp3vhh0B4z7VXQXMW4+cFQeBnjj8KGdmY7SBjjFUjLN5YCkgdMA0xGdstjHPNK3ZBz9WXZbsZAZcY7gcH8KZ5y7SUcfjVcEt95BnOMk0BAT8zcUWZPtUiYXEkhbLAn60+HcxAByep9qgClWxvAH0qVf3St8wyeeapR1M5VuhejlK4DAMD17VMfLZSQ5UY4GMms+QsODgHPalVyYzsLCQdh6Vexk5XNAuPLADgsBzUDzsrYHT371SFyysC/wAwz3FK1yGJIGR9KCeYtPLuJK8A0zcZOrEYPQ85qp5/DBPlIFCMHBLNgj2pD5i/vkjBZTjPp0qHz+G27UwOnUk1UL7W4OfelJRl4b5jyTTsLnLCOWGFJ460SHAJxk+tVUb5TknGM565prSjjaOozyORSsCkTqWzucj6GleXIAPTHaoEd92R82OcUx5xk8DJ7UWByLCy4Bzg+xpFlKNlf0qAOwj3Y3DPTuKQOM5Iwx7U0Q5ExkYtxwKaWbIHGM8VWmkwysSPoDzSlhtDDii1w5rFxjkDOSfSonlVSQDk/wAqqtMcgZI7cGmswz0wKLE8xeivJ1EiRPIiS4Dqp+/g8cd+ea7G9mgsbr7LeeMNWjmUDePKJEZIBwTu6jNeftKyAlGA2ncCD0I713SW51mNNR1Dw7O13MoYhb1IVuTj72xvm59qpImUij4l0gI15cJqst/Pa+WbkTptby2+66nJ3L0orN1XX53j1SC6sfs+oXbpDIDkCGFMbYgv4dTRQ0JSKb3G7jaoUHkdh/hUU0yhwY1bjggnINRQ3PzsyjrxtIzRI0LEnBjJOQo5pOOhpexMZ4mCqPkbGSCTg1IoVgcyA5HGGxVEAIOAdg7+tTAqo4xn0IoSDmJWYBsMM4Hr1piSEEAOVQn6j8qjZ13AKMDHIp28YYDBGO/alyjUi2LkYMcse/0dDgflULsjq2wsT7VWMpVAVXB6H0qMMRIxyRx2NMfPYniG4kNMsZ7buhqYmSN9jhSG6nqMfWqjTKFHmIFIHUU1niAAjYg+3akoIftWXhNECSAwGcdanknt3ESglXxgnHNZhkiXaGYFweSBj86Uv8zcggc4zwadraC57molw6yCNGWRHGMPinGRoy2+OQMGxyelY00yxkB84HODz+VPttR8tyoDSITnBahbhzGutzGnGNxPU91qB5Ucn5gCp5B6ms+4uxNloYTGSfzqSG4SNmW4RAepb+IUWKjOxYBEiEO6Lg5G4kUjygKeOB0wc5pkU8BcMxzuHGfmH/66hcR+UrRSBh0PGCPrU8pqqhM1yH27hjsMDr9aqyXLkYztHY0IZEdcEFfemTmOVxsAXtye9S4hzkkEsiyoVbGOlTu7t5pLBmznjHNUNrBx044xmptgX5ihVD61SjoS6hYimIjLyDhegNW0upHXasJI69ayZ5mkAC5CDp61JE+AAy7yTy27Bx6U7W0QvaX3LouA8oDKAD6dqJRvbqrH1U4z+FQPLZwxFkW4YngAkYxVN5Yi4aPeuRySc0dBpotSMzrmQNGBxyvH51T2uXLIc4PY01LonKDdtz2PFSxlVbM0RDZ5OcZqOW+pTmSq4cqXwuOBgYprBNxO4ErwBRLc+YCqkkejDOPxqNCi8kfNnPXFVyol1CQnjcVYc9B6UiSASg8jFP8AMt1Cskkgfr8y5FRsqO2UmQse2COaOQXtSyX3/MpySORmnJJ8g3Hkn/PNU3UqrDuBkYpIrl0GVcjPGCBgU3EXtDQ88qq7ixXP8HXFDSxuR5c3bGGHNVHmkaIqdpB9BgiqyMVO5lJJ9aGgUzVZ2kBOVJX04ojfAwG68EZ6VnieRQCCdp60+OXzHHmuQvqKB8xqYyuQMqKbn5z7djVFZT0RiVzyKkSYEgbjjPeq3M3KxIznPOetDXDhQGAx6kc1Czpuwp6etROS7AjGR6UWI5y4krNnPX3qMyFGG1vmqAM4OUcde9I4Bwc80uUXMTSTktycnuM0jThUAOQO9RAIpPmAdKruOckZ9KfKLmLO8knB+U88VMjrgjBJqlDKixsrL8x/A0bmB3sWzjnHejlDnL28BRyMk+tNdzgg49ye1VBIWwQQMDPIpkkxlYlvm9cdDTsLmLay8ZDY+lOd9rgqdw7nt+dUmJ6NxkdKaw4IBKjNHKCkXjcblCAkLnJAPU0xJVCkMcnsarCQKu0DcT1NNRwzZUDPpRYdy4zMFBxx3xUUkzJz0P54qtKSxY7iDjJA6UzaxQHdwR64osJ9y3ERLyT+Jod+Ov45qp5jbdv40FgEyc5P40+UlyLKyjb85PtUbSlgMn5qreYexApTJkngY+lNRJ5iyJAnJwQCCRj73tXVa5pyeIdWl1Wx1nT1tZgr/wCkXHlyW/AG0qeePauRtLa7vGYWVvNcbR8wijLY+uOlTSaHqjK5bS77OP8An2c/0ppEuRo+LdQttQ1t57SYzRrHHD55BHnFFCl/xIoo8cKLfxAsYjEeLS2ym3GD5QzketFFg5ihHcRbSDuQ9QVprzlnUklgO+Kon93ImBlKlW6i5DL0PBrOzN+ZFwXTkMoyU7inrIWxk4X1rMM4GduMHvirMV1DLHh42RgeqscVRDdtizKcBtrLkfnTfOGASvTqRUT8gbeSelQ4dR8uQR15osJSLbXKZYAllI6Him7j5fBI/rVOR9o3FRzUokDoo6FemDSsPmJi24kHIHbNCMUIUqpwehGf1qKaV8ZyDx0FRxTlFLHIJ6cUJBzFmdoZMsF8pj75FSQQNIpa3BLAfwn+hrPlkYkZIyeaRYZGYYIUkZ64q+W4XLcgdQfPViQflOKhdlOSq7ccYHFMZ7m3QlSdp7ZzQ140kYDgtnrihxFzE8N48XyJyp6q3IpZZY5VyIyHHJw1Vg8ZOMuDjPQUyGZFyrtwT/dpJdAUiR5YcrnehHUipo3CgDztyn261BIluMFi4JpFt4mGUmUP6NU8popl4kKAwJBHUdQajyDlv4f5VEbeYMm0lhjqpqR4wAWdpEHdcZo5RqRbgkiKfvHVJCPlBGOfrUe9gdshwMHg9Krs0CEbHeQd94ApDOjfwgj0z0osK5I23BJyD1HPSm+aVUrjJPORVaSVTjAA7daRH+cBdwA96CkydiG2luQPzp4OWIUED2pGlGW4ByPxp0aEglc5PY8UrdClIbB8rDnr3IpokbJySV64p8TFHPmjBAOO1PlEZAIUpnt1FFhc9yAM24sNoJ6CpAxaIs3XPc0m1VUlWLMO2KiaTbnPUmhIHIl8zOADkUkY3kkqMiq5JZ+VyO2KlEm1M5wM4wavlM3Isoq5z5o9CKmitpCu5Lf90BkuxwCPWqTtGQPkcY5xkYapIrgSMkU7SKmCGkBycduKaSJ52TTGPzAgkj3Yx8pOPxNQsMnAGCODzVqPTIJSdtzGoxwz8ZqDU4wgjQ/MVGDKnQ+1N0+41UQyTdEm5zgH3zTFmXacHJzTIZDuKhlK+5FSeU0jAFo1J6YH+FRylKY4yKQpHynofen7xgbT81Qxrtby5HAycA9qdNE0DlH2tjoy8g0cthN3JfLkKhzwG9DSb/LDDnf246VDtkYDByPrwKd9mk3kCRR9TQLlF3evB96UOMdiM8c02SOZUwArD2qBywGOmP7tAmi9HMu07wWGOmcVAznn+tV/MK/cJJ756UhndD90H2ParRDZPgso6Z96XeI1AKknqMdqqh2djuz64HahhIT+7Ib6miwrk5Yt/ETn1qRY9pBLgCqRknDjA7Y4p2JZBgKST2oAtyTFhtQZB+8xHWolDnIVScDopqvvkiPPHbAqSOSTBJcqR0x1oGDShRwCD6UwOzEElfxqRijsd+Q575pPLMRBwhf+6eaOUXORmRifugL2FTIsjrkIQo/SmGR5FG5u/YY/So5A+88OQO9VYTmSujI37w7T6etMbP3gBgfjTQWKbmyfrSh+Djb+NOxDkKudpPQ0jlgcdfpSg8fOFP8Au9aNhOCAxHT5hRYXMWNO1K909pDZXs9oXX5vKcrnHTOKsr4l11ums35PqJ2qx4etLH7Nqupahbtew2EastuGKB2ZsAsRztFT3GnafrOmz3vh+3Nrf2ymS50/cX3J/wA9IieSB3WiwXZhXNzdX1w011M9xcEDMkjZYge5orS8Z2NtZ675FlEkUP2aB9qnjLRgk/iTRTsK7MsYZMEEuD+Qpq7M5LHPpiqgmbI+XEmfzqZJFIfeG3DgbelKyNUxRguQAMAZp5+7kdSemagQneCCfYVKbhlTaY0bnuKm1gbHrOQffFPExb5cZ75J61AoSQkshTHPBpHUDLRnjsDRYm5OZSpK469VambkZieQAO1IrM5zIwJxyaa4VWPVh6igOYlBAwAwOafwy8gj/ZzUC425Xr6GkLsuTxz6UrBzE80yOV+Uj3FDyKyKMdOKrBwN2VG3tmpVZChBBHensPmHuTjAJx3HamOIzGvlblk756GmByVwCfxoXlgCwoFclSPKZJA/maaUjwDnJz0I60FjtP8AFTlRiMgnA/GmhXGsY3JHzK3bmo/MKAcb8fePTFTMoJzlT3NNfqAuefypNDUi1DexuuyN9h77/wDGrADuMknHqDkGsp0AySo+lOimMbgKSvsDxSsXzmg1tuG5BwexqOa2YNkAevHakivpOQWyv+7Uq3qHdiMH8cZpOJamiJoZIkXMYdH55FM2vGBlRz2q0LpHCqYm4984pZJw4HysRj6Yo5R86GqyzKI3KR+hIqYWc+04yw+maqKQ5AO0Y7sad50ka7UlYehVsUcpPOSzM0cJVwHx1LL0qCJ0kYKCVI9BQ8m6P5yWJ9aquqg7eSfVe1PlFzF1pYjuQy+33eagkZUVdpzjoPWqflsp+UmrCQuUJUbm6UaDuxm87sqXGeOoNOYswB3EdsEUCN0PzLz/AEp5GVUOOBzjFNCY4PEse0AGT1qLG58YYY/WgOAxyB+IpwROCjJn8ae5I1+wwOT0IqSOVo3zhcAc7T1pDE+CSSfTB6UnzIj7gSpX0/DNOwtxksiv8zRIpPGV4NJG6Yzzn1PahImA3Mx9sjrQI2bG0gt1ORg0rodhJSQQANpx3OalincR7TgqT69aYY9nDKSfXGaVIo3JCNyKRSZft3Hlgof3mcFGHBqdslySNpPNU40YAKW+UdMc1bRwsBBlAJ/lRy3K5xuCcenSo50ZiTgg478VK8rqqMoJVweo9KhYyS5LE0KApTKjOEJAB/GoWyWPytWjHbRc7ptp6kbeaieBDITvz74q1AzuUhnb824dsGrEEUUrHdKkWOQG71OIQuC5DMegFDW2TnYx56Yo5QuQtE+GIG5ezK1RqjdFZgw7EdKuxwooAVTxzS5wSFAB7g96fKLmKIicthsH0zQ8J7j5emauBQAdwP1Ap4YOGAyD6t0p2QcxmvAqtndgHsBSJCQTtUkeo61ohduTxUQ3BiU+U57CjlFuQBHJztYkdz2qRbdyvJPPo1SOzn73P071PApC528E9CaQuUqC1lAXhuffIqT7O24N5eSOwq4Iy7d8fWpNqgfNnPTOaYWsZ5t1BJaNs56UrRbc7cj2q7Iu0phie31oEalPnck0CsWPDp1mC8km0O3nlkC7ZYxF5iMp7OvQin2uieIrK+ju7XS9TiuEbcjxwkYP+HtS6RqM2k6lBc2W4y7trRAkiVT1Ugdcj8q0btdV3ySrZ6tBbFiyqTI20dhnvSuNIxvEUl7e6y82s27QXrIiyIY/LIAGAdvbIoqpPfJLMWuHeRzwWdiTx7mijmCxisNo256d6jVW3fKcA8/WrKwnIBHB71M1u0eAy/SpsSmVkJ/iQH3qxDFBJyzmP8OKUxlRhT15pcheCOPpTsVcWW0CsypIrY9KjmhZVUBSPUmpRhjuUfnSq7ldoJI9KBMrxhYwzN34HtQxVicMPoanwDncvHtTWjQjKEfiKQFfYG53Dj0oAWSQAHBPQY61PHbls7ec+hprRndzkMPagCN4wrHzAc+lOj2LncCfUZq2ibl/eE5oY7ch1Vl7YHNAyJlgXBQtzTPs6tt2yjk85FTWpOWUleW+XI6e1PlXGUb8eKAuVJYTGSgYcdSvSo1zgFcn6VcMa4AySKcAqnKbgT1GOKAKuxScuvJo8teynGPWragMfmXOOtDRbgNgGB2FAFXYQvAGB3NNEZIyuM571cWMYPHPvTvJBHJOaVwsV+VVVKoffvSHcuNpYfjVjysjGMj3prx7RgrnFAJELO64JdjSRiSRm2sQp9TQwJHyJkfSljim3dMUiuUEVSAXJJxgUHAban61ItuTjuPSnLZSZJxg9s0xqNiJwVILEbenBpwPBIJxUrWj7SDgimJaMOMDPpRcdh8UcbLl1HX1q3bGNsqm5fpVMW0i9R+VKkTEEZKge9K40aBgtiQA4LHqc8Cqs8cSnAk/FaIoTznke9OETnhYgaegFZUGCp2n3ao/s+8gbQSPfFaX2ZG4dMMO1SCEoMHbQDMwQHO1Acn0PFTsHQFQQQMcMOOKviKMNlhjIpjQpnDBSCeOadrAimwOB8gbPPTpTvKgIH3437jtUrRKhxyoHQk1HKUchdy4+tIBRbHZvQKy9zuqAhwuMY7ZGM0/akS5ZxgcAA01ZohnmlcTY8L3XIpRDkgk8e4piXKgHjGTThdqVyoOfQ1SaJuSyxjOSOgwMU8qAgbuV6VVa+ZQAAOevFM+2tuy3Tp0puSFdIn8vI5Gc9KcsPyNk4x0wO9UJbuUNjoeo4qFp5mzliM1LmgujSeLIB3cj2qcIi/KHb09KxkeTksx/Cnb2znecilzhzGrsjjOQBxToBDNOgWSNT/Fk1ju7suCWOf1pgt1Tkk7j2BpqYjeuTbxjaGjck9qh+QqBwO+ayhFnHUY7VKi44bJH8qXtBmofJI5mGfYVFK9so5kyf8AdqlIQoOKgwDz2pc4XLEl1HvPy7lFKLp+yjHaq2zngA09eD6UuZjuWFuJCTzg00ySN1P0pNpDc9aTocYo5mFgcujcv07VCZWH8RNSsm49KYIsZpXbBo6DwZcMv9qRWlzFaavNCq2c0rBQPm+dVY8KxHQ1bi0jxrHMJFurqFgc+c98oUe5JbBrL8P2FjJa6nqGqxST2tlGp+zxvsMrM2ACey+tWb3TLHVNInvtAjlie2G66sJZDI0a/wDPRD/Evr3FAin40lt7rxFPLaPFL8kayywjCSyhQHZfYtmineLrC30/W/s9lH5cH2eCQKDn5mjBJ/OigDPXDR4NPDMow+GXGMVz8GsjcA6nB/SntqxBBxkVrzMi5tH5SCBx2pGBxnbWMuuAN8w4p51sA4GeaLhc14trZ/hP86ecKcZ5NY41ePoRyKDrcXO9M+lF0BrMBjg4FMK/MBkGs5dVRgABkGo5dVjU/d5pXGahR1f5Tx7VaSSTZhsMPcVz661GPapV1lTjBzRcLm2wUjP3WzyB6UCNfrmsJtZ7YyDxinR6zyB91+gJ6H60XHc2HiCycdPanursBkj0rFk1sb9rfK44welMbWCuOuPWlcasbQjkbjINKttKSQKyF1VgchgVPQ0smttn5WxRcaaNc28ijKnNIqS46Y+grJGuso9acPEGUPy5PuaVxpo0XjlHuPenJE5IHGPWsVtdlZhlQB6ZqJ9amycYA9BSuVodUsXygHipfJjIJZeneuR/tuZxgNtIpraxdMNu85p8xPMjsRHCBuXgjtSmFd29mAz6Vw0mo3IPzyn6A07+0ZiAPMYfjT50HMjuFWJYmJkXPvUck0QILTAZFcUuoTsdpkyPSh5g5G92B9qXNoDkdojxPH5iygqODVX+1LVGO9AAO45zXLJOxBRXIX61A5JyAf1ochcx2f8Aa9kudm05HftTH1a0IwT81caoftmnfNkE5zU8zHzs6r+2LdQ20ZqBtcG7McYP41z6q27OQad5bE5UH8KOYHUZsHW5mb7oHrUL6ncb87+OoIFUVQr1PWlDZUKaLk8zND+0Gmj5YpIP4geDVaWe5QqSzY7HPBqEfKegx3p5DIhDv8vZfWi4rj3u5mAUytjrTFdi+4ZyaiA3HjhRzVmEDcKSbYXLGCERQcnGT9akRf71Iq4FNZuQaoVyUglhTzy/A4FNU5HvUkYFUSxCoIFMdcDjpVkLwRimsmaGhkMbhfldA6dgf8aayIc4LIfQ8/rTnTHelCmRenzj9algIkYZc+amPrQwjDg5zx/DTdp3VKkYwoPWhDuNBzkIu36cmnKlWFjAXikK4oYDQnFBGD7U9WWlcjHGKVhlZwWz6VHtwasgetNdTnOO1FhXGbfSkUZPApyg96lC98Uh3HThQsbKc5Xn61HHhuTxT8EjHahVwKdguBWgrkVIBTwm4fLz7UWYXH6NqVzpVxJJbiN1kTy5YpU3xyr6MO9Qafez2GoJd2U3k3CElSvQA9QR3HtWx4d06O6lmnnh+0JEyRR25baJZnOEUnsvUn2FaVvdSXOoXljIukXcMKsUhS2EazheWEbgZU4BwSecUWA5nXdRm1jUnvblI0lZEQrEMLhRgYFFWNas47G+McDNJbyIs0Lv94owyM+4zg/SiiwXPL0+pqZm4BqKLoakk+6K0MxhIIOKiaTB4zxSHv8AWo2+8fpQhj5XJYFScUm9v71MPaimMeJXB4Yg1ZjvpANsirIPeqg704dKQy0XikHAMbfpTRDMPmQhh6g1APu0oJHQkUgJcuThtw96cX+ckc+5pV+6PpTFpDQ4NkHeAfc04OyY2nj0NN9aUdKQE8UqHCSAqD0I7GkkgZXYAg4PTNQnpU91/q4D320wGHIGGBBpp54q2nNu2eeKqHrUggyfWnDcW9aa33RU0X+pk/CkO4xTzzUkTEEv2qM96V/9UKB9BRITkkdaUNnpxTB0NIO9AJEvRgB+dJk56803t+NKKAsSISc0inn2pYep+lIvekIkBJGckUoJz1oPQUL1oEPDdMgfhT1duzGoqcv9aAJCxxkdaeuaYvQ08daBD+oFA+f5T97saVerUdmpsBOM4A+tW4Fz83QYqse1Xbb7lCAeTgUwAkEU5qUVoST26kn6CpEHPFLD9x/pTk6D6U7APVRimv8ASpV+6aY/ShgRYB60BOQRxilanR/dqWMNgPOMHvTQvNPXqaF70gJIxkYpWTjODTY6sJ92mMpmPnpShMc1Yf71MP8AFQBG4w3Sk68GpJOtMP3hTEAQU9UzxSLViKlbUZCF56UgXGanH3jUXegBFHPtUijHIJzSrTv4aYGroF5HC8tvcSmBJikiXCrnyZUOUYjuOoPsa12iihlluhHpFi0gYNeQ3Zm2huGMUPUMQSBnpntXKN2pCBu6dqAuWdXnS/vnkgjMcCKsMCHkrGowuffufc0VAvUfWiiwXP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory plaques with peripheral vesiculation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15108=[""].join("\n");
var outline_f14_48_15108=null;
var title_f14_48_15109="Translation RNA to protein";
var content_f14_48_15109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Translation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 665px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKZAegDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopk8scEMk0zrHFGpd3Y4Cgckk+lfNnxH+KeoeJJ5dP0CSSx0cEq0inbLcD1J/hU+g/H0HpZZldbMZ8tPRLdvZf8HyMK+IjRV5HvOoeL/DmnXLW99rmnQTr96N7hQy/UZ4q3p2u6TqVu0+n6nZXMK/eeKZWC/XB4/GvjaPTQV6c1INLGORX08uFMPy2VZ39F+X/BOBZhO/wn1pceOPC1vK0cviHSldeo+0ocfka1dJ1jTdYhM2lX9rexjq1vKrgfXB4r4zfTl9KSwm1DQr9L7SLqa0uo+kkTY/A+o9jxTnwlRlC1Kq+bzWgLMZJ+9HQ+26K81+EvxLg8XwjT9SCW+uxJlkHCTgdWT39R+I46elV8di8JVwdV0ays1/V15Hp06kaseaOwUUUVzFhRRRQAUUVxWq/FDwjplxJDcasrvHneYInlVcdfmUEH8M1E5xh8Tsb0MLXxLaowcrdk3+R0uvaxY6Fpz32pzeVArKgwpdndjhUVRksxJAAAya8d/aG8f6zoGpadpXhTUGtL6C2k1S7225m8xFO2OE4U43kScnH3R612Hgm4h8d6kviy5ljeztnZNKsN2TbDGDPKvaZhnA/gRsdWau3XTLBb25vFsbUXdyginnES75UGcKzYywGTgH1qk09UZThKD5ZKzPHvF/xh1O1UXXhjT9NutOTw9D4hke7mdXMbzGMxqFGNwwOuMHOfSmal8RtZkXUbHVrOC3vdO1vS7fdp13IqtFdBXUFiASQDhhgBvQV6onhLw5Hbm3j8P6QsDW/2QxiyjCmHeX8rG3GzcS23pkk9anl8PaLLLLJLpGnPJNJFNI7WyEu8QxGxOOWQABSeR2xTJPLtM+KXiCfXNNa60nTRod5rd1oo8mWRrnfFv2vgjbg7OmSfpVz4bfE/UfFGuaRbX1lpyWus2M9/bCzmZ5bVY5AmyfPGTnqMcgjFejx6Bo8fk+XpOnp5Nw13HttkGyZs7pV44c5OWHJyaXTtC0nTLy6u9N0uwtLq6O6ea3t0jeY5zl2ABbn1oA8v+IHxXv8Aw14zk03T7axvrK0ntIL5CHWWIzkY+ckLnDAgANx1I7VNe+JGsXmh+Lb6BdItNM02W+sRbm8eLUWeCNzvXHAJK524yFy2eK9U1Hwt4f1PUBf6loWlXd8Aqi4uLOOSQBTlRuIJ4PI9DTbzwp4dvb+a+vdB0m4vZozFJcS2cbyOhGCrMRkggkEHtQB4n8R/iPr0mg63ZaLNb6bHpMGktNcPO/2yd7hom/dYx8oUlWJzn5q+hqxNQ8JeHNSmim1Hw/pF3LFGsUbz2UcjIinKqCV4APIHatugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8Z/aH8UyW1nbeG7KTbJeL510QeREDhV/4EQc+y+9eK2FtyBit34jaj/bHxE1u5zmOOc26emI/k4+pUn8ar6ailhX6fl1BYLBQppatXfq/8tjwa0/a1Wy1a2QYDirosFI5FXbSNQoq8kVc9TEO5cYI5m5sQAcCsq5tsAgiuzngHOaxNQhAycV0UMQ2yJwOME9zo+qW9/YStDdW8gkjkXsRX2L4N12LxL4Y0/VoAALmMF1H8Djhl/BgRXyJrEQKnjpXtn7MWotNoGsaazZFrcJMoPYSKRj80P51x8T4aNfBLE/ag/wAHp+djXATcKvJ0Z7TRRRX54eyFFFFAHnvxh1G6Sx0bQrK4a1k1y9SyknUZKRkgNgZH94d+mR3rhIvhybewiSB4rqWWWRAFGB5ajcJCc91IbHoRXo3xZ8NXniDQIJtGYprGmzrd2hBwSw6qCeh6Ee4FfOVr4m17Qna0klu7WSGVnMbgqyuQFbIPqABg9q8jGSjCreorp7H6Hw5Rq4nAqGCqKMot8ye7etn3ta33M9B8Jabf+BvE9lffbIVgvNRXS7izDZ3BghV89CRvB9QPqRX0HXz18JtN8Q+Ktfh1HVZLkaHbzreHzVws0ygBNnHbauSOMKB6V9C104H4G0rLoeJxU/8AaYxqSUqiXvNfgvVflYKKKK7j5cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPiqGU3Estw/3pXZz9Sc1u6aPlFY9/aNperX9hICHtbiSEj/dYj+lamlvkCv12vaUeaOx85DR2Z6b4BtrR49SvLxFk+yQhkVo/MAJOC23Izj345rqJrJbNNU1Dbb3U4tYJrfNuqhVdiCTH0BAFea6LqF1p84msp5IZcY3IcZHoa2YdbvlvWu1vJhcsMNJvOSPQ+3tXymKwtSVVyT0f/A0+f67HoU6kVFI7CePS7W+aa7hjtZriygl802vmxW8rZ3Ap0BIAx+NcF8RrWW11OISizIkgWRHtY/LWRSThivYmri69qUF1NcRX9ws0uN7bz82OmfpXL+Ib+W8mea6meaZuru2Sa2wOFqU6qk3pb+v6v8ia1RONjltRUMhr0r9mHK6n4hH8JihJ/N68xv3+Q167+zJakQeIbsj5XeGJT7gOT/6EK9TOpcuWVb9bfmjnwqvXj/XQ9xooor8zPdCiiigCK6mW3tpZn+5Ghc49AM15pcxz6y7Xl2fMccqD0Qeg9K73xM/l6DfH1jK/nx/WuW0oAabKPavnc4vWrRot6JN/P+kexlz9lTdVb3sb3hDUZL6xkiuDumtyFLeqnoT+o/Ct6uP8Cgi91Idtsf8ANq7CvRyqrKrhYSm7vVfc2jix0FCvJR20/FXCiiivROQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPm34+6BJpXi4avHHiy1JRlgOFmUYIP1AB9+fSuE0+5CMOa+tPFvh6z8UaDc6XqAPlSjKuB80bj7rD3B/qO9fJPizQNU8H6w2n6vCVPJimX7ky/3lP9Oo71+i8P5hDG4dYab9+Kt6ro/l1PFxlF0p862Z0ttdrsGDVhb0butcJFqe0YDVYj1T1NerLAO5zqsdnNert61h6jdBieay5NS3DANUZ7vOSTVUcG4sUqtx97PweeK+oPgjob6J8P7Lz0KXF6zXcgI5G7G3/wAdC14r8Kvh3d+L7+K/1CNodBifLu3BuCD9xPbsT/WvqZVCqFUAKBgAdq+Y4pzCHLHBU3dp3l+i/wA/kd+X0Xd1ZfIWiiivij1ApCcDJ4ApawfG0skWhOI8gO6o5HZT/kD8awxNZUKUqrV7K5pRp+1qRh3K3irVbKfR57a3uY5ZnKgCM7ujAnkcdqzNOjYWPORkV8/23inUV0ZIBqkg1X/hMRY+TuHm/Zt33NvXbitK5+JF7D8WUnW+uB4VjvxpDweQ/k524M5kxs4lOOucDpXhujVxFX21S17W0/rzPUVSnRp+zhfe+v8AXke5+FbqGx1K9W6lSESqu0ucAkE9/wAa7RWV1DKQynkEHINfMHhjVIde1nUb7xB4tubHV4dXe1i0ZZ40jEauAkZiIy+4fxD+hr3TwDJIYr2EkmGNlKegJznH5CtcBXlhqkcHLVO9n97M8VSVaDxC0atp+B1lFFFe8eWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVRm1jTIbxLSbUbOO6diiwtOodmAzgLnOcc4oAvUVzHiLx1oGg6TY6lc3hubS9u1sLZrCNroyztuwiiMEk/KwwO/FZV18WvB9p4bTXbnUpItOOoHS3aS2lV4bkKWMciFdykBSTkUAd5RXPDxloZfxAovRt0KJJr99p2Ro8XmqwbowKc8Zqbwb4p0nxjocer6Bcm4sndo9zIUZWU4IKnBB+vYigDbooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3X9E03xBp72Os2cV3bNztcdD6gjkH3HNc74w+JPh7wxI8FzcNdXycG2tgGZT/ALR6L+Jz7V5dq3xv1u6dl0jTLS0jPRpS0z/0H6GvYwOT46varRjyro27fd1+45quJpQ92Tv5HRal8AfD07lrDUdStM/wllkUfTIB/U1Y0f4E+GrQMdQub+/YggBpBGo9wFGc/jj2rzib4jeNrrk6s8Y/uxQxrj8Quaqt448YDn+2r38x/hX031POXDkliV97v99rnB7TCp3VM9IuvgFobzbrXVtThjP8D7H/AFwK3NA+DXhTSZkmnhuNSlXkfbHDJn/dUAH6HNeQQ/E7xpZkH+1WlUfwywRtn8duf1rpNF+OerQsF1nSrW6j6FrdjE/1wdwP6VjicFnrhyqtzLydn+S/MuFXCJ35bH0BFGkUSxxIqRoAqqowFA6ACn1yPhD4heH/ABSUisrryb1v+XS4wkh+nZvwJrrq+Nr0KtCbhWi0/M9OE4zV4u6CiiisSgqO4hjuYXhnRZInGGVhwRUlFJpSVmNNp3RxFj4M8Mam6azpiAySZCXSIu/AypG5l3diOtTH4eaIbM2bITaFt5h8uPYWznO3bjOefrWZ4R1q40DRf7MvPD2vvJBc3OGhtN6FGnkZNp3dNpXFaU3j63gu7a1l0HxEtxc7vKQ2PL7RlsfN2FcX9m4X+Q6Prlf+Ybe+BfDtvJLq17GxmgjLvcsiGRVUZPIXdwB2rptEiso9MgbTAPssqCVG5y4YZDHPPTHWuU17xRJe6FqNrB4b8RmWe2kiTNlgbmUgfxeprqPDcMlt4d0uCdCksVrEjqeqsEAI/OtaWDoUXzU4pMipiKlRWnK6NGiiiukxCvP/AIw3ni+00zS/+EGz9pa6JvNiwM4twjFiqzMqkg7e9egVi+KPCuh+K7WK28R6XbajDE++NZ1zsbGMg9qAOX+GWp6l4s0nw74jj1uW60Z7GYSJJbLby3FwZdu50XIUIEZQFbknNehVwnjXxhpXw1sNJtI9Kb7JKrxwQ2gWNIlTbwB0x83auU/4X5pP/QGvv++0rnniqVOXLKVmevhchzDF0lXoUnKL2enTTuezUV4z/wAL80n/AKA19/32lH/C/NJ/6A19/wB9pUfXqH8x0f6r5t/z4f3r/M9morxn/hfmk/8AQGvv++0o/wCF+aT/ANAa+/77Sj69Q/mD/VfNv+fD+9f5ns1FeM/8L80n/oDX3/faUf8AC/NJ/wCgNff99pR9eofzB/qvm3/Ph/ev8z2aivGf+F+aT/0Br7/vtKP+F+aT/wBAa+/77Sj69Q/mD/VfNv8Anw/vX+Z7NRXjP/C/NJ/6A19/32lH/C/NJ/6A19/32lH16h/MH+q+bf8APh/ev8z2aivGf+F+aT/0Br7/AL7Sj/hfmk/9Aa+/77Sj69Q/mD/VfNv+fD+9f5ns1eLeJvhBca1rev6hLFossl/rdjfxSTqWdbaFVEkbHYcFsH5QSDnkin/8L80n/oDX3/faUf8AC/NJ/wCgNff99pR9eofzB/qvm3/Ph/ev8yrqXwe1K50xtOtbmwsrQ+NV8QILWaSFobPywpSMqnySjkjGAOu6iw+Eesr4b0vQNTl0e9srHxMNWluJHkMt9bFZQ/ngpzMd4GckEdxjm1/wvzSf+gNff99pR/wvzSf+gNff99pR9eofzB/qvm3/AD4f3r/MxbT4KeIbHRfFOg2utWjaXrV9ZoLiWR2ni0+EEeXjZguFEaAZ2kA5I6V3fwv8Eax4K13xMLjUbW+0bVJ1vYSqeVKlwRiXMaqECtx0P8PSue/4X5pP/QGvv++0o/4X5pP/AEBr7/vtKPr1D+YP9V82/wCfD+9f5ns1FeM/8L80n/oDX3/faUf8L80n/oDX3/faUfXqH8wf6r5t/wA+H96/zPZqK8Z/4X5pP/QGvv8AvtKP+F+aT/0Br7/vtKPr1D+YP9V82/58P71/mezUV4z/AML80n/oDX3/AH2lH/C/NJ/6A19/32lH16h/MH+q+bf8+H96/wAz2aivGf8Ahfmk/wDQGvv++0o/4X5pP/QGvv8AvtKPr1D+YP8AVfNv+fD+9f5ns1FeM/8AC/NJ/wCgNff99pR/wvzSf+gNff8AfaUfXqH8wf6r5t/z4f3r/M9morxn/hfmk/8AQGvv++0o/wCF+aT/ANAa+/77Sj69Q/mD/VfNv+fD+9f5ns1cV8WHmXw0RZ67caTegmSFLe7t7aS5IH3d8wICjO44xwOtcd/wvzSf+gNff99pVzRfHvhn4kaza6FqfhmO7Vt8iDUIYp40KqTnDA84FVHGUZNRUtWZ1uHMzoU5ValFqMVdu62XzL3weudV8U+GPCfibUNdmu4v7NlilhWMxCa4Mu0yOBgHaEKjjBJLDqK9MqK1t4LS3jt7WGOC3iUIkUahVQDoABwBUtdJ4gUUUUAFFFFABXL/ABO1C+0vwFrN5pO4XkUPysvVAWAZh7hSx/CuoprosiMjqGRhgqRkEehrWhUVKrGcldJp2726EzTlFpHxBE3mtuZiWJySTkk1v6ZHC2AwxXrvjD4JWt3NJd+F7pbGViWNrMCYs/7JHKj2wfwrzLVPA3jHRmPn6NczRr/y0tR5wI9flyR+IFfptHNcJjo/u6iT7PR/8H5HhSw9Sk/eR6t4Z0HSovDN9HHLpd1PLYmaWYzIzQt2XGfkAB5PqfYVdtbK0LWOmCxtzpM+lfaJZfIUksVJLl8ZBBx344rwQapqmlmWN/tdp5q+XIp3R717qRxkexqzF4w1NNPNiuoXS2ZGDAJTsx6Y9K8+pkuIm3JVL3f6b+q6G0cVBaWParO1s73SIrPTFgs5ks90tneacrLOduWfzSM89jn0rxPUbaDJMWKuJ4m8Q6jZf2fa3Op3NsRs8iNncEemB29qu6R4B8X6uw8rSJraM9ZLz9yB+DfMfwBrowtD6g5Sr1Ek+7X/AAL/AIvzIqT9tZQjc4m4doGWWJ2jlRgyspwVI6EHsa+yPB13eX3hTSLrU1KXs1rG8wIwdxUEnHbPXFed+DvgvYWE0V54knGo3SEMLdBiAH3zy/44HqDXrgGBgdK+d4izXD41QpUNeW+v6I7cFh50ryl16BRRWV4r1KfR/DWp6hZ2c99dW1u8kNrBG0jzSAfKoVQScnAr5c7zSjljk3iORHKHa205wfQ+9Pr5Z8JaN488B2niWBNG1RLrXNEku1ubTddEajGC247VxGzhzhT1KgDNaXjjw94zvfDPi7RzceJtWt7nRbK+iW5TcWuvM/exJhAPujJjHPSgD6NS8tpLuW0juIWuolVpIVcF0DdCV6gHBx9KztT0l7zxDouorKqpYeduQjl96BRj6Yrz3wsviabxVrx0iS8itm02xNld+INPkO9t0nmBwPLYvjHGRjIyKreJpPFMXjFI/EM/iM6cthF9kk8LWj+VJd7z5nmD5yvGzAkbZjOTmgD2OoPtlt9uFl9oh+2GPzhBvHmFM43beu3JxnpmvDdLufiJ/wAJYwjXW21Hz9R+2R3cWNMEARvsnksRtJLeX907vvbuK5fR7bxu2oXur6VbeKJPEn/CHyQyXOr2roFvjcxNJHCXULgDeUUcHHHegD6hor5/WTxvNE9vpM/i6PQ5tf02C3ub2BhfJbspF2zB0JEattIZhtHPavRPhEmuW1j4jsvEE+p3K2etXFvYXGoqfNltQqFG3EDeMl8MOO3agDvKKKKAPD/2l/J87wr9p3eR5k/mbeu3MWce+Kz/ABtaedo2vXEWo28GgQrCLC2t4IGgnhJTGx87hIDuzxn3INelfErwDD45XThPfyWf2MyEbIw+7ft9SMY2/rXD/wDCgLP/AKD9x/4DL/8AFV5VehVdSbjG6fnbpY++ynNcvp4PDwrVuWdO91yuW8+bTSydla+tk31MbxgtyL+MJ/Zg+HXmWm3yPJ/1W+Pdt/5ab87s98ZzxU+oprJ8daal+ulHwqdWiFiIhb7TFuOzbt+bG372eM/hWl/woCz/AOg/cf8AgMv/AMVR/wAKAs/+g/cf+Ay//FVm6Fdu/L+K+708jrjmmUxgo+3Wia/hy6pe9v8AHprLr2Q3WI9Bude8L3N6LO60lNSuorq7eKOIxOC3lwyKoxsDAcsTkemayNNXVz4ttB44/sjzPLuf7LD+R5fn7Rszt/5Z5+7u79Oa2f8AhQFn/wBB+4/8Bl/+Ko/4UBZ/9B+4/wDAZf8A4qm6Ndu/J+K8v8iYZjlMIcn1m+jV3CV1dyd12+KzstUktDk4rbWTro1Lxu+nxvp9s8qGTyiCzHbGJBEDxuJI4JwPTFPv9OsZNQ186cbSUatpy3FmqkAF9w3qmcYOQTjg4NbkHwU0qbWbzS08QXf2u1hiuJFNqANkpkCEHdzzE/5Vd/4UBZ/9B+4/8Bl/+KrxsTkeJr1nWUmr2VtHtZ911X3aeZ0/23ld1JYi2lrKElGyae3r57aHMhbOG9jtrT7GNet9Ct4YlbYQs4J8wDPymTaRirOm28Vt4jula8trzXm0XzNOa8iijKTl2+Rhkr5oHTJ/St3/AIUBZ/8AQfuP/AZf/iqo6Z8FdL1KbUIrfXrsNY3JtZd1qo+cIr8fNyMOKMJkeIw1ZVd7en4O+i627kSzfKmmvrL1X8j/AK5e8et3qcl8Q9Cvp9QgK3/2+aHTDezmeOKCWFA+CrhWIZhkdyefQVyl14a1K1tbq4mSERW0ENxIRMpISUgJgZ5PPI7d69m/4UBZ/wDQfuP/AAGX/wCKo/4UBZ/9B+4/8Bl/+Kr0p4KrNt8n4o78NxRl9CnGn9YTS/6dyXXy0XXp9/XxnVfDOpaVHeveJCq2k6W8u2ZWw7LuGMHkY7isWvoD/hQFn/0H7j/wGX/4qj/hQFn/ANB+4/8AAZf/AIqs5ZfWvpH8UdVLi/LFG1Std+UJL/M+f6K+gP8AhQFn/wBB+4/8Bl/+Ko/4UBZ/9B+4/wDAZf8A4ql/Z2I/l/FGn+uOU/8AP1/+Ay/yPn+ivoD/AIUBZ/8AQfuP/AZf/iqP+FAWf/QfuP8AwGX/AOKo/s7Efy/ig/1xyn/n6/8AwGX+R8/0V9Af8KAs/wDoP3H/AIDL/wDFUf8ACgLP/oP3H/gMv/xVH9nYj+X8UH+uOU/8/X/4DL/I+f6K+gP+FAWf/QfuP/AZf/iqP+FAWf8A0H7j/wABl/8AiqP7OxH8v4oP9ccp/wCfr/8AAZf5Hz/RX0B/woCz/wCg/cf+Ay//ABVH/CgLP/oP3H/gMv8A8VR/Z2I/l/FB/rjlP/P1/wDgMv8AI+f6K+gP+FAWf/QfuP8AwGX/AOKo/wCFAWf/AEH7j/wGX/4qj+zsR/L+KD/XHKf+fr/8Bl/kfP8ARX0B/wAKAs/+g/cf+Ay//FUf8KAs/wDoP3H/AIDL/wDFUf2diP5fxQf645T/AM/X/wCAy/yPJvh3Z21/4ge3u4Y599rN5cbjOXCkrgetdTo2g6etp4Wi1CwiGpPb3szW0y7GuJA/7pXHBxjOPpXYp8A7RGDJ4guVYHIItwCP/HqfL8CIJpfMl8R3kkn99oAT+e6uDEZHi603KMrL/gNd/P8AA8zFcRZbXqOUcS4r/DLe0l/7df5I4aTw1Nfan4bbUobC3t7gzT3HlWn2Uxxx7S6yDAGByAcd+pGKyPiRpdrBLp+p6ZDbRWd7Fho7aRXjSVOGAK5Hp+tepv8AA1HdmfxPfMzKUJMWSVPUfe6e1Rn4DW5iER8RXZiU5CeQMA+uN1KlkeNhOM3LRX06a38/T7vMmhxHl9OpCbxGkbq3JJKzbf8Al06eZ8+V6H8A/wDkpun/APXKb/0W1d7/AMKAs/8AoP3H/gMv/wAVW/4G+Elt4U8R2+rxatNcvErr5bQhQdykdcn1r1aGBrQqRk1on3RtmnFWWYjBVqNOpeUotL3Zbteh6fRRRXvn5IFFFFABRRRQAUUUUAFFeI/Dj42Xfi7UdIt5NI09E1G2up2NlfG4lsPJz/x8x7BsDkDbzzketaFt8WpxdeHWfT31Ky1LRptTkbTbV2l3JIF+VGbhcEk5OePfFAHrxAIwRkelQ/ZoN2fIiz67BXAXHxh8Kxwx3EDahd2Qtoby5ura1Z4rOKU4Rpj1XODwASMHir4+JmgyeLLnw/bi8nubV9lxPFEDFCdu75jnOAOSwBUetNNrYDthxwOKK87tPi94antbi5kTU7a3Sxk1KCS4tGQXdvGcM8X97GQcHBwQcYqpN8bPDMEV1Jc2Wvwpa+S85k02RRFDL9ydj2jPv83oKQHp9FcVrPxJ0TRvGNr4b1KK+hu7q4itYZzEPKeSQAqAd24jLAbtuAcjPBqz8MfE1z4t8LnU72GGGUXdzb7Is7cRysgPJPJCgmgDrKKKKACiis7xFrFr4f0K/wBX1AuLSyhaeTYMsQozgD1PQUAaNFeXT/GbSJodCfQtL1HV31a2lukihMUbQiJFeRX3uBuVW6AnocE0upfGrw3p+neD9RuIL9NO8SCQxTtGoFsEZFZpRngAuORnoT6UAeoUV57qPxV0ix8MazrT2d7Iun6u+irbRhTLdTrIE/djOCDkkZIOAa6zwlr9n4p8NabremFjaX0KzIG+8ueqn3ByD7g0Aa1FFFABRRRQAUUUUAFFFFABRRVDX9Xs9A0S+1bU5PKsrKFp5nAyQqjJwO59BQBzmorrGl+OtQ1Sw0OfVLS9020tswXEMZjeGW5Y5EjLkETr09DUeseM9W0jS7rUL/wdqaWttGZJGF3asQo68CXJqLw/8QJL60l1HXfDuo+HtE+yG+i1G/lh8to8rgMFclHIYEKRzg+lN8QeK/CfiXwFrj/8JBb2+nbPstxcMrB4GcDaDGwDZORgY57UAaf/AAkWv/8AQl6l/wCBtp/8dp/gW11CEa7dapYvYSX+otcxwPIkjKnlRIMlCR1Q96w9H+LPh29t9Xur2cWNnZah/Z8Mkm5mum8tXysYXfnBPGCRitbUfiR4P07TrG/vNfsktL6JpraQMW85FOGKgAkkE8jqOfQ0AdbRVXS9QtNV062v9NuI7mzuYxLDNGcq6kZBFWqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNPDnwa8PeHToj6Rearb3GlwzW3nrJHvu4ZXZzHP+7wwBY4wARxzwKd/wqHS4rXR4dP1zX9PbS9Pk0yKa2mhDvC7bmDExHnI6rit74r6hdaV8NfE1/p07295bafNLDKn3kYKSCK8cn1Hx3PoGv3nhqbxZNbPp+nGOW9tW843rXCecbdCgJi8okkgbevagD0S6+DXhqSH7NaT6pYafLawWd5Z2twFjvYofuCXKlieSCVKkgmreofCnQdS8XRa/qM17cywy+bFbP5QiQ7du0MIxJsx/AX2+1ch8RrXxXo99BZWuo+Mb/TY9Jnezu9OjEs8upGViouPKQARhSoGQEwDnpWVFpnjKw8d63qRj1oeI7/w7A1u0MW+xe9W2kDxyOFKKFflAxHzEdQaAOxm+E/hfTtKuIdT1jVDZNYyaTam8u49tjDKQCkJKDknaAX3HgCtPV/hVoeq2mt29xdakqatY2unzlJEBWO3OUK5Q4Y985HoBXlGnyePJPDV+sr+JLuZpdPY297psxeGQTqJirOuGBXJOzKjGQQK6GVPHH/CQvqi3niTbF41WxSx8o/Zm0ttm6UrsyUGW+fO0Y4wcmgDsdR+EuiX3ixtea/1aKZtSt9Va2jkj8priHG0nMZfHHK7scnGK6jwd4as/CejHTNOluJIPPmuN07KzbpHLsOABjLHHHT1ry74UXPjKT4g3qeIBr13p7Rzubq7jltYUO8bEMLpszjgGJiOuc9a9toAKKKKACqWuaemr6JqGmyu0cd5byW7OvVQ6lSR781dooA8ZvvgfHrdj4bsfFGtx6jaaJYTafEkVj5JaNokSNs+Y2HQoGzzk9gK2Lf4WNcweEoPEerxarBoVneWEiGy8oXcM8axgHDnaVVByM568HmvTqKAPF/D/wAC10yx0nTpvFF9Lp2n6jcamqwRGCZ5pFVYyZQ5wUAbkDnceldx8L/BZ8BaHdaNDqT3unfbJbizSSLa1tG5z5Rbcd+Dk7sDkniuwooAKKKKACiiigAooooAKKKKACsvxRodn4l8O6joupBzZ30LQSbDhgCOoPqOo+lalFAHl8vw01rUvCl34c8Q+MpdQ0prRLa2WPTo4XiZHjeOR23HzCvlgY4BBOeeaivPhPdagmp32o+I/M8SXl/Zagt9HYBIYntAREPI3ncMM2cvzkdMYr1WigDyW2+Euo2+ptraeKI/+EjXVJdTiuv7N/cqZYBDJGYfM5BA4O4Ee/Wr3h/4UxaNc6DNFqzzHTbW+gl8y3GbiS6be78NhADnCgHjHPc+mUUAc/4A8Of8Ij4N0nQftX2v7BCIfP8AL8vzOSc7cnHX1NdBRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBe2ltf2c1pfW8NzazKUlhmQOjqeoZTwR7GpYY0hiSKFFjiRQqoowFA6ADsKdRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcX4r+Iel+H75rFYbi+vUH7yO3AxHxkBmJxn2Gaic4wV5Ox0YbC1sVP2dGPMztKK820H4vaLqOqRWF/bXWmSyttSSfaYy3YFgePxGK9JpU6sKqvB3LxeAxGCkoYiDi3t5+j2CiiitDkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCnrN09lo99dxLukggklVfUqpIH6V4/4b07R30gX01w8upy6cL2aORss0jDe0mfQ7sY9c0fH/4jyaLEfDmhThdQmTN3Mn3oUI4UejMOfYfUEfP2nX0wKpCz+axwFX+I+1dGOyXGwwkMeqfNB30W6XSVuz/rc+i4ZxOFr1KmCnW9nN2afSVr3jf9OvyPdvEngWxnNx9oubmVjaSzQra2pJeRQrDYScSDBPAIPHajw38b9J0fwhptpqkV9e6tDF5UgiQYwpIUlmIySu3pnmvEtThvrcqb+2uYmf7vmxsu76ZqpDYNIS7jJNdvCGSRzGcsViIONK1lr8TuvwWvzfqb8aYyGDw1PBRrKrVvfZe6rNPbvdaeVz6As/2h9HecLeaLfwxZ+/HIkhH4HH869V8LeJ9H8U2P2vQ72O5jGA6jh4z6Mp5H+cV8ZCwXGNtWtFvtS8MarDqei3D29zEe33XHdWHcH0r7HG8LYOrD/ZW4S6Xd0/W+v9bH53SzCrF/vNUfbtFcn8N/Gln420Fby3AivIsJdW2cmJ/6qeoP9Qa6yvz6vQqYeo6VVWktz2YTU4qUdmFFFFZFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmeJtXh0Dw/qGq3PMVpC0pXP3iBwv1JwPxrTryv9pLU2sfhw1shw19dRwH/dGXP6oB+NdmXYb61iqdB7SaT9Ov4GVafs6cp9kfLWrahc6tqd1qF7IZLm5laWRj3YnJ/CvTvglpEUkV3qciK03meRGSPuAAFiPruH5V5NXvfwUgC+FYW/56TSP+uP6V9r4iV5YbJHSpu3PKMdO2rt+H3HFw9BVMbzS15U3/AF950/ifR473TJrSVQwkQ7c/wt2P5149BZAqOK961lNuyvGLdlLH618Z4f16lNYmgn7qcWl5u9/vsvuPW4ghGXsqnV3X3W/zKbadxnFULu3wCCK6sspi6CsDU2XJxX6PQrSlKzPm5xSRb+EPiFvDHxBs1Z8WWosLOde3zH5G/Bsc+hNfWlfCWqzGOZHiYq6sGUjsR3r7k0y5+26baXWAPPhSXj/aUH+tfO8X4ZRnSxC3kmn8rW/P8Dty2pdSh2LNFFFfGHphRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheMPFui+DrC3vfEV21rb3FwtrEVgkmLysGKqFjVjkhW7dq3a4n4r+HLnxNotjb2uj6bqzW12LkQX15NahGCOqujxAncC3Q8cnuBQBp6Z4z0fVbrR4NPkuZn1WKee33W0kZEcLBXZ1cBkG5gBkc5445ro65L4X+G9R8NeDdMsPEF8upavbxukl1lnIVnLCNXb5iqggDPp0HSutoAKKKKACvDP2q2YaHoKjOw3MhP12jH8zXudeUftJ6Q2ofD37XGMvp9ykzf7jZQ/qyn8K9jh+pGnmVGUu9vvVv1ObGRcqEkj5r0bw7farAbiIwQWocR+fcyiNC56KCep9hXvfw405dE0saZLd20t1ZZe5Ebj91vJYbh1Ax3OM4rzt7GTW/hJp8Ohwi5ubO6inkgVgHYpLuYDPGSDkZqzeW3iG5T4g3+laZcWs3id7KwtFuSFeJFjMcssgUnauCcHr7V5fFWf4jNcRUwVdqFOnN2XW8Xyptt9U29NPU9LLMDDCU41qacpSitemurt80kevale2dzpv9oW97ay2QBJuElVowB1+YHHFeKm3dluLvTJ7bUdPR2/f2cyzKo687TxxVb/hFfEdl4X1zw0NMilsIdSt9VtraG4Lw3EO7MtsHcL0wpwQOc9a9F0a+sms7+9/4R5/D1sMbxcRxRtIAvJKoTwOgz1rxctzepktWVXC2nz2Tj3ttazvfV9/Q66+EWOioVbx5b6/100POZNUHl8NWLfX4YH5qw5r1mdtmQmTtB9KqvKz9TX9BUcEo6nwUqt9B91N50me1fdPhRSnhfR0bhls4Qf8AvgV8MafaSX2oW1nAMy3EqxIP9piAP5198QRLBBHFGMJGoVR7AYr5PjeSUaNNf3n+R6OVJtyfoSUUUV+fnsBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcj4t+IOi+FNSgtNZTUY45DGGu0spXtoS7bVDygbQSR0zmuury74teDPFHjO6tLXTpdEtbC3mingvpZJ/tVs6srMViAMcmdoxu6ZPfmgDvNF1211i91a3s0m/4ltz9klldQEeTYrMEOcnG4AnA5yO1atIiKmdihcnJwMZPrS0AFFFFABXhH7Tc2r6TL4Z1HRfEet6ab6+i0ya3tLny4dh3sXC4z5nOM5xgDivd683+Knwxf4g32nyT+I77T7WxKSxWsEMbKJlLYlyRnOGAx04oAz/EnjXWvCfi7QPAugaW3iG+utOaZLvUL8RyMU3DMjbcHhMkjGc9K4zxF8VX8RfCKPWdR0m6tLy18QJpdxb2eovBiRV3FhIoyVww+U9+9eoxfD5W8b+HvFN9rF1d6lpNg1iS8aKLjcGBkbHQ/OeBxXOSfBDTn8HXnh46vdiG51w64ZfLXcHKhdmPTjr1oAxvDni3xxcftB+LdEW1hutJtZLdWtpLzatpbsE/fJ8vzMyHeV4wSRnvUHgbx/cWfwqudY0uKyhb+25bRz4g1pvLQBM7hIwyeQoEYHcn1rubn4bzx/FC48ZaL4ju9OkvhAuo2Yt45UuUi2jaGblAVQAkc9cHmucf4DWMfh3TtPsdevLe80/VZNVtrtreOQK77cq0bfKwGwYz+tAHN3Hxm1nxR8LfHNxpFpbWmsaF5Qe7s7vfEY5C2JYyVySNh4Pr17B154w14+BPhxeeK9OlEl/qGnx29xZ6q8bXKvED50oVec9TGeOetdvpfwes7ax8a2+oa3qGoSeKo41u55EjR0ZA/zLtAXq+cYxwBVeL4P3E2g+HtK1nxXeahBoN9b3difskcXlxwrtWI46j/AGiSelAGbq/xg15pPFOo+G/DFrfeHfDNw1tezz3vlSzMh/eGJdpACjnnqOnpV7WPi1qM3iLwxpPhHQItUk1/Sv7Tt2uLv7P5YIY4b5T0C8/lS638F1u73Xk0nxTqek6Jr832jVNNhijdZXJy2x2GY93fGc9DkYFdFB8NdNtPGfhvX7K4mgXQtOOmW9oAChj2soJbrnDfpQAfBvx3N4/8L3WoXmnDTr2zvZLC4hWTevmIFJKn0w4/EGu7rkfhr4HtvAmm6pZ2l5Ndrf6jLqLNKoUozhQVGOw2D8666gAooooAKKKKACiiigAooooAKKKKACiiigDyf48eL9b8K/2H/YV4Lb7T5/m5iR923y9v3gcfePT1riLfxX8T5tMhvv7StoorhDJAk4tIpJlHVkRgGYfQc9s1sftRf8yz/wBvX/tKuXh8Y+Gb2ztrjW7Gaa+t9LXTvs5tUljLICI5EcsCnXJGD7dOfFxFR+3nFzaWnW3Q/TsnwdN5TQqxw8ZyfNduCk/idu3330t81oR+K/ii+ijVTfwx2jQtcIJUtUkkjUZZ1QgMQAM8D6U658UfFO20tL+4voYo2RZRG6Wol2MQAxjI3YyR2rl/EGt+HfEWlWFxftqdvq9lpy2KwQxo0MjICEbcWyoyeRg+3rUvi7XvDniK/bXmbVIdYlSHfarEhgV0CqSH3Z27V6YzmsHVdnab/wDAv6+49OGAg5RUsLBJt3/dXtqrLfW6u+bZW21Oj1vxP8VtEgMuo3CqglEB8qO1mKyEZCkICQT2zVfxNqnxLl0x9P1ieGeK+ItJLRFtnlzIPlVkUblJ7HjHsal8UfEnSdTaaaxt5ree31SDUIAIlVbwIF+WbBzkEHB5GMfWseXxN4bsfGcXirSv7VnvZL03UtrcRoqRq+fMAYMST83y8DHetHW5JXhVenW+3mYUcHKdNe1wVNSs9PZrV2Vlvpe71d+2jVjnrjw14g8K3EBjb7PPcSi322t4jnzP7jhGODz0Nar3Xji31WTS3llW9iiMzRsYj8gGSd3Q8e9Lb6j4R0vxDHq2nyatdvG8lwkVzCiKGwdikhiSdxyW9uhq2njXSpLvS72a2uknitpbG4AYSHymHysGONxGTwcda8fNswxtau3K9TTeT5temt9tPxWp008HGjFKjhIWs9qaj72ttL3tpbzutUZsWoeM7tNNaGeeQakXW12eXmTYcNwOmPU49aq6npHibV7y1sJ5m1KW5kMcUUF2kq715IIVsKQOcnGK07Xxdp2lvoNrax3V1Y6fFcRTSsgjkkExySq5OMdsnn261Y0jxboGhX+kSWNnLOkMc0F3MtukEkkbrtBGGOXA5ycZ9s8Z4HHYuliYON4K71V00ruzvfTRL7/uqvhOdNfVISTUrJwWusrXvtoo6Pdvp04vXPC1zoqxveC0eN2ZA1tdxzgMvVTsY4Iz3rI+zxf3f1NegaxqHg67t9EsYY7tIrYSi6vYbOOGWUbf3QI3NuIIG4nrkmufhj0A2sZmn1EXH2SUuFRdouM/u1H+wR1PWvpJ53mafu4qf/gcv8y8Nk+WSpp1sFC//XpLq7aWfRfiu5laVPJpWpW1/YkR3VtIJYnKhtrA5Bwcg813H/C3vG3/AEGF/wDAWH/4iucmj0AWshhn1E3H2SIoGRdpuM/vFP8AsAdD1rFrhxGY4yu061aUn5yb/NnoUMmyuz5MLCP/AG5Ffod7/wALe8bf9Bhf/AWH/wCIo/4W942/6DC/+AsP/wARXBUVz/Wa387+9m39i5d/0Dw/8Bj/AJHe/wDC3vG3/QYX/wABYf8A4ij/AIW942/6DC/+AsP/AMRXBUUfWa387+9h/YuXf9A8P/AY/wCR3v8Awt7xt/0GF/8AAWH/AOIo/wCFveNv+gwv/gLD/wDEVwVFH1mt/O/vYf2Ll3/QPD/wGP8Akd7/AMLe8bf9Bhf/AAFh/wDiKP8Ahb3jb/oML/4Cw/8AxFcFRR9Zrfzv72H9i5d/0Dw/8Bj/AJHe/wDC3vG3/QYX/wABYf8A4ij/AIW942/6DC/+AsP/AMRXBUUfWa387+9h/YuXf9A8P/AY/wCR3v8Awt7xt/0GF/8AAWH/AOIo/wCFveNv+gwv/gLD/wDEVwVFH1mt/O/vYf2Ll3/QPD/wGP8Akd7/AMLe8bf9Bhf/AAFh/wDiKP8Ahb3jb/oML/4Cw/8AxFcFRR9Zrfzv72H9i5d/0Dw/8Bj/AJHo2n/E/wAf6jci3stSM0xBYItpDnAGT/B6VNB8RviNPHaPDeySLduyQFbOE+Yy9QPk7VyXgbVrfRfElveXof7PteNygyVDKVzjvjNdLpvijSdFTQrKKaa7htBcie5jjKFfN4BQHnIrgxGYY2nNxp3enn2l+qX3nm4vL8PSm40sHCWl17i7Svra26j95c1P4g/EjTGiF7fGMysUTFtA2WHUcKeeRxUGqfEv4haVdG21HUGt5wA2x7SEHB6H7lVLa+8K2V3ociOJXsmea4kihkUXDKB5QKsThiRk9utUfG+uad4h0/TrmA3CajAXhlSc72eMncrbgAOCSMY70qWZYyU4xfNZ3u9V3tpd9vxWxFHA4adSEZYOPK73fs0tdbaa6afiti7/AMLe8bf9Bhf/AAFh/wDiK7T4RfELxN4h8b2un6vqIntHjkZk8iNMkKSOVUGvDq9F+AP/ACUux/64zf8AoBr1sPXqyqxTk911LznKcDTwFecKEE1GVmoq609D6pooor6U/EwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdY0LSta8n+19Otb3yc+X58QfZnGcZ6ZwPyrO/4Qbwr/ANC7pX/gMn+FdHRUOnFu7R0QxdenHlhNpdk2c5/wg3hX/oXdK/8AAZP8KP8AhBvCv/Qu6V/4DJ/hXR0UvZQ/lX3F/X8V/wA/Zfe/8znP+EG8K/8AQu6V/wCAyf4Vxfxe0zw/4U8DXuoaf4c0r7YzLBC5tEIjZj94jHYZx74r1eszxJoll4j0S60rVIy9pcrtYKcEEHIIPYggGunBxw9OvCdaCcU1dW6GdXHYxwajVlf/ABM+FYZHeUbnPNdLptvHIBvRW+orq/GfwW8Q6BcPPo0baxp+SVMI/fIPRk6n/gOfwrj7d7ixmMN1DJDKnDJIpVh9Qa/VlSy3G0+fDRg/RK/zVro+f+v4+lK1SrNf9vP/ADOtsdJs3A3W0J+qitObQbFYtwtLf/vgVzNtrXlAZq4/iTKYJryamURctKcfuR0xzbE21rS/8Cf+ZBqOn20edsEQ+iiuW1FAmdgC/Sti+1kS5xWZbafqeu3PkaTYXN5KT92GMtj646fjXqYbLcNTXNVpxSXdI56maYyTtGtL/wACf+ZnaNqj6ZqkF2YYLtYmy0FygkjkHdSD/PqK+xtL8I+E9Q020vE8N6Yi3EKTBWtUyoZQcHj3ryP4cfAu5a5iv/GZWKFCGWwjcMzn/pow4A9gST6ivohVCqFUAKBgADpXxvFNXLa9SEMJGN43u0lbyXmell+Lx8Yt1Kste8n/AJnO/wDCDeFf+hd0r/wGT/Cj/hBvCv8A0Lulf+Ayf4V0dFfKeyh/KvuPR+v4r/n7L73/AJnOf8IN4V/6F3Sv/AZP8KP+EG8K/wDQu6V/4DJ/hXR0Ueyh/KvuD6/iv+fsvvf+Zzn/AAg3hX/oXdK/8Bk/wo/4Qbwr/wBC7pX/AIDJ/hXR0Ueyh/KvuD6/iv8An7L73/mc5/wg3hX/AKF3Sv8AwGT/AAo/4Qbwr/0Lulf+Ayf4V0dFHsofyr7g+v4r/n7L73/mc5/wg3hX/oXdK/8AAZP8KP8AhBvCv/Qu6V/4DJ/hXR0Ueyh/KvuD6/iv+fsvvf8Amc5/wg3hX/oXdK/8Bk/wo/4Qbwr/ANC7pX/gMn+FdHRR7KH8q+4Pr+K/5+y+9/5nOf8ACDeFf+hd0r/wGT/Cj/hBvCv/AELulf8AgMn+FdHRR7KH8q+4Pr+K/wCfsvvf+Zzn/CDeFf8AoXdK/wDAZP8ACj/hBvCv/Qu6V/4DJ/hXR0Ueyh/KvuD6/iv+fsvvf+Zzn/CDeFf+hd0r/wABk/wo/wCEG8K/9C7pX/gMn+FdHRR7KH8q+4Pr+K/5+y+9/wCZzn/CDeFf+hd0r/wGT/CrWmeFtB0u7W603R7C1uVBAlhgVWAPB5ArZopqnBapImWNxE04yqSafmwoooqzmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqte2FnfKFvrS3uVHQTRhwPzFWaKak4u6Bq5ztz4I8L3JJl0HTcnrst1T+QFVh8O/CQORoVn+IJ/rXV0V0LG4hKyqS+9keyg/sowbbwd4bth+50HS1PqbVCfzIzW1BDFbxLHBGkUa9FRQoH4CpKKynVqVPjk36saio7IKKKKzKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8u8XfFddPupLfQNNOpCI4e5Z9sWe4XAJb68D0zXY/EC5ntPBGuT2pImS0kIK9V+U5I+gya8zsLzwo3hsQrLax3K6ZCWO8FRJtQsRzy+XIK9RsNcmJqyT5Iux9FkuCo1IvEV6bqK9rK/lq7a9dPmX/Bvxps9U1OPT9eshpssjbUnWTdFu7BsgFfrz+Feu1826voXg23ur5YbyO8aTT52g36jAo81Xj2lWHQsrNhXGflI5JyOMHxP8dxWIsodTuPs6fKr4i37e3zkbv1zXZkmEr5hOVFyV1rezf/pKY+J8Ng8LCGKwkHGMnZp97Xuru/dP8D6g8UeL7DQZBbsr3V6wyIIv4R6se386wLP4nW/2tYtT06S0iY481JPM2/UYB/KuL8CQRa1ZS3Op3M0l9B5dxcTSylmeAL8/J7jA5963F8L2979gvJ2c29w3MRXbw0bspVwxzjb7GuCpUq875Hpf9T4B4rE1Xz0mku3+Z6xbzxXMEc1vIskUgDK6nIYHuKkrg/g3cSzeGJopCTHBcMsZPYEAkfmSfxrvK6qU/aQUu562Hq+2pxqdwooorQ2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqO5mjtreWeZgsUSl3Y9gBkmhK+iA8J/aP8ZSxtD4V02YoZFE18ynnafuR59/vH22+9eNWGn6hefu7KGWZsZKxgnFO1PUJvEHiK/1W5yZbudpcHnaCeF+gGB+Fe3fDbSI10O2AUBpAZHOOTk8fpivo+LsFhMuymjSnT5qt7Jp2d2rtt2d1pa3odfC2c4zC4ypUoSXI1qmrppbdVrrv6nijaLeQTbb6CSA9drjBNT/ZAO1ezePNPifTZPlG+IhlOPfBrzeSz+XIFXwPVwywUp0ocs72ld3u1qu2muwuLcyxmY4mLxEk4pXikrJX36vXTe47SGdo0g2szjhdoyT7Va1Vn0yHzLyGZAfugoeT6Zrp/h5YIYpZmA3s+wHHQAD/AB/Suo8WaTDcafNaFQwljIGezdj+dfHZ3icHTziS5H7JSSnZ21e7Wmlvx6WPKocNQxFFVeZqUk2l0/pnmnwk+ItzofjD7LqcmNH1KRY2UniB+iuP0De3PavqWvhPVLfaTxX2B8K9ZfXvh9ot/M5ecweVKxPJdCUJPuSufxr73ijK6OHp08Rh48q+FpeS0/BfgcuW1Wr0n02Osooor409UKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisfxd4j03wl4eu9b1yZoNOtdnmyKhcjc6oOByfmYUAbFFclZePdKvYtNe3t9U3ahf/2dDFNZPBJvEZkZysgU7AoJLDPpya62gAooooAK5P4sXbWXw48QzKcE2jRZ/wB/5P8A2ausrjPjJA9x8MfECRjLC38w/RWVj+gNdeXpPF0lLbmj+aM638OVuzPlDSFGRX0f4LHkadaLjpAg/wDHRXgXgvR7vWrny7RPkTHmSHoo/wAfavo3QbXyIFVhjaAort8RMXTqV6GGhK8ottrtorX9TTh+lKNOpVktHZLz7mH4xO6yuc/3f61582PKOa9P8S2DTQSop++pAPoa8vlsb3+0BZCFjMeQB0I9c+lcXBWKo0qNelVmoyUubV20stfRW1Nc6pTnKnOCurW+d9jtfAyAWEOO7sf1rpddGHT6VmeFLD7HaRxM6O8WQ+09CTnFbeqRGePPcV8Rmk1ia+Iqwd1Kba81fT8D3MKvZRpxl0ST9T5i1lRuavo/9naQv8M7ZT0juZlH/fWf614J430qbS7pi217aRj5UqHKn29jXv37PMez4Y2TD/lpPM3/AI+R/Sv2rPMVSxeTwr0ZXjKSs/k/x7nxGGpTpYpwmrNI9Kooor4E9YKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorH8U6zLoWl/a4NKvtVk3hBBZ7Nw4J3EuyqFGOue4oA2KK4nwv8Q7TxPZeG7vSNNv2h1lrgEyoF+zLDkOzkEjG4BRg87h7121ABRRRQAVWbULNWKtd24YHBBlXIP51Zr408DeDLnxR4u8bSw+D9H1+GLXJkkmvr6SBoQZGOFCEZ9eaAPsFdRsn1F9PW8tmv0j81rYSqZVTIG4rnIGSOferVfOninX5PC37QHjnXLeATzWPg4zRxtnazCWHGcc4zjPtmptI8a+N9Eu/hvqeueILTWtP8YSxxSWCWUcRtPNClTG68tt3jduz098gA+haK+XNX+IXxEbwn438TWXiSzt7Tw3rbWaWZ02N2njMqIFZz0A3joMnnnpXWy+MfF/i34j6jomha1b+HbHSNJg1GU/Y0uXunkjSTHz9EG/GRg8e/AB7tRXzdpHxO13Vvhh4TurjxLd2fiXVbm5RItN0eK8uLpY3IAWNsIgAxknr+ZHMeKvFvijxd8AfHlv4gvv9J0LV4bad5bJIprmITKojkRGKxuH2sSpP3dvOd1AH1dd6jZWc9tDeXltBNctsgSWVUaVvRQT8x5HAq1XzzqlxrmgXPwitNY1DTtbk1DUV2TzaTCj20JSDakZO4qwO471IJyPQVm3PxF8eah4M8T/EDT9esbHTtI1I2sWhSWKOskaui/vJD84c+YOAR04xngA+mKK8L1Txd4y8S/FCy8O+GNZg0K0vfDseqhp7FLl4XY9BnHPIHOQOeCa6z9nzxfqnjb4Z2Wra68cuoCaWCSVECeZtbhio4BwR044oA9IooooAKKKKACiiigAooooAKKKKACuc+Ieiz+IfCd3pltZ6XfPM0ZNtqbSLBIFkVsMY/mH3cjg8gZBFdHRQBwfwi8Hah4Q0K8t9Zubaae4vZbqK3tnkkgskYACKJpPmI4J5x16eveV4R+0VrOp6ZrWkJpuo3tmj27llt52jDHd1OCM1xmoReJdMs0bU/Gz2moPbfalsJL6483Zt3AEgFQ5HRScnI9a4KmO5JuHLex9ZguFZYrDU8Q6yjz3srNvR2e34vZH1VRXytqFt4p06wSS+8ZSQ6jJCs66a2oTeeVb7o4+Xcc525zUuo2HimwuIrKfxv/xNmkiiexGpTmSNpCAATjaSNwyATgetT9ff8j+9G64Ri7WxMdf7r6dfTVa7eZ9SVBqFpDf2NzZ3K7oLiNopF9VYYI/I18y6to3jmwaBYfE1xftLf/2Zi11CclLjGdjbwvbv0psmn+K31a30vTfGp1HUJJjBJDb6jPmFgCWZi2AVAU5IzTWYSi7qDuSuE6co3WKjazez2W7fZepiWsb+C/Gvh2LUpJYLXSr+/h1GRQ20b4VEDMB/C2MqTVU3+sah4E07w/bx6w9xquo3d/I8B2zraKx2Y3suAzFepHCn1FWdQ0nUJvENgtl4kttY1G9cwfaILmRnjK4++zANtwcgjIIBx0qxLYeKYdU1OwbWZfM0+za9dxdSFJIwAfkOOSdw6471wZrnUKmLlV2lL3mm/Xt0u9PKy6XOuhwioUlTeIW3Zp2ulez9LepXl8RHW9O8FnxouoJoVrHPaaokfmAfbIwFQzbOcEYYdsk+9dZdvbT+BLyz8GyzJdSWM32ASs4m2knABf5hn+HPPSuattP8UXTafs1mUJeWzXfmNdyBYYlOGZz2x7ZqrYeHb3V9YSHS9btLsmN55boyyItuiY3PJuUMByOQDmuCni6OJqKLbur2UdVe7328+uqRuuGlSTtXi+7s9EtHr02di/De6TYeBLi18G+E9VsvFF1YppryyWckQ8yRlV97twWHzNu5xjqM1m21lr+m/D7xR4Qg0zUYora7iu4IUffJLZyMDLCjpwzDBJAOTuI9q1LPTdZvJ5YtF8Ww30cVrNdsyXE67VixuBVlBBOeOMHnmlsdF8XX66K8Gsvs1SGWdGa7kVYY4zh2kOMAD2zXX7evsop9e/b+vmZPhelHWWIS9U10b2fkm/kVPEs3hiLwlejw7o1xpQmlhAWa1e3ErDdyqt1KjILAfxDk19K/DTSG0HwHomnSqUmjt1aVT1V3+dh+bGvl6+0SfUda0y3stdtdaurybyI5EeXdEwK8tvUEL82QRkcH0roptL8cxeK5NCfxHdebFB9qe6/tGUW6w7QTJuPO0Zx0617NHNvZZfHBRg37zk3e+rSSS9Ectbg9Tr+1liIx93RcrTsnq2n5n1LRXyzbWvia8vZksfHBuLCCD7TcXw1CcRQLnGGBG7cT0AHPFYGta5r2m3vkQ+Lby/jKh1ntb6YqQe3OCD6giuaWZKKu4fii6XBcq0uSGITf+GX49n5PU+xaK+K/+Es8Rf8AQf1b/wADJP8AGj/hLPEX/Qf1b/wMk/xqP7Wj/KdX/EP6/wDz+X3M+1KK+K/+Es8Rf9B/Vv8AwMk/xo/4SzxF/wBB/Vv/AAMk/wAaP7Wj/KH/ABD+v/z+X3M+1KK+K/8AhLPEX/Qf1b/wMk/xo/4SzxF/0H9W/wDAyT/Gj+1o/wAof8Q/r/8AP5fcz7Uor4r/AOEs8Rf9B/Vv/AyT/Gj/AISzxF/0H9W/8DJP8aP7Wj/KH/EP6/8Az+X3M+1KK+K/+Es8Rf8AQf1b/wADJP8AGj/hLPEX/Qf1b/wMk/xo/taP8of8Q/r/APP5fcz7Uor4r/4SzxF/0H9W/wDAyT/Gj/hLPEX/AEH9W/8AAyT/ABo/taP8of8AEP6//P5fcz7Uor4+0PU/FGsf2h5HiPU0+x2cl4++9l+ZUxkDB681qWkPi64Syk/4Se+jt7i0e9eV72YLDEpwS3PX2GawqZ/Qpu0tP6uc1Tgt0m1PERTXk+1/yPq2ivkaK+8QXmsWNhpPi+/vTdtsDrdTp5fqWB5AA5yM8VX8Rap4p0LVZLG58RalIyqrrJHeylJFYAgqc8jmqjnlGUlBLVq9utio8ETlNU1XXM1e1mnbbZn2DWB420rU9a0Q2ekXen27u+J01CyF3BPEVIaNk3Lwcg5z/DjvXyV/wlniL/oP6t/4GSf416X8ANc1bUfHE0Ooapf3UIspGEc9w7rncnOCcZ5NdNLMo1JqCjuZY/gutgsNPEyqpqKvazPYPhn4Uk8F+ELTRZtQfUHhZ3MpTy1XcxbYiZO1BnAGa6miivSPigooooAK8y1H4E/DjUdQub288OeZdXMrTSv9uuRudiSxwJMDknpXptFAHPy+DtAm8R32vTackuqXtkdOuZZHdlltyQTGUJ2YO0ds1ieGvhL4M8N6zDqmlaSVu7fd9m824llS33Zz5auxC5z2Fd3RQByD/Dbwm+ha1ozaTnTdZuvtl/D9pl/fTblfdu35X5lU4UgcdK4X4o/CS98Ta7bXWjWnhgW8Nkloj6glz58QXI6xuFkGCMCQMOOc5r2migDyzQPgn4btvBHh/QdcSTUp9IaSWK8jlkt3DyNufaUYEKeBjPYd66Cy+GHg+y0HWdFttFRNM1d/MvYDPKwkbOQQSxKkHBG3GCBXZ0UAcPpXwr8I6ZFpSQafPJ/ZV2b2zaa8mcwylUXIy/IxGg2nIGOnJqvqXwd8Dalrk2q3miK88832ieITyLBNLnO94g2wnJOeOcnOcmvQKKAMQeFdGHi0eJhZAa2LX7ELkSP/AKnOduzO3r3xn3pfCHhbR/B+jLpPhyz+x6ertIIvNeTDN1OXJP61tUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfPP7Tn/Id0X/AK9n/wDQq56T4kQz6dqP2nSpH1O+086fPILgeS/ybVm2FCQ4HHDY6/h9SPFHIQZI0bH94Zpv2aD/AJ4xf98CvPqYKcqkpxna/kfX4TiXD0sJSw1bD83JfXma3d+i9PuPkzW/F+nawkV/d6PKPEUcMcQu0usRFkwFkMe372AOM4qTVvGGjajrMWtnQZotZM8M80i3hMW5GUsVTbwWC45JAzX1f9mg/wCeMX/fAo+zQf8APGL/AL4FQ8BN7z/BHVHizCxso4Zq10v3ktnbTbbRabHzFrXxSk1Oe0u2sWW+0/UWvLN/N+URseYpFx83HG7g4/HOdD400nTfEcGtaHoMlvdmZ5bhZ7wyI6OrB41G0YB3ZycngV9XfZoP+eMX/fAri/jFcT6V8N9au9KjEd0qKokjUBkVnVWYehwTz261vQyutia0KSqK8mldrq3a5j/rVgaFNqOEajZqyqPVPdbbbv1b7nz7b+JdC0q/N5oOgzQTiGVFNzdmYBnwBxtHCgMPU7uTxUv/AAnMUklvJcaYm46fJpl0IZNgeFiNuzIO0qB3zmvNoyWkyxJJ6k1v6XgMM19Fi/CqnOTqzxF3/ha/KX9PXc4V4g4SbvLCNvu6rb+9xv1OkXxokN5apb6eTpkNi+ntbyzZeWJ+Wy4AwScdBV2L4gRW13aiHTHlsVsprC5jnnG+4hkxkblUbSNowcHpUdj5ZUZC/lWiyW2zqua82Hh5Tw9WNSFb3l/dfn/e13Zs+OMHNa4P/wAqPrf+7vq9d/uQx/iRbre6f5GlTNZW9lPYTCa5UzTRy4ydyoACMADg8VVj+IKWd3pMen6Yf7JsLSWyNvcT7pJ45Tl9zqoAPTGBxjv0qC7WLB+7XO6jJEobGK9elwRWqv8A3j/yT/7byMXxvgIK31J9f+Xj63/u7+89d1fQ7YfEiyt5tJkstHlMmk21xFaSXNwrt5ku0Kz7UXIRQQB1II5yOYk+JUbNpz3GiwM0VhNpd3HFIY0ntXI2ovUptx1yepryxLqa1vUuLSV4Zo23I6HBUjuDX3B4VaS+8MaTd6jaxx3s9pFJMhjAw5QFuO3PauLOuFK+VRhN11JS/u22t5svC8Y4DENr6m1b/p4+t79O8m/XVbHzDp3izRdMlvrSz0Kc6Lf2wguoJbzMrsG3LIH24Uj0xg96x72+0CRbxbTRriHd5It2e7LlNpPmFuACWBA6DGK+y/s0H/PGL/vgUfZoP+eMX/fAr5x5dJqzmvuR6sOMqFOTnHDyu7X/AHktbW301elvTTY+NZr/AMPtOWi0WdI/tyTbTdE/6MB80OcdSed3UVS1K50ya1RLCwktpxPK7SNMXBjJ+RMeqjPPevtf7NB/zxi/74FH2aD/AJ4xf98Ck8sb+0vuNocc04NNUJaf9PG/0Phaivun7NB/zxi/74FH2aD/AJ4xf98Co/sl/wA/4f8ABN/+Igx/6B//ACb/AO1Phaivun7NB/zxi/74FH2aD/njF/3wKP7Jf8/4f8EP+Igx/wCgf/yb/wC1Phaivun7NB/zxi/74FH2aD/njF/3wKP7Jf8AP+H/AAQ/4iDH/oH/APJv/tT4Wor7p+zQf88Yv++BR9mg/wCeMX/fAo/sl/z/AIf8EP8AiIMf+gf/AMm/+1Phaivun7NB/wA8Yv8AvgUfZoP+eMX/AHwKP7Jf8/4f8EP+Igx/6B//ACb/AO1Pi7wzrR0S7uXa3Fzb3VtJaTxb9haN8Zw3ODwOcGtgeNfLuII4tOQaXHZNYNavKWZ42OSS+B82ccgcV9c/ZoP+eMX/AHwKPs0H/PGL/vgVzVOHqVSXPN3fz/z389zkq8Z4atNznhbt/wB9/wCW/nufJ83j7dewXUenFpbaze1t2uLjzSpY8ux2jccZGOOtYnibxB/b8Gm+dZxwXVpCYGkiOFkQH5AFx8u0ZHU/hX2X9mg/54xf98Cj7NB/zxi/74FKnw5RpSUoOzXr5+fmTS4wwtGSnTwtmtvffn5eb+eu58LV6p+zh/yP8/8A14Sf+hpX0r9mg/54xf8AfApUhijbMcaKfUKBXdRy32U1Pm28v+CGY8bLG4WphvYW5la/Ne3/AJKSUUUV6p8EFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFR3EMVzBJBcRpLDIpR0cZVlIwQR3FSUUJ21QHg3jP4CJNdvdeEryO3ViWNpdE7V9kcAnHsQfrXn158PfFWjORdaNdOq/x26+cuPXK5x+NfXVFfS4binG0oqFS00u+/3/AOdzhnl9KTvHQ+N3+1Wp2TRyRsOzqVP61C97L6mvs1lDLhgCPQioha24ORBFn/cFdceKo/ao/j/wDN5e+kvwPjNVvr5ttrbTzse0UZY/pWzpfwx8Ya26iPSZbWJusl4fJC++D835A19cgADAGBRSnxdVStRpJerv/kCy6P2pXPG/h98ELHRLyPUPEc8epXcbBo4EUiFCO5zy5+oA9jXslFFfOY3H4jHVPaYiV3+C9EdtKjCiuWCsFFFFcZqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF9dRWVpLcTkiOMZOOp9q5j/AITB1l3PYH7OehD/ADY/LH4VteJrSS90W4hhGZQA6j1IIOP0rjtPMV1Z+W/3q8HM8ViKdeNOlLlVr7LV9tfkergqFGdJzmru9vRHe2N3DfWyT2zh42/MH0PoasV57pV7JoOoZck2kpxKvX/gQ9x/Ku/ikSWNZI2DowyrA5BFd2X4761C0tJrdfr6HLi8N7CV46xezH0UUV6ByDJZEiieSVlSNAWZmOAoHUk15T4h+Lc0TOfD+j/a7VCR9pnkKB8d1UDOPckfSt/42XM9r8NtVe2JBby43I7I0ihvzBx+NcbdX3g57C8srW8t7Z0lgiZy+VhDOFLKSfmGMsfT2rixNWSlyRdtL/n/AJH0+S5fRnSWJr03UTly2V7K3Ldu2v2lb09DZ8BfGCw8R6nDpepWbadfTHZEwffHI3Zc4BBPYc/WvU6+X9V8PeHdMs9cls737RqMMMVzZsL2INGwkYMV2nD8BTjGcHjsT7DD8S7BdPAvtP1yz1HyCypd6TcRRySBc4EmzYBkdSwpYStOSaq7r+v0J4kwODwrjXwacYO90+6Sd1fW2tvVM6zV9e0vR9o1K9igZhkISSxHrtGTim6P4h0rWGK6bfRTOOSnKtj12nBrzGw0oatbf2xf3AuHuY2ld3GMOG27PzIx7Vl3ugX2iy3Wpxym1e0RLiApht+ZAnUHjGfxoeJqL3uXQ+Clj6yfPye7+NvyPd6z9W1nTtIQPqV5Fb7vuhjlm+ijk1y9r8TvCY02F7/xFo8GoeWPNszeRiVZMcpszuzntiuUsYIdft73WtTuC1zuG9DHkLnO1VOenH/669bDUlVXPL4f8z6nLcHDFp1ajagrbbu+x6XpHiXR9Xl8rTr+KWX/AJ5nKsfoGAJrYrwrWvCt/p+sO2mugWEu6ziZU27NpYnn5SNw61654Q1OTV/DtneT7TMylZCvQsrFSR9cZ/GtMTh4U4qdN3TOjMstpYenGvh580H33X9WZs0UUVxnjBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVw/inT207UBewLi2nPzgdEf8A+v8AzzXcVmeJXjj0G9aZQy+WQAfU8D9SK8/M8PGth5Nuzjqn2sdeCrSp1UlrfSxzEixXdkCcZrPSO/tUKW91PFF12pIQP0p+nT7YAp60XFxJPIltao0sznAVepr5ac4Tip7S8tz3IxlFuPTzN/whq89zLLZXjmSWNd6OepXOCD+YrqKw/DWh/wBlq89wwe7lGGI6KPQVuV9VlsK0MPFV9/xt0ueFjJU5Vm6WxU1XT7bVdNubC+jEtrcRmORT3B/r7181eKfg14j02/kGjwDU7EnMciOquB6MpI5+mR9OlfUFFbYjCwxFuY9DKM+xWUN+ws0909vXpqfPvw3+Dmorq9vqPiuKKC1gYSLabw7SsORuwSAv4nPTFd/8ZvG9j4U8OyWkkYutR1CNoobfdjCkYLt6AdvU/iR3l7dQ2NlPd3TiOCCNpZHP8KqMk/kK+L/FmuXPi7xTe6xdbgJnxDGT/q4xwq/gOvvk96+j4XyCliajdRfu47+b6L/P/gnl8R5/icxkp12r7JLZLr/X+R2+keIrp9KjisbyRLXzRP5YONsgHU981a1XxNqE1pMt9eFoXXay7FG4bt+OB/e5rz2yhaMgoSp9QcVp+Q0nLsWPqTmuupwTCNfSs/Z9ra27Xvb52+R8YqE9uZ2OfuofPvnujGokZ94OOnPFeg6Trdw2nSQ28xSKba0sfuucfzNc+tlz0rt/Avhu3nUXVxGsjsxWNW5Cgd8V7PEWNwmAwSqVF8NlFLq+i/DfpY+w4Vx1XCV3SjFShKzafS2zW+xV1DxRfrBcSXl+RFIH8wsF+beAG7d9o/KvcPhtNp8/grS30i5S5t/LyXXs5OWBHUEEng1478UPClq+kz3MMKx3Nuu8FBgMvcEfTnPtWL+z14pbQvFx0S6c/YdVIVATwk4+6f8AgX3frt9K8PCU6OdZXPFYa6nTesdOi/HR3T9VY9HP84lKvDDKCjTeqt1e2ui22t53ufUdFFFfOnlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVW1G0jvrKa2lyEkXBI7eh/OrNFTOCnFxlsxxk4tSW6PP4PDericw7Ykizjzi4Ix6gda67RtHttKjbysvM335W6n/Ae1aVFefhMqoYWXPG7fS/T0/q5118dVrrlei8up8sal8efE3w8+IOs+GPEthHrtpaXRSCVT5Nz5TfNHkgFWOxl7An1r6K8HeIJPEukJfy6Jq2jhsYh1KJY5D7hQxIH1xXBeKvgtonjDx5r2t+IojJb3thDa24ifa8cq53Sg+oAjAzn+LIxiuZt774jfBxRbanaTeNfBkIxHdW4P2y0jHZl5JAGeuRgD5lHFekcZ9AUVxXgX4o+EfG8aDQtYga7Yc2c58qcH02H731XI967WgDzz49amdO+GuoIpIkvHjtVOf7zZb/x1Wr5i06EYFe7/ALT8zL4f0SDPyPeM5+qoQP8A0I14npgGBX6Rw3T9llqkvtNv9P0PExz5q9uyNS0t8jpWgsOMUtmoCjNXBtzXTUqO5EY6DIoAe1ekeCIQlpbDHqfzJrhbZNxAUEk8ACvR/DMTQxQhlIIUZFfn/HFdOjRpX3nf7k/8z38jh785+VvxRH46UNpl+CODbyA/98mvmySWXT7+3u7c7Z7eVZYz6MpBH6ivprxZA1zZXEajmSJkH4givmrXI2ikeORSjqSCrDBBrv8ADapG+JpvdtO3lZmXEUXalLyZ9vWdwt1aQXEf3Jo1kX6EZqasjwfk+EdE3dfsMGf+/a1r14VWKhOUV0ZcXdJhRRRUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK81+Pj3C+D7EWviaHw07ajEGu5byW1WRQjsYvMjBI3AfTj1wD6VTJY0mjKSoroeqsMg/hQB5Z8Hon8VeE/C+uXU+qxjT5rpliubyS5F2xJRZfMfDMgG4qCOM+wr1avKfi18R9S8FazZWWm2dlNFNb+aTMGyDuIwMEccVzdv8VvHVxpjajb+FoZbBQWNwltMUwOpzu6Dua5J42lCTg73Xke/h+GsbiKEMRHlUZbXkl+Z71RXgdv8AFnxvcaW+pQeGLeTT0BZrhbeYxgDqd27GB3PalPxY8cDS11I+F4P7PbGLj7NNsOeAc7sYJ4zU/X6Xn9xt/qnj07e7vb4lv29fI97orwHU/i5430qJZdU8MRWUTnar3NrPGCfQFiKkvviv45sLWC5vfC8NvbzkLHJJbTKGJ6AEt1Pb1o+v0vP7hrhPHu1uXXb3lr6HdeOfg/4L8Zu8+p6Qlvftz9tsj5E2fUkcMfdga47/AIV78T/CHPgfx2NWslORYa8m8gDook+Y/lsFVNT+LXjfShAdS8MW9oJziLzreZN59BluvtUDfGXxgt49o3h61F0i72hNvNvVcZyV3ZAxzmolmeHg7Sdhx4RzCS5o8rX+JHIfGjxP49udBs4vG3gWSxFlceY2oafL50BBBXGBu25JGMt7YriPC2s2+pxu1v5g8shWDrgg16f4m+JviPxP4ek0q80K2+y6opjieKGXMhVhzGdxDEMB0zXnz6Nq2mXMFvPp13HPOdsUbwsGkPHCjHJ5HT1r6rJOLsFhqKoVqtld2jy3+5373urM8/FcD5lOpeMY3f8AfXTfTyOit5flGKtJISay5dO8TWE8NvPoV8k0oZo0a2k3OFGWwO+B19KrJe6qYraZdOkMV05jgcRPtmYHBVD/ABHPGBXqT4sy2+8v/AWYQ4HzWSTjyv8A7fX9dH9x0tnrFxp3ijw1aQrC0OpXEsMxdcsqpHuG0545NTWfxC1u5ht7K1+w29/e67dabHdvCzJBDCAd2wH5nIPAyATXNeIrbV7WO2XxD4flhUuHgaaOWFg47o6lWB56A/Wi6lngsoPDF14UhhCyCWK0eKdJvMJ4dTu8zcc/ezk1+eZ1iqOIxssRBOSdulrff+XU+gwPC+YLDqF4rd6STvtfb8+h1V34+vrqx0/T9L1ey1C8v9UlsP7Ql06W3FsscSu6tCxBMoLYGMA8DrmuT8U3cWtaEt7HqEOp3cV+9iZo7J7RzhFOx0fncpPUccjvmrFxp1/aW8fh+48GMpu7g3kcMiXBmkmxzIrl95bA5IOayrqC88OaxZpeaS1gbe5F+LOdZMTOSMuxclm3bACc9vrWuQ46lgcwhi6l4KF76b6PTTvppoupOL4Wx+JoOjTcZOS095d91/n8j7M0y2+xabaWv/PCFIuP9kAf0qzXzh/wvrxB/wBAzSv++ZP/AIqj/hfXiD/oGaV/3zJ/8VVPM6Mndv8AAhcFZotOVf8AgSPo+ivnD/hfXiD/AKBmlf8AfMn/AMVR/wAL68Qf9AzSv++ZP/iqX9pUO/4D/wBS81/lX/gSPo+ivnD/AIX14g/6Bmlf98yf/FUf8L68Qf8AQM0r/vmT/wCKo/tKh3/AP9S81/lX/gSPo+ivnD/hfXiD/oGaV/3zJ/8AFUf8L68Qf9AzSv8AvmT/AOKo/tKh3/AP9S81/lX/AIEj6Por5w/4X14g/wCgZpX/AHzJ/wDFUf8AC+vEH/QM0r/vmT/4qj+0qHf8A/1LzX+Vf+BI+j6K+cP+F9eIP+gZpX/fMn/xVH/C+vEH/QM0r/vmT/4qj+0qHf8AAP8AUvNf5V/4Ej6Por5xT47+IXOF0rTGPXASQ/8As1L/AML28RYU/wBlaZhvunZJz9Pmo/tKh3F/qXmn8q/8CR9G0V86zfHHxNAwWfRtOjY8gPHKCfzao3+O/iFG2vpWmKw7FJAf/QqFmeHezBcGZo9or/wJH0dXhP7TGp2lhZq1n4kudO8RQxRSQ20WpTQP5RkI3xQp8s0hIK4YjgdR3xv+F9eIP+gZpX/fMn/xVdn8KPiLf+N/Ek1lqmn6fGtvbNcRvEjbgwdB1Yn+9+gq6eOo1JKMXqznxfCuY4OjKvViuWOr1R3+haSItVvtckubuSbUobcCG4G37OiJ90KOASzMW9zjtW7RRXYfOBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB85ftM/wDI2aX/ANeX/tRqhu9a8LaxZpf32oeU8GjraW9mGnSW2nRCuECDYyNkZJPbkda9m8Y/D/RPF19Bd6wtwZoY/KXypdo25J9PesD/AIUp4R/5533/AIEf/WryqmFrOpKUUmn3PvsFn+XRwVGhWlOM6aavFLq9f6+WzZ5L4j1PTNc0TS7q08SHTnstKFm+mGOXc0iqQQpUbSHyAST0656VN421XS9b1BtcsfEpghkhgQaR5coaPaFBj4GzbwWznr2r1T/hSnhH/nnff+BH/wBaj/hSnhH/AJ533/gR/wDWrN4Su000tfNnXDiHKacoyjKp7t7e7HZtNrby3389zjfGHjXw9em5l065RvI1i3vZ4XDsL+JAv3CwwhGCCuBnGfasa513SLLx5F4l/wCEkbVLKbUBcfYBFKGjQ7sFgw25jyMAZzjjFel/8KU8I/8APO+/8CP/AK1H/ClPCP8Azzvv/Aj/AOtVyw+Jk7tL8Tno5xktGHs4yqWs09I6ppdd+m6s1tslbyRZNHs/Eseo3niv+17VJ5L0QLHKCzAEpneAA5OBjnockVc/4SfQ7nVtM1SW8lWd7Oawumli+deDskYLkHqQcZPSvT/+FKeEf+ed9/4Ef/Wo/wCFKeEf+ed9/wCBH/1q8nFcPzxVT2knZ2to+mvdPvf5I3lxBlM7OcqjdrbRWmvay6/gjyjTvEWk6THoGntfCU2ltdxSXtvG5WF5myrLkBjjHOB3qTQda8OeHNc0GaO7LssdzHd3FuZZFhd1CpKgcDnucfrgV6k3wW8IKpZkvgAMk/aP/rV8w65e2U+s3B0WB7fTt2IUlbe5Ud2PqeuO3616eS8E43F13Vwr1hq7vRttvXTzf3GGJ4oySmmqkqnvXvZLW/Nf/wBKfltpvf1rRdY8K+HdV8PSpqQnmAuE1CeBp5I8um1Zdrgck8sFHHvxTdG8U6H4bbwbZSXyX402S7e5ubWNykXnAhSu9QWIzk8fTJry+0gjkA35/A1r2uk2kuN2/wD76r6OfCGa0ukPvfl5eRzPinIqt+eVV3TvdLW/OvwU2l8ux2lpJ4OsrrQpbjV0upra5e8vXiad1uNi5jJWQAB2bGR255xWq3jfw5d67oPiCa8uUvI47iwuXli/fRKwYxzALkHaWYcHODXEL4csCucyf991Vn0SyjJA3/8AfVYw4YzLaKh97/yHU4lyOo+apOq3ZraOzvdfj+C7HSeHNR0vQdSvLa58Vm7F/Y3Fsl7FHMRZO5XD/MActjnb0wOfTldYsLHEwPiePUJLW2UxYil2uxkOYkLYwADuzgDkiqN5ZW8QOzd+dYFzM0chCEYreHA+aVo2Sh/4E/8AI3hxxk9Co6inUu7X92Gtvy000t9+p091pGlRPdCHXoZhFJCkZEDjzVcZdh6bDwR37VX1PTrC1tp5LTV4ruRLtoEjWFlLxBQRNk9ATxjrXq3wj8DeFPG3hNb+5tryK9glNvcKk52lgAdy8dCGHHrmu2/4Up4R/wCed9/4Ef8A1q+dxOTYjDVZUakUpRdt2erR42y+SjNTm1/hjrt/Xz9D5dor6i/4Up4R/wCed9/4Ef8A1qP+FKeEf+ed9/4Ef/Wrm/syt5HX/rzlnaX3L/M+XaK+ov8AhSnhH/nnff8AgR/9aj/hSnhH/nnff+BH/wBaj+zK3kH+vOWdpfcv8z5dor6i/wCFKeEf+ed9/wCBH/1qP+FKeEf+ed9/4Ef/AFqP7MreQf685Z2l9y/zPl2ivqL/AIUp4R/5533/AIEf/Wo/4Up4R/5533/gR/8AWo/syt5B/rzlnaX3L/M+XaK+ov8AhSnhH/nnff8AgR/9aj/hSnhH/nnff+BH/wBaj+zK3kH+vOWdpfcv8zwT4d3ttZeIWN5OkEc1tLCJJDhVZlwMnsM966nTNS0zSm8I2N7e2j3FlHd75onE0UEkrZjYsMg4/SvUv+FKeEf+ed9/4Ef/AFqP+FKeEf8Annff+BH/ANauDEcO1K83Jytf/KS/KTPNxXE2VYmbnJzV12XaUe/aT/A8tSLThe6FNq/iA3Rtmlu7yOW/S4QFACPLxj77AfLknH0rE+I11Y6wumavaXsNxcyxmC6UAI+9OjlM5AIOPTivbf8AhSnhH/nnff8AgR/9aj/hSnhH/nnff+BH/wBalS4drU6kanPqr+lnfy8/wRFHibLKVWNbmneN/sq1ndtb+a69EfLtet/s0f8AI76h/wBg5/8A0bHXo/8AwpTwj/zzvv8AwI/+tW74P+Huh+EtSlvtIW5E8sRhbzZdw2kg9MeqivWw+X1adWM5Wsis44uwGMwVXD0lLmkrK6/4J19FFFe0fmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAARkc18xfE/4Majpd7NqPhSB77TXJc20fMsHsB/Gvpjn2719O0V6eV5tXyyo6lHZ7p7MwxGHhXjaR8IRTy2srRXCPFIhwyOCCD7g1r2upoMZNfY2q6DpGr5/tTS7G8JG3M8CucfUiuSvvhB4JumLf2P5DnvDPIn6bsfpX1sOLcJVX76nJPys/wDI855dUj8Mkz53TVV28PVa51RMZLV9An4I+ESeBqCj0Fx/9apoPgt4MjYGWzurj2kunH/oJFUuI8tjraX3L/MX1Ku+x8wXmoCQHBrR8JeBPEPjC6UaVYuLYnDXcwKQqP8Ae7/QZNfWOleAvCulYNloGnq46O8IkYf8CbJrpVUKoVQABwAO1c9fjGMIuOEp695f5L/MuGWNu9SX3HM/Drwja+CvDUWl2shmfcZZ5iMeZIQATjsMAAD0FdPRRXxVatOvUdWo7yerPUjFQSjHZBRRRWRQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVBfXdvYWslzeTJDBGMs7nAFcfL8TNDjl2iO/eLP+uWD5frgnd+lROpCHxOx04fBV8Sm6MHK3Y7eiqelalZ6tZJd6dcR3Fu/R0P6H0PsalvruCxtmnupBHGvc9/Yepqrq1znmnTbU9Gt7k9FcvJ4uUEtHYTND/eLAH8v/r1taRqlrqtuZbSTO04dG4ZD6EVMakZOyZjCtCbtF6l6iiirNQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyf4tagZvFGl6TIxFukH2krnhmZmUZ+mw/manuNO00aEHBTzMdKn+MPhLUNZjtNW0JBLf2asjwZw00ZORt9wcnHfJ9hXjU/iTVUb7BJZXiXY+XyWiYPn0x1rya9T2VSXOt9j9AyrCLHYOksNOzh8Svre+79e51PgHxHP4e8azWtraXuoW13G260tFVnLryHAZgOACDz0Ndr4i8RSarqFnHcaXqOmRxgsIr5ERnJ/iAVmGP/AK9Ufgx4H1HTr+bxF4giMF1LGY7e2b78anqzDsTjAHuc123j3w3Lr1nBJYyLHfWxJTdwHB6qT26DFa0YVPq7063t5Hy3GU6dfENYV8zSSbXVrf10svkUvtdn/Zm3C78da57whfNF46t4YG/d3CukgHQgKWB/MCsCWx8TRObZtJvS44ysRZf++hx+tdR4b+HUskD3Wt3d3aXzYMBsbgxyW59dw4J7YORjrnsQc6k42VrHxdOVSvVglFqz1O91rWbDRbcTajcLErcIvVnPoAOTWBb/ABC0WWYJKLu3QnAklh+X9CSPyrzy5+03Hiye01bUJtQayYwJNOqqzKCeoUBc+4HNdLrel2KaWrIylivIr6KOFpxUVO92foVPKsNShCNe7lNX06X+R6XDLHNEksLrJG4DKynIYHoQaS4nit4zJPIkaD+JzgV5P8PPGmlaHZ3On6/qlvZQrLm2a4fapBzuXJ4GDg/jW5d6jHr+q+ZBOk1iuPIaNgyOp/jBHBB7H0xWawb9rKDeiPmc7vldV0d3ey+avf7jsYtXsJXCJdxbicAE4z+dX646/wBLiS0DDbyKi0vxpo2lWgtvEmuabp0qsREb27jhMi+24jOOn5VNXDxUPaU3ojzsPjZuqqNZJN7WOm1nWdP0W3E2qXcVtG2Qu88sfQAcn8Kw7P4h+GLq4EI1IQsTgGeJ4lP/AAJgB+ZrzKa+Txl4xvLtrhJrJJDFalGDJ5QOAykcHd97PvV7xj4atbWxypQ5XPFVHDwVozbuz2VTitHue1g5GRyKx9c1yPTWWGNPPumGRGDgKPUmvNvhX4q8Q3GhS6bY6Ouqmwk8pbia9WBVQjKqflZjjnoOmK2Le5nfXLmTVoo4bssPMjSQyKhx0DEDcB64GfQV4ua1Z4S0Iuzbtc6MHho1KkufVRV7dzW/4Su+t3DXdlE0PfyyQQPxzXV2F5Bf2qXFq++N/wAx7H3rj9eubZ7f92AOKyPDXjDRfDayweINSj0+Kdw0Mk4ZYs9DmTG1T93qRXn4TF1I4lUJS5k/wOrE4WnLDuvGPK1+J6fRXnmueIJNcvBa6Ndg6eAD59vJkT5Gchh1X6dazrjS7zSgLi1uJoZRzuVjz9fWuqpmPLJ8kLpbs+ani7N8sbpHqlFYnhLWf7a0vzZFC3ETeXKB0z6j2NP8Q69b6KkYdGmuJc7IkOCcdyewr0aElXipU9bnZS/fW5NbmxRXDnxhqMR8ybTYjD/dVyGx9cf0rqNE1a21ixW5tGO3O1lbhkb0NbzozgrtG1ShOmryWhoUUUVkYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFUtZ1Ww0TTZtR1e8gsrGHb5k87hETLBRknpkkD8aAPN/iP4XvodWfWtHieZJcGeOMZZGAxuAHJB/Q1xq32r6kwtLe3mllPGxEJP/1q908P6/pHiKza70HU7PUbZWKNJazLIFb0ODwenB9a069Clj3CKjKN7H0WF4glRpRp1Kak46J/59/wOV8AeGT4f0Z0u9r3lyQ846gei++Mn8SaxvEljLo+qvcwp/okx3LtHCnuPau6sr+zvzcCxu7e5NtM1vOIZA/lSgAlGwflYZGQeeRUd5fWcV9aaddEme9DmKMxsysEALZOMDgjqRntmsqWLlCo6ktb7ny2bUpZm3OpK073v/XSx55PrbyxBBkk8Yrq/DGgxxWBk1K2ikuJm37ZEDFB2HPStyKws4ZN8VrBG/8AeWMA/nirNXiMXGpDkpxsup5+Cy2VGp7WtPma28jwP4g6Pe+DPEVxqlnAzaNeOZQ8a8QOeWVsdBnkducdq5fUfGFzrGyzso5bm5k+VIolLMx9gK+o2AYEMAQeCDVe2sbS1ZmtbWCFm+8Y4wpP1xRDGJJc0btHvRrJLVHKfCjwrN4W8M+XfEHUbuQ3FwAchCQAEB9gPzJq94o8NtqM32uxdY7rGGDcB8dPoa6aivNxdKOMTVVXv/WgUsTUo1PaQep5tH4V1m4lCTqkSZ5ZpAR+Qya7nSdKt9N077JGodDkyFxneT1zWhRXJhMto4WTlC7fdm2Jx9XEpRlZLsjyW/Q+H/Et1EYxHAzmSIKuF2E5AHsOn4VY1nxEtxbBMgnGBXoer6RZavCI76ASbfut0ZfoaxrTwNo9vMJGWefByElfK/kAM1w1MBiIylGi1yvv0Pn54Wqm1B6M53wj4c1G70xr2213U9HaRzsW2SF1kA7sssbZ5z0xWTqZu7PxZLBrF81/NEqKtw8Sx7lIyPlXgdccV6+iqiKqAKoGAAMACuT8ceFP7dWO5s3SK/iG3LcCRfQnsR2PvXv5bCGFiqbelrXPZy3kw7UJPS1rmbqOoWbaaFUKGA5NU/hXM7axqiJn7OY1Y+m4HA/maxF8HeJZZfJe32J0LtMu39Dn9K9K8JeH4fD+nGFG8y4kO6aXGNx9B7Cu+tKnTpuKd2z0K8qVKk4Rlds5b4pfFzQvhwY49YtNVnuJVzEtvany3Pp5jYQ474JI9K4H4Y/HhPGvi+4Os32keGNDtU/cW1zcL515I2QN0j4AVQM4AByRyRkV7l4g0TTPEWkz6ZrllDe2E4w8Mq5B9x3BHYjBHavIvCfwI8LeHm8RW2vWFhqegyOlzZ3N2As9uuGEkbSDB2rtUg5A5PQ5rzkr6I8k9ptriG7gSa1mjmhcZWSNgyt9CKlr4p8aReGvD+tMfhFqWv6VKrYkmhvW+zvjsqn52HuzY9j1qax+NfxR0Zo2vJ7bWLaMAHNsm4geu0An/PNew8ix0IKpUpuMX+Hqldr5o5vrdJvlTuz7Qor5Zi/aR1fV4Fh0200y0u8YcSK7Pn/ZBbH86rQ/GnxxbXAklubS4QHPlSWqhT/3zg/rXTheGcXiqftKco2/xf5JmdTHU6b5ZJ/cfV9FeWfDb4w6Z4qmTT9VjTS9VbARWfMU59EY9D/sn8Ca9TryMXgq+Cqeyrxs/wCtu5006sKseaDuFFFFcpoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXAfHvw9qnir4T67o2g2v2vUrnyPKh8xY922eN2+ZiAPlUnk9q7+igDxbXfhbqcT2c1tqF5qd7qfiS2v9auLeQWGLVIpEIUI4IA3DO0liTntxU13wD4mTxq7aRbXDW6XWnnS9VOonbp1pCqrLC0bPvcttbs2/dliDXulFAHzxffDbxPbWfjW00XTZoZL7XBqEc66gAl9ZEoTbAF8q2QxJYAEcZIqz4e8EeL7KfRRFa6pDYwf2wXhub2HMImt4hCoVJGG3zBJtALbeScZr36igDxn4X+Bdc8NeJ/Dl/cW93Eknh8waw0t/wCcGvA6FcqXbJA3YKjaBxXs1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzf+0J45n1DVZPC2lylLK2I+2Mh/wBbJ12fRe49fpXu/jLWV8PeFtU1ZsE2sDOgPRn6KPxYgfjXxhD5t1cS3Fy7STzOZJHbqzE5JP419hwngI1KksXUV1DRevf5L8zzcxrNRVOPX8hbKyHHFbEFiCOlOtIsEcVr28QAr7CviHc82EEcxrXhDT9WQtPFsn7TR/K4/Hv+NYlhpmuaffrZ3ZS+sGB23JOHTHZu5/X616WyDbXVeC9BguFFzPEssjsQgYZAA749a+YzfMaGU0/r0k1K6Xu6cz7Po/V6roelg8LPFz9itvPoeKXdkV+ZeCOhFfSHwE+IL+IrBtD1iVn1ezTckrnJuIgcZJ7suQD6jB9a534heGbd9LnmjgSO4gUuGVQMgdQfXivI/D+qzeGPFWm6vbkg2swZwP4kPDL+KkitsHj6HFuXTcYctSDej3UrX37P+tiMRhp5XXSbvF/iv+AfblFNRldFdSCrDII7inV8AeqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5R+0lfNbeAIbZTj7ZexxsPVQGf+arXzzpyZAr3b9qBG/4RfRpB9xb7afqY2x/I14bphBAr9K4cio5Ymurf+R4eNd67v5G5aQZxWpHB8vFVbPtWij4Wtq0ncmKREImLYr03wNGIre0BHQZ/Mk153b73lVVUsxPAFeoeFoWiSHeMFUAP1xXwHG9b93Qo315r29E/8z6DI4a1J+VvxDx2AbS7z0MD/wDoJr5o1ePlq+nPFsLXNvKi/wAcbJ+YxXzTr8clvPJFOjRyIcMrDBFd3hzUj7XE0763i7eVnqY8QxfJSl0s0fZHhC4a68J6JcOctNZQSE+pMan+ta9Y3guI2/g7QoWGDHYQIfqI1Fad5d21lCZry4ht4gcb5XCLn6mvGxFvayttd/mVD4UTUVXN9aCe3hN1AJrhS8MfmDdKowSVHcDI5HqKsViUFFFFABRVfULSHUNPubK5DGC4iaGQKxUlWBBwRyOD1r5ftvhp4df9oq78Jsl//YcekC7WH7dLu8zK87t2e54zQB9UUV81a/8AFrxSmu+I9N8IQpFaeHJvsFvaHSri9e8aMlW3ypxHnacZ5Pc966S9+IvjbVPHXhvQPDtnpOnz6r4dTVJYtVilzbzFpAynbycbQACB6n0oA9xor5/8V/EDx/F4r8d6Ro0+gww+GNMi1CSSa3kZ5MW6SyKnOOSWxkcDH1B4d+KHjSbxH8Op9ZXRf7G8WxyIttaxuJIWRVy5Zj1LMDjkYyOvzUAe+xSxy7vKkR9p2ttYHB9DT6+YI/iLqPhX4e+Pta0LTdItLy18UyWmEgbZKCRl3G7lz6jH0rtdK8d+LNJ+JWt+GvGV3oIgj0Z9XhureN44rbacYYsclRznPPA+lAHtVIzBVLMQFAySegFfOvhT4t+JH+IPhjTrq+tta0TXZJIluV0iaxQFQDmF3P7wAkZ9uuCQay/hnc+L9/xWm1DUdMvdPsbvUF1C2mikbzZBHLgRZb5I9wHyn+HjNAH07HIkqB4nV0PRlOQadXzh4N8e69d6H8OvCnhC30fR77WbO4u5Z2t2aC3jSSTiOPdyTsbqT198izqHxg8T6b8OvGs13FpjeJfDGpx6e80cTG3nVpNu/buyDw3GfT6UAfQ1FeOeEvGnjGD4vW3hTxa+j3FvqOk/2nA1hE6eR8xAXLHLfdbOfY8dK9joAKKKKACiiigAooooAKKKKACvNfj49wvg+xFr4mh8NO2oxBruW8ltVkUI7GLzIwSNwH049cA+lUyWNJoykqK6HqrDIP4UAeWfB6J/FXhPwvrl1PqsY0+a6ZYrm8kuRdsSUWXzHwzIBuKgjjPsK9Wrzf4yeNdS8FWmlPpEVo/2l5FcToWAChcYwR615f8A8L08U/8APrpP/fl//i646uOpUpOEtz6LL+F8dmFCOIoJcrvu+zsfTFFfM/8AwvTxT/z66T/35f8A+Lo/4Xp4p/59dJ/78v8A/F1n/adDzO3/AFIzTtH7z6Yor5n/AOF6eKf+fXSf+/L/APxdH/C9PFP/AD66T/35f/4uj+06HmH+pGado/efTFFfM/8AwvTxT/z66T/35f8A+Lo/4Xp4p/59dJ/78v8A/F0f2nQ8w/1IzTtH7z6Yor5n/wCF6eKf+fXSf+/L/wDxdH/C9PFP/PrpP/fl/wD4uj+06HmH+pGado/efTFFfM//AAvTxT/z66T/AN+X/wDi6P8Ahenin/n10n/vy/8A8XR/adDzD/UjNO0fvPpiivmf/henin/n10n/AL8v/wDF0f8AC9PFP/PrpP8A35f/AOLo/tOh5h/qRmnaP3n0xRXzP/wvTxT/AM+uk/8Afl//AIuj/henin/n10n/AL8v/wDF0f2nQ8w/1IzTtH7z6Yor5n/4Xp4p/wCfXSf+/L//ABdH/C9PFP8Az66T/wB+X/8Ai6P7ToeYf6kZp2j959MUV8z/APC9PFP/AD66T/35f/4uj/henin/AJ9dJ/78v/8AF0f2nQ8w/wBSM07R+8+mKK+Z/wDhenin/n10n/vy/wD8XR/wvTxT/wA+uk/9+X/+Lo/tOh5h/qRmnaP3n0xRXzP/AML08U/8+uk/9+X/APi6P+F6eKf+fXSf+/L/APxdH9p0PMP9SM07R+89e+NWhPr/AMO9ThgUtc2oF3EB3KckfUruH418p6Xcfd5r00/HTxQetrpB/wC2D/8AxdeXXEglvZ7lIo4PNkaTyohhEyc4UHOAPrX1mQcXYLBUJ4fEXte6sr+p52M8Ps2qzU4KP/gX/AOss5SQMVr23zDmuGh1OeEAKEOPUVaTxFeIOFh/75P+NdtXjHLJfC5fcZR8Pc4W6j/4F/wD2HwZbwHzJZMbt23PoK7u12IMIQFr500zxPrkQmmsIg6RLumKRMyqvq3oPetuDxv4sae3to9NRp7hBLDH9mk3SIejKM8jg8jivzPOsZDEY6eJpy5k++jVlsfRYThXG0aCpVOVNb+8vW57hd4kUqxBWvIPi9pEd22lJaIpv7m7W0jI6sGzge+Dj86oXXjPxfb3sdlcaasd3L9yFraTe/8AujPP4Vz7+K9YtvFlrqt9HHJe6e7eXbXEZEcT4I5TIOQeeTnIHpWmQZhDB5hTxspWUU3pq3o0l6N73FjOE8biMM6NPllzW6rvufYlvEsFvFCn3Y1CD6AYrhPjPDY3Xhlbe/0O81R5GYQSW2kDU/sz7cbzFnqQSAexPUV5N/wvTxT/AM+uk/8Afl//AIuuk+HXxZ1/xH4z03Sb+DTltrkuHMUThhhGYYJY9wO1elHMaU5JK92edX4PzHD0pVpqNopt69ErnWfBPwwdO8EeF7zWNKlsNdtNOex8qaVnaKNpdx4PQttRiOo4XtXpFFFdp8sFFFFABXNx+C9Ij8eS+L1Sb+2ZLX7GzeYdnl8fw+vA5rpKKAPP9c+FGhal4gu9ZtL3W9Gvr3H2xtIv3tVucd3C9fwx1J61q2PgLRLLxLpWuwJc/wBoaZpq6Vbs8xYeQucBs/eb5jyea6uigDkbn4e6Fc6x4n1OWO4+1eI7P7DfkSkBovLEeFH8J2jrUEHw08Ow/wDCJ7I7n/imN/8AZ2Zj8u/bnd/e+6K7WigDz28+EPhW70DWNGmhuzZarqB1O5AnIYzHuD2HtWrrPw98P6z4jvda1K3lmu7zTX0qZTKQjW7dRgdDz1HNdbRQB5toXwa8M6Pf6JeR3GtXU+jOzWP2u/eVYQcfIqH5VUY6AD3zxVhPhPoEXiPV9XtbnV7Y6t5xvbKG9ZbadpUdHdo+7fOxGTwTkV6DRQB55d/CHwxPoWh6bD/aNk+ibxYX1pdtFcwBySwEg6gk9x9Kevwj8KDwTe+Fvs901hezi6u5WuGae4lDBt7yHknIHt+Zr0CigDmz4L0g+M7LxRsm/tW0sf7PibzDsEOWOCvc5Y810lFFABRRRQAUUUUAFFFFABRRRQAUUUUAeIftP/8AHh4f/wCus38krwCvs/xX4S0fxXHbJrls0625Zo9srJgnGfukZ6Cud/4U94L/AOgZL/4FS/8AxVeRisBUrVXOLVmfomQcWYLLsDDDVoyclfZK2rb7o+UqK+rf+FPeC/8AoGS/+BUv/wAVR/wp7wX/ANAyX/wKl/8Aiq5/7Lrd1/XyPY/17y7+Wf3L/wCSPlKivq3/AIU94L/6Bkv/AIFS/wDxVH/CnvBf/QMl/wDAqX/4qj+y63df18g/17y7+Wf3L/5I+UqK+rf+FPeC/wDoGS/+BUv/AMVR/wAKe8F/9AyX/wACpf8A4qj+y63df18g/wBe8u/ln9y/+SPlKivq3/hT3gv/AKBkv/gVL/8AFUf8Ke8F/wDQMl/8Cpf/AIqj+y63df18g/17y7+Wf3L/AOSPlKivq3/hT3gv/oGS/wDgVL/8VR/wp7wX/wBAyX/wKl/+Ko/sut3X9fIP9e8u/ln9y/8Akj5Sor6t/wCFPeC/+gZL/wCBUv8A8VR/wp7wX/0DJf8AwKl/+Ko/sut3X9fIP9e8u/ln9y/+SPlKivq3/hT3gv8A6Bkv/gVL/wDFUf8ACnvBf/QMl/8AAqX/AOKo/sut3X9fIP8AXvLv5Z/cv/kj5Sor6t/4U94L/wCgZL/4FS//ABVH/CnvBf8A0DJf/AqX/wCKo/sut3X9fIP9e8u/ln9y/wDkj5Sor6t/4U94L/6Bkv8A4FS//FUf8Ke8F/8AQMl/8Cpf/iqP7Lrd1/XyD/XvLv5Z/cv/AJI+UqK+rf8AhT3gv/oGS/8AgVL/APFUf8Ke8F/9AyX/AMCpf/iqP7Lrd1/XyD/XvLv5Z/cv/kj5Sor6t/4U94L/AOgZL/4FS/8AxVH/AAp7wX/0DJf/AAKl/wDiqP7Lrd1/XyD/AF7y7+Wf3L/5I+UqK+rf+FPeC/8AoGS/+BUv/wAVXzv8UrnQLPxFc6X4U04QW9nIYpLl5pJGkccNgFsBQeOmTjOa9DLeF8bmVV0qFtNW23ZfgY1/EPK6EeacZ/cv/kjmqKZaEyY381s2lnBIPnU/ma9ap4f5lT3nD73/APInPHxMymX2Kn3R/wDkjR8G39nBaa3Y3twtqb+18qKZ1YorBsgNtBIB9cV0jeJNK+2/YkvjGg0OPS11BI22rIuSSBjdsOcZxXPwaRYuvMZ/77NR3GkWaA7EP/fRryavh1jK1RylOOvm99Nfh8vQ4a/GuTVpupKNTXyjvor7+S8vI6G3v/DOk6mt9Z3jbrWwKJHbtJJi4clSYzIBwqknt+dc98Qb3TtV1mLU9MlL/a4VaeNl2tHKBg5HTkAHj3rFvbeOLOwY/Gsh7h4pgcKyg52nofbjmuvDeF+YqoqsasW7W1k9u3w99TOjx3k1Cqq371yStqo7dvi76lqu4+Cf/JUND/3pf/RT13/wo8M+BvHWgPcnR3g1C2YR3UK3UpUEjhl+b7pwfpgjnqfRdB+GvhfQtWt9S0yweK8gJMbm4kbGQVPBOOhNedPJcTg8R7OtZOL1PTxnHGXYzB1KdKM7zi0tF1TX8x2VFFFeqfmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfKvxh+F+r6Tr99qukWc15pFzI0+YVLtAScsrAc4Bzg9Mda+qqK9XKc2rZXVdSmrp6NPqc+Iw8cRHlkfB9gwwK3IJVUCvq3XfAfhnXHaTUNHtjO3JmiHlOT6llwT+Oa5K8+CXh+Qk2l5qFuf7pdXUfmuf1r6+PFeDr/AMROL+9fh/kea8vqw+FpniMF0qjrUVzdr617I3wNtc/JrkwHvbg/+zU+H4G6fn/SNZu3H+xEq/zJp/27lyd+d/c/8g+qV+x8/X0ytms+x0q/1rUBa6TZXF5cH/lnChY49TjoPevqrTfg14RtHDXFvdXzD/n5nOPyTb+td1pWlafpFqLfSrK3s4OuyCMICfU46n3qKvGFCjG2Hg5Pz0X6v8hxy2cn77scP8FPAkvgjw/P/aDq2p3zLJOqHKxhQdqZ7kbmyfU+2T6LRRXwuLxVTF1pV6rvKR61OnGnFQjsgooornLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15109=[""].join("\n");
var outline_f14_48_15109=null;
var title_f14_48_15110="Approach to the patient with anal pruritus";
var content_f14_48_15110=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with anal pruritus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15110/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15110/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/48/15110/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Itching of the anus or perianal skin is a common disorder usually arising from benign conditions, but capable of causing significant annoyance and discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of anal pruritus is difficult to estimate since almost any anorectal discomfort is often attributed to symptomatic hemorrhoids. However, the prevalence of anal pruritus in the general population is much higher than seen in clinical practice, since the majority of patients with symptoms referable to the anorectum do not seek medical attention. In one telephone survey involving 102 randomly selected individuals in the general population who were between the ages of 21 and 65, 20 percent had ongoing symptoms referable to the anorectum, the majority of whom had not consulted a physician [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary factors and fecal soilage account for the majority of patients with anal pruritus. Most of these patients probably do not come to medical attention. However, a variety of other disorders can also contribute to or underlie the development of pruritus (",
"    <a class=\"graphic graphic_table graphicRef76063 \" href=\"UTD.htm?15/42/16044\">",
"     table 1",
"    </a>",
"    ). Specific diseases (such as malignancy or anal fistulas) among patients with anal pruritus should be suspected in patients who have clinical features associated with these diseases, or demographic characteristics that place them at increased risk.",
"   </p>",
"   <p>",
"    The causes of anal pruritus were evaluated in a prospective study that included 109 patients who had anal pruritus as the only presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/2\">",
"     2",
"    </a>",
"    ]. All patients underwent anoscopy, rigid proctoscopy, and colonoscopy. The mean age of the cohort was 52, with a ratio of men to women of 2 to 1. Symptoms were present for an average of six weeks prior to presentation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      25 percent had idiopathic pruritus.",
"     </li>",
"     <li>",
"      75 percent had coexisting pathology in the colon or anorectum including hemorrhoids (20 percent), anal fissures (12 percent), rectal cancer (11 percent), anal cancer (6 percent), adenomatous polyps (4 percent), and colon cancer (2 percent). The contribution of polyps and colon cancer to the pruritus was uncertain. Patients who had pruritus associated with cancer had a significantly longer duration of symptoms than patients with benign causes. The high prevalence of neoplasia in this population may have reflected referral bias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study, fecal soilage accounted for approximately 50 percent of 75 patients who presented with the complaint of anal pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/3\">",
"     3",
"    </a>",
"    ]. An underlying skin problem was found in six patients (8 percent), the majority of whom had psoriasis. Patients tended to worsen the problem by application of many medications and overzealous cleansing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fecal soilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool that is loose or pasty is more likely to cause fecal soilage than formed or bulky stools and thereby worsen anal pruritus. Fecal soilage in patients with anal pruritus can be due to any cause of diarrhea or loose bowel movements. In addition, some patients have a primary abnormality of the rectoanal inhibitory reflex and a lower threshold for internal anal sphincter relaxation, or transient internal anal sphincter relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of abnormal internal sphincter relaxation was investigated in a study that included 23 men (median age 41) with anal pruritus who were compared with 16 male controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/4\">",
"     4",
"    </a>",
"    ]. Evaluation included computerized ambulatory anorectal electromyography and manometry. During internal sphincter relaxation, the patients with anal pruritus had a greater rise in rectal pressure (29 versus 18 mmHg), a greater fall in anal pressure (39 versus 29 mmHg), and a longer duration of internal sphincter relaxation (29 versus 8 seconds). Abnormal internal sphincter relaxation was associated with the development of anal pruritus within one hour in 74 percent of patients.",
"   </p>",
"   <p>",
"    Thus, fecal soilage in the majority of patients with otherwise unexplained anal pruritus may be due to a primary abnormality in the internal anal sphincter mechanism, which is analogous to the transient relaxation of the lower esophageal sphincter causing gastroesophageal reflux in the majority of patients with gastroesophageal reflux disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that certain foods can be associated with anal pruritus including coffee, tea, cola, chocolate, tomatoes, and citrus fruits [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/5\">",
"     5",
"    </a>",
"    ]. The reasons why these foods can provoke anal pruritus are not well understood. One explanation could be that some cause abnormal function of the internal anal sphincter. This is analogous to the relaxation of the lower esophageal sphincter associated with specific foods (such as chocolate), which can exacerbate gastroesophageal reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anorectal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a variety of anorectal diseases can be associated with pruritus including abscesses, fissures (",
"    <a class=\"graphic graphic_picture graphicRef51583 \" href=\"UTD.htm?34/14/35040\">",
"     picture 1",
"    </a>",
"    ), fistulas, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/2\">",
"     2",
"    </a>",
"    ]. Internal hemorrhoids usually do not cause anal pruritus unless they prolapse (",
"    <a class=\"graphic graphic_picture graphicRef75759 \" href=\"UTD.htm?35/27/36272\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"     \"Overview of hemorrhoids\"",
"    </a>",
"    .) Suspicious lesions should be biopsied. Skin tags do not contribute significantly to anal pruritus since their surgical removal does not lead to any benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dermatologic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal pruritus can result from a number of skin diseases including psoriasis, contact dermatitis, atopic dermatitis, hidradenitis suppurativa (inflammation of perianal apocrine glands), Paget disease, and anal squamous cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef65025 \" href=\"UTD.htm?34/10/34983\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/7\">",
"     7",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Contact dermatitis should be suspected in patients whose symptoms correlated with use of a new cream or toiletry in the area, or a change in laundry detergent. Once incited, skin irritation can be worsened by scratching or by the use of additional skin products to relieve the pruritus (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/34/14882?source=see_link\">",
"     witch hazel",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infections can involve the anoderm including sexually transmitted diseases (condyloma (",
"    <a class=\"graphic graphic_picture graphicRef55494 \" href=\"UTD.htm?17/24/17794\">",
"     picture 4",
"    </a>",
"    ), herpes, syphilis, and gonorrhea), and Candida, particularly in patients who are at risk for intertriginous candidal infections (such as patients with diabetes mellitus). Parasitic infections, such as pinworm, are uncommon in adults in the United States. Erythrasma (infection with Corynebacterium minutissimum, a gram-positive, non-spore forming bacillus) has been described as a possibly under-recognized infectious cause of anal pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=see_link\">",
"     \"Erythrasma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have included psychologic assessment in patients with anal pruritus have not demonstrated a different psychologic profile compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/3\">",
"     3",
"    </a>",
"    ]. However, some patients become obsessed with the pruritus or anorectal function, which can contribute to the severity of symptoms. Many patients are concerned that the pruritus could indicate colorectal cancer; reassurance and the appropriate investigation may help to relieve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful physical examination including a digital examination of the anorectum should be performed (",
"    <a class=\"graphic graphic_picture graphicRef88892 \" href=\"UTD.htm?16/43/17079\">",
"     picture 5",
"    </a>",
"    ). Suspicious anal lesions should be biopsied, which can be done in the office using a 3 or 6 mm skin punch biopsy. Patients who develop anal pruritus associated with a change in bowel habits or other symptoms suggestive of colorectal pathology should have an appropriate investigation, which may include a colonoscopy in patients who are older than 40 or have a family history of colorectal cancer or occult blood in the stool. Visible rectal bleeding accompanying pruritus should be investigated endoscopically, usually by colonoscopy.",
"   </p>",
"   <p>",
"    Treatment of anal pruritus should be aimed at the underlying cause. Conservative treatment and reassurance are successful in approximately 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/3\">",
"     3",
"    </a>",
"    ]. Although diets eliminating foods that could be associated with anal pruritus have not been well studied, avoidance of foods and beverages known or suspected to exacerbate symptoms is reasonable (",
"    <a class=\"graphic graphic_table graphicRef76063 \" href=\"UTD.htm?15/42/16044\">",
"     table 1",
"    </a>",
"    ). Foods (such as lactose in patients with lactose intolerance) or drugs that could be contributing to diarrhea or loose bowel movements should also be avoided or substituted. Fiber supplementation can help to bulk stools and prevent fecal leakage in patients who have fecal incontinence or partially formed stools. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be instructed about appropriate anodermal care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/8\">",
"     8",
"    </a>",
"    ]. The anoderm should be kept clean and dry, but without excessive wiping or use of astringent cleaners. Bathing following defecation is helpful, if possible. Alternatively, a premoistened pad or tissue can be used for wiping. Following bathing, the area should be dried using a soft towel with a dabbing motion, or with a hair drier. Unmedicated talcum powder can help to keep the area dry.",
"   </p>",
"   <p>",
"    A 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    cream applied twice daily can relieve pruritus and promote healing. It should not be used for more than two weeks to avoid skin atrophy. A protective ointment, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    or Desitin (TM) or Balmex (TM) (which contain principally zinc oxide) can be used in conjunction with the steroid cream. For patients whose symptoms are worse at night, an antihistamine (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) may be helpful until local measures take effect.",
"   </p>",
"   <p>",
"    An occasional patient has intractable symptoms despite conservative measures. In such patients, local injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Methylene blue injection destroys dermal nerve endings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/9\">",
"     9",
"    </a>",
"    ]. In one report in which injection was performed under general anesthesia, substantial improvement was noted in five of six patients, which lasted for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/10\">",
"     10",
"    </a>",
"    ]. Three patients required a second injection. Adverse effects included transient urinary retention and fecal incontinence. All patients had perianal numbness, which persisted during follow-up.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    , which is found in chili peppers, is believed to deplete substance P, a neurotransmitter involved in pain sensitization. Topical capsaicin (0.006 percent) was beneficial in 31 of 44 patients with intractable anal pruritus in a placebo-controlled crossover trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/13\">",
"     13",
"    </a>",
"    ]. Such a concentration is not commercially available. It was prepared by the local hospital pharmacy by diluting a commercial capsaicin preparation (Zostrix&reg;) with white soft paraffin. Patients were instructed to apply a very thin layer of the cream three times a day for four weeks. In responders, the benefit was either immediate or was evident within three days. The main side-effect was a burning sensation upon application, which tended to decrease over time but caused four patients to drop out of the study (a fifth patient dropped out due to urticaria). Patients were followed for up to eight months during which they required approximately one application every other day to minimize or eliminate symptoms.",
"   </p>",
"   <p>",
"    Finally, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (0.1 percent ointment) has been suggested as a treatment. In a small randomized trial (21 patients), there was a trend toward improved Dermatology Life Quality Index scores during treatment with topical tacrolimus compared with placebo (-3.77 versus -1.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15110/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/7/28786?source=see_link\">",
"       \"Patient information: Anal pruritus (anal itching) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Itching of the anus or perianal skin is a common disorder, usually arising from benign conditions, but capable of causing significant annoyance and discomfort.",
"     </li>",
"     <li>",
"      Dietary factors and fecal soilage account for the majority of patients with anal pruritus. Most of these patients probably do not come to medical attention. However, a variety of other disorders can also contribute to or underlie the development of pruritus (",
"      <a class=\"graphic graphic_table graphicRef76063 \" href=\"UTD.htm?15/42/16044\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful physical examination including a digital examination of the anorectum should be performed. Suspicious anal lesions should be biopsied, which can be done in the office using a 3 or 6 mm skin punch biopsy. Patients who develop anal pruritus associated with a change in bowel habits or other symptoms suggestive of colorectal pathology should have an appropriate investigation, which may include a colonoscopy in patients who are older than 40 or have a family history of colorectal cancer or occult blood in the stool. Visible rectal bleeding accompanying pruritus should be investigated endoscopically, usually by colonoscopy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of anal pruritus should be aimed at the underlying cause. We suggest conservative treatment and reassurance, which are successful in approximately 90 percent of patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This includes avoidance of foods and beverages known or suspected to exacerbate symptoms (",
"      <a class=\"graphic graphic_table graphicRef76063 \" href=\"UTD.htm?15/42/16044\">",
"       table 1",
"      </a>",
"      ), and instructions on proper anodermal care. A 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      cream applied twice daily can relieve pruritus and promote healing but should not be used for more than two weeks to avoid skin atrophy. A protective ointment, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      or Desitin (TM) or Balmex (TM) (which contain principally zinc oxide) can be used in conjunction with the steroid cream. For patients whose symptoms are worse at night, an antihistamine (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) may be helpful until local measures take effect. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In uncommon patients who have symptoms refractory to the above, two approaches have been tried: injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      and application of a topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      (0.006 percent, a concentration that is NOT commercially available and has to be compounded). Experience with both approaches is limited. Of these, we suggest a trial of topical capsaicin as described above (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Methylene blue injection can be reserved for patients who do not respond. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/1\">",
"      Nelson RL, Abcarian H, Davis FG, Persky V. Prevalence of benign anorectal disease in a randomly selected population. Dis Colon Rectum 1995; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/2\">",
"      Daniel GL, Longo WE, Vernava AM 3rd. Pruritus ani. Causes and concerns. Dis Colon Rectum 1994; 37:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/3\">",
"      Smith LE, Henrichs D, McCullah RD. Prospective studies on the etiology and treatment of pruritus ani. Dis Colon Rectum 1982; 25:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/4\">",
"      Farouk R, Duthie GS, Pryde A, Bartolo DC. Abnormal transient internal sphincter relaxation in idiopathic pruritus ani: physiological evidence from ambulatory monitoring. Br J Surg 1994; 81:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/5\">",
"      Friend WG. The cause and treatment of idiopathic pruritus ani. Dis Colon Rectum 1977; 20:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/6\">",
"      Jensen SL. A randomised trial of simple excision of non-specific hypertrophied anal papillae versus expectant management in patients with chronic pruritus ani. Ann R Coll Surg Engl 1988; 70:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/7\">",
"      Kr&auml;nke B, Trummer M, Brabek E, et al. Etiologic and causative factors in perianal dermatitis: results of a prospective study in 126 patients. Wien Klin Wochenschr 2006; 118:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/8\">",
"      Ozta MO, Ozta P, Onder M. Idiopathic perianal pruritus: washing compared with topical corticosteroids. Postgrad Med J 2004; 80:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/9\">",
"      Eusebio EB, Graham J, Mody N. Treatment of intractable pruritus ani. Dis Colon Rectum 1990; 33:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/10\">",
"      Farouk R, Lee PW. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani. Br J Surg 1997; 84:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/11\">",
"      Mentes BB, Akin M, Leventoglu S, et al. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani: results of 30 cases. Tech Coloproctol 2004; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/12\">",
"      Sutherland AD, Faragher IG, Frizelle FA. Intradermal injection of methylene blue for the treatment of refractory pruritus ani. Colorectal Dis 2009; 11:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/13\">",
"      Lysy J, Sistiery-Ittah M, Israelit Y, et al. Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut 2003; 52:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15110/abstract/14\">",
"      Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol 2012; 66:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2549 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15110=[""].join("\n");
var outline_f14_48_15110=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fecal soilage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anorectal diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dermatologic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychologic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2549|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/14/35040\" title=\"picture 1\">",
"      Chronic anal fissure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/27/36272\" title=\"picture 2\">",
"      Prolapsed internal hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/10/34983\" title=\"picture 3\">",
"      Anal squamous intraep neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/24/17794\" title=\"picture 4\">",
"      Anal condyloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/43/17079\" title=\"picture 5\">",
"      Pruritus ani",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2549|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/42/16044\" title=\"table 1\">",
"      Causes of anal pruritus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=related_link\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/7/28786?source=related_link\">",
"      Patient information: Anal pruritus (anal itching) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_48_15111="Emergency airway management in acute severe asthma";
var content_f14_48_15111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency airway management in acute severe asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Peter Shearer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Andy Jagoda, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15111/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/48/15111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a severe asthma exacerbation can be managed successfully with aggressive use of beta-agonists, anticholinergics, glucocorticoids, and other medications. Infrequently, medical intervention with bronchodilators and oxygen is insufficient to reverse the immediate course of disease and endotracheal intubation is required.",
"   </p>",
"   <p>",
"    The medications and techniques used to perform advanced airway management, particularly endotracheal intubation, in the patient with a severe asthma exacerbation will be reviewed here. Other aspects of the diagnosis and management of severe asthma and of emergency airway management are discussed separately:",
"   </p>",
"   <p>",
"    For the medical management of severe asthma in adults: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    ). An algorithm outlining treatment is also provided (",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the management of mechanical ventilation in asthmatics: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the management of severe asthma in children, including mechanical ventilation: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For evaluation of severe asthmatics: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=see_link\">",
"     \"Evaluation of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Severity assessment'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the assessment and management of the difficult airway and the performance of rapid sequence intubation: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF SEVERE ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe asthma exacerbations have several important pathophysiologic effects. Among the most important are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased work of breathing from severe airflow resistance due to bronchial mucosal inflammation and edema, constriction of bronchial smooth muscle, and mucus in the bronchial lumen",
"     </li>",
"     <li>",
"      Increased intrathoracic pressure from air trapping, which further increases the work of breathing, decreases preload, and increases afterload",
"     </li>",
"     <li>",
"      Depletion of catecholamines during prolonged exacerbations",
"     </li>",
"     <li>",
"      Dehydration through insensible losses (more important in children)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE DECISION TO INTUBATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to intubate is a clinical one. Asthmatics in obvious respiratory distress that the clinician judges to be unsustainable require prompt intubation. Beyond that, there are no studies or consensus guidelines that predict precisely when intubation is necessary in the asthmatic.",
"   </p>",
"   <p>",
"    The clinical assessment that a patient in respiratory distress requires intubation involves the patient's appearance, vital signs including oxygen saturation, and the response to therapy. As an example, the patient who is clearly tiring, speaking only in one or two word phrases, and demonstrating either increased distress or declining mental status should be intubated prior to the inevitable respiratory arrest of which these findings warn. It is a combination of the severity of bronchoconstriction and the exhaustion of the patient trying to overcome it that sets the stage for respiratory arrest. When the clinician decides that respiratory failure is advanced, progressing, and unlikely to be reversed by further pharmacologic therapy, intubation should be performed expeditiously, before crisis ensues.",
"   </p>",
"   <p>",
"    It is important to note that unlike other conditions in which intubation essentially \"solves the problem,\" the dynamic hyperinflation potentially caused or exacerbated by mechanical ventilation of a severe asthmatic can have devastating consequences, including cardiovascular collapse and barotrauma. Therefore, intubation of a patient with acute status asthmaticus should be undertaken only when judged clinically necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link&amp;anchor=H10#H10\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients (including those with asthma), a simple assessment consisting of three clinical evaluations distinguishes those who require intubation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is there failure of airway maintenance or protection?",
"     </li>",
"     <li>",
"      Is there failure of oxygenation or ventilation?",
"     </li>",
"     <li>",
"      Is deterioration, particularly of the airway, anticipated? (ie, What is the expected clinical course?)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This general approach to emergency intubation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H2#H2\">",
"     \"Emergent endotracheal intubation in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with severe acute asthma, the most important indication for intubation is anticipation of the patient's continued deterioration. Without prompt intervention this can lead to severe hypoxemia or respiratory arrest. Irreversible failure of oxygenation or clinical suspicion of ventilatory failure may also develop, prompting emergent intubation.",
"   </p>",
"   <p>",
"    Clinical findings that portend imminent respiratory arrest in the asthmatic may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to maintain respiratory effort (ie, extreme fatigue)",
"     </li>",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Cyanosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note that these findings are not sensitive indicators of severe attacks; many patients with severe airway obstruction will not manifest these signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Severity Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs associated with a severe asthma exacerbation may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accessory muscle use; chest wall retractions",
"     </li>",
"     <li>",
"      Brief, fragmented speech",
"     </li>",
"     <li>",
"      Inability to lie supine",
"     </li>",
"     <li>",
"      Profound diaphoresis",
"     </li>",
"     <li>",
"      Agitation",
"     </li>",
"     <li>",
"      Rapid, shallow breathing (respiratory rate &gt;25 to 30",
"      <span class=\"nowrap\">",
"       breaths/minute)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a peak expiratory flow rate (PEFR) or forced expiratory volume in one second (FEV1) less than 40 percent of predicted (less than 200",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    in all but the smallest adolescent and adults or based upon height in children over six years of age (",
"    <a class=\"graphic graphic_table graphicRef64420 \" href=\"UTD.htm?1/12/1229\">",
"     table 1",
"    </a>",
"    )) indicates severe disease, such evaluations are often difficult to obtain, highly variable, and unreliable in patients with severe asthma exacerbations. Arterial blood gases are also rarely helpful in determining the need for intubation in the emergency setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONINVASIVE POSITIVE PRESSURE VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotracheal intubation and mechanical ventilation increase airway resistance and can lead to severe complications in asthmatics. One possible alternative in patients who are not on the brink of respiratory failure and do not have other contraindications is noninvasive positive pressure ventilation (NPPV) using bilevel positive airway pressure (BLPAP). BLPAP offers positive airway pressure on inspiration and a lower level of continuous positive airway pressure on expiration.",
"   </p>",
"   <p>",
"    In some patients with severe respiratory distress, NPPV reduces the work of breathing, decreases airway resistance and the feeling of dyspnea, re-expands collapsed alveoli, and provides rest for the thoracic muscles of respiration. The role of NPPV in patients with acute severe asthma remains unclear, but a trial of BLPAP prior to invasive mechanical ventilation is reasonable in patients experiencing a severe, persistent exacerbation despite maximal bronchodilator therapy, if they do not already require immediate intubation. NPPV is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H18#H18\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H5#H5\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Initiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Noninvasive positive pressure ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RAPID SEQUENCE INTUBATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The asthmatic in need of endotracheal intubation is often exhausted with little physiologic reserve and at high risk of sustaining a rapid decline in oxygen saturation and blood pressure after receiving sedating medications and neuromuscular blocking agents. For these reasons, it is important to plan for and achieve intubation as early as possible once the determination has been made that intubation is necessary. Rapid sequence intubation (RSI) is the preferred approach in such cases because it is the most rapid method for securing the airway with the highest likelihood of success.",
"   </p>",
"   <p>",
"    Aspects of RSI of special relevance to the severe asthmatic are discussed below. The general performance of RSI is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Preoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving adequate preoxygenation in an asthmatic experiencing a severe exacerbation is extremely difficult, if not impossible, due to their high residual volume and functional residual capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinician must anticipate rapid oxygen desaturation when performing RSI in such patients, despite maximal efforts at preoxygenation.",
"   </p>",
"   <p>",
"    If the patient will tolerate it, preoxygenation via active breathing through a bag valve mask provides significantly higher inspiratory oxygen concentrations than a typical nonrebreather mask. The use of noninvasive positive pressure ventilation may also improve preoxygenation, even if it does not successfully reverse the patient's respiratory failure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Noninvasive positive pressure ventilation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many patients with status asthmaticus require positive pressure ventilation either before or between attempts at intubation. Such ventilation should be delivered by bag and mask using a small tidal volume and high inspiratory flow rate with a prolonged expiratory phase, mimicking the approach used during mechanical ventilation. If a normal tidal volume is delivered at a normal rate, breath stacking and increasing auto PEEP may lead to further declines in oxygenation and impair the ability to ventilate the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H18#H18\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Ventilation strategy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Ventilator settings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Positioning and ETT placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications for RSI should be administered to the patient while they maintain the position of greatest comfort, which is generally sitting upright. Once the patient loses consciousness, place the patient in a supine position and perform laryngoscopy and intubation.",
"   </p>",
"   <p>",
"    Placement of a large endotracheal tube (8 to 9 mm) is desirable in order to minimize airway resistance and facilitate aggressive pulmonary toilet during mechanical ventilation in adults, but tube size should be selected to achieve the most rapid possible intubation. If necessary, the tube can be changed later to one of a larger diameter.",
"   </p>",
"   <p>",
"    In children between one and eight years of age, the tube size can be calculated based upon age (",
"    <a class=\"graphic graphic_table graphicRef72932 \" href=\"UTD.htm?2/4/2123\">",
"     table 2",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/26/18849?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). A cuffed endotracheal tube is preferable for all age groups and a cuff pressure should be measured, especially in pediatric patients. Older children and adolescents should have the largest possible tube placed (up to 9 mm internal diameter).",
"   </p>",
"   <p>",
"    Although cricoid pressure is now considered optional during rapid sequence intubation, it may reduce the flow of air into the stomach should bag-mask ventilation be necessary, particularly given the increased airway resistance in the asthmatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pretreatment with lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment should be viewed as a supplementary (ie, optimal but nonessential) step in RSI. A detailed discussion of RSI pretreatment, including the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for reactive airway disease, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link&amp;anchor=H5#H5\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\", section on 'Lidocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    reduces bronchospasm during laryngoscopy and intubation, and there is no evidence that the drug causes harm when given appropriately. Therefore, when time permits, we suggest pretreatment with lidocaine in the severe asthmatic adult undergoing RSI. The dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given intravenously approximately three minutes before induction.",
"   </p>",
"   <p>",
"    No studies have been performed to assess the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for pretreatment in a child with a severe asthma exacerbation who is undergoing RSI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H13#H13\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Lidocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of induction agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    have bronchodilatory properties and thus are suitable induction agents for the severe asthmatic. Ketamine is preferable because it aids bronchodilation through both direct and indirect mechanisms and helps to maintain blood pressure. Barbiturates, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    , should be avoided because they can exacerbate bronchospasm through histamine release.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a dissociative anesthetic that provides several benefits in the severe asthmatic. It acts directly as a smooth muscle dilator, increases circulating catecholamines (thus indirectly dilating smooth muscle), inhibits vagal outflow, decreases production of vasodilatory nitric oxide, and does not cause histamine release. Ketamine is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H20#H20\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large randomized trials to assess the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in the intubation of asthmatics are lacking. However, a number of studies and case reports suggest that ketamine improves pulmonary function and is of benefit in severe asthmatics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one placebo controlled double-blind trial of 14 mechanically ventilated adults with bronchospasm, the seven patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      showed a significant improvement in oxygenation, but no improvement in lung compliance [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/2\">",
"       2",
"      </a>",
"      ]. PaCO2 remained unchanged in the treatment group but rose in the placebo group.",
"     </li>",
"     <li>",
"      In a case series, 10 spontaneously breathing children with severe asthma unresponsive to standard therapy had significant reductions in their median clinical asthma score and median respiratory rate, and an increase in oxygen saturation, after receiving a loading dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      followed by a continuous infusion (0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/3\">",
"       3",
"      </a>",
"      ]. Four patients had side effects consisting of hallucinations, flushing, or hypertension.",
"     </li>",
"     <li>",
"      In one case series, five adults with severe asthma requiring intubation showed rapid improvement of their PaCO2 following induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an older case series, 26 of 40 actively wheezing adults given a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      induction for anaesthesia were noted to have a subjective decrease in bronchospasm [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple case series suggest that infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      improve pulmonary function in patients with severe asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H4#H4\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Anesthesia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    have been favorable. One randomized, double-blind, placebo-controlled trial of intravenous ketamine (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus followed by an infusion of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour) in 53 consecutive nonintubated adults with acute asthma failed to demonstrate benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the rate of dysphoric reactions, a well-known side effect of ketamine, led the investigators to reduce the initial bolus to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    after the first nine patients. Larger prospective trials of ketamine in severe acute asthma are needed.",
"   </p>",
"   <p>",
"    Case reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    has bronchodilatory effects and is therefore a suitable induction agent in the severe asthmatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, propofol can cause hypotension, so it is less ideal than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in these patients.",
"   </p>",
"   <p>",
"    No large study has been performed to assess",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    's role in the intubation of patients with severe asthma. Propofol was associated with decreased airway resistance compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    in one randomized trial involving nonasthmatic smokers undergoing general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15111/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POST-INTUBATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation in the asthmatic can be difficult to manage and is fraught with potential complications, including cardiovascular collapse and barotrauma. Minimizing airway pressures while maintaining adequate oxygenation is the primary goal of management. Mechanical ventilation of the asthmatic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Endotracheal intubation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intubated asthmatic is usually hypercapnic. To avoid subsequent tachypnea and loss of synchronization with the ventilator such patients should be deeply sedated and receive parenteral opioid analgesia with a non-histamine releasing opioid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) in order to achieve complete relaxation and comfort for mechanical ventilation. Whenever possible, sedation and pain scores should be used to determine whether treatment is adequate. In a few instances, neuromuscular blockade may be required to optimize treatment of patients with severe disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=see_link&amp;anchor=H19#H19\">",
"     \"Mechanical ventilation of adults in the emergency department\", section on 'Sedation and analgesia for the ventilated patient'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to intubate an asthmatic is a clinical one and can be difficult. Asthmatics in obvious respiratory distress that the clinician judges to be unsustainable require prompt intubation. Further guidance is provided above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'the decision to intubate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of respiratory distress in the asthmatic may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inability to maintain respiratory effort (ie, extreme fatigue)",
"     </li>",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Cyanosis",
"     </li>",
"     <li>",
"      Accessory muscle use; chest wall retractions",
"     </li>",
"     <li>",
"      Brief, fragmented speech",
"     </li>",
"     <li>",
"      Inability to lie supine",
"     </li>",
"     <li>",
"      Profound diaphoresis",
"     </li>",
"     <li>",
"      Agitation",
"     </li>",
"     <li>",
"      Rapid, shallow breathing (respiratory rate &gt;25 to 30",
"      <span class=\"nowrap\">",
"       breaths/minute)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to note that unlike other conditions in which intubation essentially \"solves the problem,\" the dynamic hyperinflation potentially caused or exacerbated by mechanical ventilation of a severe asthmatic can have devastating consequences, including cardiovascular collapse and barotrauma. Intubation and mechanical ventilation must be managed with great care.",
"     </li>",
"     <li>",
"      The role of noninvasive positive pressure ventilation (NPPV) in patients with acute severe asthma remains unclear. Nevertheless, a trial of NPPV prior to invasive mechanical ventilation is reasonable in patients experiencing a severe, persistent exacerbation despite maximal bronchodilator therapy,",
"      <strong>",
"       IF",
"      </strong>",
"      they do not already require immediate intubation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Noninvasive positive pressure ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid sequence intubation (RSI) is the preferred approach for securing the airway of the patient with acute severe asthma. The asthmatic in need of endotracheal intubation has little physiologic reserve and is at high risk of sustaining a rapid decline in oxygen saturation and blood pressure after receiving sedating medications and neuromuscular blocking agents. Therefore, it is important to achieve intubation expeditiously. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Achieving adequate preoxygenation in an asthmatic experiencing a severe exacerbation is extremely difficult. Many patients with severe acute asthma require positive pressure ventilation either before or between attempts at intubation. Such ventilation should be delivered by bag and mask using a small tidal volume and high inspiratory flow rate with a prolonged expiratory phase. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Preoxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      should be viewed as a supplementary (ie, nonessential) step when performing RSI in the adult asthmatic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link&amp;anchor=H5#H5\">",
"       \"Pretreatment agents for rapid sequence intubation in adults\", section on 'Lidocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV) be used as the induction agent for RSI in patients with severe asthma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ketamine aids bronchodilation and helps to maintain blood pressure.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      may have bronchodilatory effects but can cause hypotension. Barbiturates, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"       thiopental",
"      </a>",
"      , should be avoided because they can exacerbate bronchospasm. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of induction agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical ventilation in the asthmatic is fraught with potential complications, including cardiovascular collapse and barotrauma. Minimizing airway pressures while maintaining adequate oxygenation is the primary goal of management. Mechanical ventilation of the asthmatic is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"       \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H9#H9\">",
"       \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Endotracheal intubation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/1\">",
"      McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med 2003; 168:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/2\">",
"      Hemmingsen C, Nielsen PK, Odorico J. Ketamine in the treatment of bronchospasm during mechanical ventilation. Am J Emerg Med 1994; 12:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/3\">",
"      Petrillo TM, Fortenberry JD, Linzer JF, Simon HK. Emergency department use of ketamine in pediatric status asthmaticus. J Asthma 2001; 38:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/4\">",
"      L'Hommedieu CS, Arens JJ. The use of ketamine for the emergency intubation of patients with status asthmaticus. Ann Emerg Med 1987; 16:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/5\">",
"      Corssen G, Gutierrez J, Reves JG, Huber FC Jr. Ketamine in the anesthetic management of asthmatic patients. Anesth Analg 1972; 51:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/6\">",
"      Howton JC, Rose J, Duffy S, et al. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma. Ann Emerg Med 1996; 27:170.",
"     </a>",
"    </li>",
"    <li>",
"     Zaloga GP, Todd M, Levit P, Marik P. Propofol-induced bronchodilation in patients with status asthmaticus. The Internet Journal of Emergency and Intensive Care Medicine, 2001; 5:1. file://www.ispub.com/journal/the-internet-journal-of-emergency-and-intensive-care-medicine/volume-5-number-1/propofol-induced-bronchodilation-in-patients-with-status-asthmaticus-1.html (Accessed on October 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/8\">",
"      Conti G, Ferretti A, Tellan G, et al. Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus. Intensive Care Med 1993; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15111/abstract/9\">",
"      Eames WO, Rooke GA, Wu RS, Bishop MJ. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Anesthesiology 1996; 84:1307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 285 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15111=[""].join("\n");
var outline_f14_48_15111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY OF SEVERE ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE DECISION TO INTUBATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONINVASIVE POSITIVE PRESSURE VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RAPID SEQUENCE INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Preoxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Positioning and ETT placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pretreatment with lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of induction agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POST-INTUBATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/285|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/62/26600\" title=\"algorithm 1\">",
"      Emergency Rx severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/285|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/12/1229\" title=\"table 1\">",
"      PEFR in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/4/2123\" title=\"table 2\">",
"      Endotracheal tube size formula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/26/18849?source=related_link\" title=\"calculator 1\">",
"      Calculator: Endotracheal tube size for children (Age 1 to 8 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=related_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=related_link\">",
"      Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=related_link\">",
"      Mechanical ventilation of adults in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=related_link\">",
"      Pretreatment agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_48_15112="Basic case 4";
var content_f14_48_15112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Basic case 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 142px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15112=[""].join("\n");
var outline_f14_48_15112=null;
var title_f14_48_15113="Irinotecan: Pediatric drug information";
var content_f14_48_15113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Irinotecan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"    see \"Irinotecan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/44/1733?source=see_link\">",
"    see \"Irinotecan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Camptosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Camptosar&reg;;",
"     </li>",
"     <li>",
"      Irinotecan Hydrochloride Trihydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Topoisomerase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"      see \"Irinotecan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A reduction in the starting dose by one dose level should be considered for prior pelvic/abdominal radiotherapy, performance status of 2, or known homozygosity for UGT1A1*28 allele. Consider premedication of atropine I.V. or SubQ in patients with cholinergic symptoms (eg, increased salivation, diaphoresis, abdominal cramping) or diarrhea. Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive:",
"     </b>",
"     Children &ge;2 years and Adolescents: I.V.: 10-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses) and days 8-12 (5 doses) every 3 weeks; in combination with temozolomide (Casey, 2009; Wagner, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma, refractory or palliative:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single-agent: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses); repeat cycle every 21 days (Kushner, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses) and days 8-12 (5 doses) ever 3 weeks with temozolomide; may repeat up to 6 cycles (Bagatell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refractory solid tumor or CNS tumor (low-dose, protracted schedule):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single-agent: 15-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on  days 1-5 (5 doses) and days 8-12 (5 doses) every 3 weeks; higher doses may be tolerated (30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) with concurrent cefpodoxime therapy (Cosetti, 2002; McGregor, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     With temozolomide: Irinotecan dose: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses) and days 8-12 (5 doses) ever 3 weeks; may repeat up to 6 cycles (Bagatell, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     With temozolomide and vincristine: Irinotecan dose: 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses) and days 8-12 (5 doses) of a 28-day treatment cycle; may repeat cycle if tolerated (McNall-Knapp, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refractory solid tumor or CNS tumor:",
"     </b>",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single-agent: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses); repeat cycle every 21 days (Kushner, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Weekly regimen (Bomgaars, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Heavily pretreated patients: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Less-heavily pretreated patients: 160 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Combination therapy: 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days 1-5 (5 doses) repeat every 3 weeks; in combination with vincristine and temozolomide (Wagner, 2010a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Rhabdomyosarcoma, refractory or metastatic:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single-agent (Vassal, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;10 kg:  20 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose once every 3 weeks; if dosage reduction necessary, next cycle was 17 mg/kg/dose; if further dosage reduction necessary due to toxicity, subsequent cycles were 14 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;10 kg: 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once every 3 weeks; if dosage reduction necessary, next cycle was 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; if further dosage reduction necessary due to toxicity, subsequent cycles were 420 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy with vincristine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High-dose, short schedule: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days on weeks 1 and 4 (Mascarenhas, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low-dose, protracted schedule: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days followed by 2 days of rest then 20 	 	 	mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days on weeks 0, 1, 3, and 4; maximum dose: 40 mg (Pappo, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic (single-agent therapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weekly regimen: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 8, 15, and 22 of a 6-week treatment cycle (may adjust upward to 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     if tolerated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -1: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -2: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further adjust to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (in decrements of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-every-3-week regimen: 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes, once every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -1: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -2: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further adjust to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (in decrements of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic (in combination with fluorouracil and leucovorin):",
"     </b>",
"     I.V.: Six-week (42-day) cycle:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimen 1: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 8, 15, and 22; to be given in combination with bolus leucovorin and fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -1: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -2: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further adjust if needed in decrements of ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Regimen 2: 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 15, and 29; to be given in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -1: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adjusted dose level -2: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further adjust if needed in decrements of ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Use in patients with dialysis is not recommended by the manufacturer; however, literature suggests reducing weekly dose from 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and administering after hemodialysis or on nondialysis days (Janus, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liver metastases with normal hepatic function: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;ULN to &le;2 mg/dL: Consider reducing initial dose by one dose level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;2 mg/dL: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians: Bilirubin 1.5-3 mg/dL: Administer 75% of dose (Floyd, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"     It is recommended that new courses begin only after the granulocyte count recovers to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , the platelet counts recover to &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and treatment-related diarrhea has fully resolved. Depending on the patient's ability to tolerate therapy, adult doses should be adjusted in increments of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Treatment should be delayed 1-2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consider discontinuing irinotecan. See tables for adult dosage recommendations.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Colorectal Cancer: Single-Agent Schedule: Recommended Adult Dosage Modifications",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col width=\"120\">",
"     </col>",
"     <col width=\"130\">",
"     </col>",
"     <col width=\"120\">",
"     </col>",
"     <col width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Toxicity NCI Grade",
"         <sup>",
"          2",
"         </sup>",
"         (Value)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         During a Cycle of Therapy",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         At Start of Subsequent Cycles of Therapy (After Adequate Recovery), Compared to Starting Dose in Previous Cycle",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weekly",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weekly",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Once Every 3 Weeks",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         All dose modifications should be based on the worst preceding toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         National Cancer Institute Common Toxicity Criteria (version 1.0).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Excludes alopecia, anorexia, asthenia.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No toxicity",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &uarr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         up to a maximum dose of 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenia",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (1500-1999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (1000-1499/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (500-999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&lt;500/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenic Fever",
"         </b>",
"         (grade 4 neutropenia and &ge; grade 2 fever)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Hematologic Toxicities",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Dose modifications for leukopenia, thrombocytopenia, and anemia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Diarrhea",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (2-3 stools/day  &gt;pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (4-6 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (7-9 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&ge;10 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Nonhematologic Toxicities",
"          <sup>",
"           3",
"          </sup>",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 20 mg/mL (2 mL, 5 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 20 mg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Camptosar&reg;: 20 mg/mL (2 mL, 5 mL, 15 mL) [contains sorbitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: In clinical pediatric trials, doses were prepared using commercially available injectable solution (20 mg/mL); doses were drawn up in oral syringes and refrigerated until ready for use; for administration, dose was mixed with cranberry grape juice (Wagner, 2010; Wagner 2010a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V. infusion: Irinotecan should be further diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W (preferred diluent) or NS to a final concentration of 0.12-2.8 mg/mL; infuse usually over 90 minutes dependent upon specific protocol. Higher incidence of cholinergic symptoms have been reported with more rapid infusion rates; consider premedication with atropine and oral cephalosporin antibiotics; pH:3-3.8.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F184500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Leucovorin calcium, oxaliplatin, palonosetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Gemcitabine, pemetrexed.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store  intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); store unopened Camptosar&reg; vials at 15&deg;C to 30&ordm;C (59&ordm;F to 86&ordm;F); protect from light. After dilution with D",
"     <sub>",
"      5",
"     </sub>",
"     W, resulting solution is stable for 24 hours if stored at room temperature or 48 hours if stored refrigerated, although the manufacturer recommends use within 6 hours at room temperature and 24 hours if refrigerated. Due to the relatively acidic pH, irinotecan appears to be more stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W than NS. Solution prepared with  NS is stable for 24 hours at room temperature; do not refrigerate NS solutions; visible particulates may develop. Undiluted commercially available injectable solution prepared in oral syringes is stable for 21 days under refrigeration (Wagner, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic carcinoma of the colon or rectum (FDA approved in adults); has also been used in the treatment of advanced nonsmall cell lung cancer, extensive state small cell lung cancer, recurrent or metastatic cervical cancer, esophageal cancer, metastatic or locally advanced gastric cancer, recurrent ovarian cancer, advanced pancreatic cancer, brain tumors (recurrent gliobastoma), and in children to treat recurrent or progressive Ewing's sarcoma,  rhabdomyosarcoma, neuroblastoma, and other refractory solid tumors (I.V. and oral)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Irinotecan may be confused with topotecan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hypotension, thromboembolic events, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, cholinergic toxicity (includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing and intestinal hyperperistalsis); confusion, dizziness, fever, headache, insomnia, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal fullness/pain, anorexia, constipation, cramps, diarrhea (early/late), dyspepsia, flatulence, mucositis, nausea, stomatitis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, leukopenia, neutropenia, neutropenic fever/infection, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ascites and/or jaundice, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: ALT increased, amylase increased, anaphylactoid reaction, anaphylaxis, angina, arterial thrombosis, bleeding, bradycardia, cardiac arrest, cerebral infarct, cerebrovascular accident, circulatory failure, colitis, dysrhythmia, embolus, gastrointestinal bleeding, gastrointestinal obstruction, hepatomegaly, hyperglycemia, hypersensitivity, hyponatremia, ileus, interstitial pulmonary disease (IPD), intestinal perforation, ischemic colitis, lipase increased, lymphocytopenia, megacolon, MI, myocardial ischemia, neutropenic typhlitis, pancreatitis, paresthesia, peripheral vascular disorder, pulmonary embolus; pulmonary toxicity (dyspnea, fever, reticulonodular infiltrates on chest x-ray); renal failure (acute), renal impairment, thrombocytopenia (immune mediated), thrombophlebitis, thrombosis, typhlitis, ulcerative colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In limited pediatric experience, dehydration (often associated with severe hypokalemia and hyponatremia) was among the most significant grade 3/4 adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to irinotecan or any component; concurrent use with St John's wort or ketoconazole",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce initial irinotecan dose in patients with increased total serum bilirubin concentration (1-2 mg/dL) who previously received pelvic/abdominal radiation therapy. Use with caution in patients with hepatic impairment; exposure to the active metabolite (SN-38) is increased; toxicities may be increased; dosage adjustment should be considered. Patients with even modest elevations in total serum bilirubin levels (1-2 mg/dL) have a significantly greater likelihood of experiencing first-course grade 3 or 4 neutropenia than those with bilirubin levels that were &lt;1 mg/dL. Patients with abnormal glucuronidation of bilirubin, such as those with Gilbert's syndrome, may also be at greater risk of myelosuppression when receiving therapy with irinotecan. Avoid vaccination with live vaccines during treatment (risk of infection may be increased due to immunosuppression). Although the response to vaccines may be diminished, inactivated vaccines may be administered during treatment. High potential for CYP-mediated drug interactions exists; enzyme inducers may decrease exposure to irinotecan and SN-38 (active metabolite); enzyme inhibitors may increase exposure; when used in patients with CNS tumors, selection of antiseizure medications which are not enzyme inducers is preferred. Administer under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Except as part of a clinical trial, use in combination with the fluorouracil and leucovorin &ldquo;Mayo Clinic&rdquo; regimen is not recommended. Increased toxicity has also been noted in patients with a baseline performance status of 2 in other combination regimens containing irinotecan, leucovorin, and fluorouracil.  For I.V. use only; monitor infusion site; may cause local tissue necrosis or thrombophlebitis if extravasation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Irinotecan is potentially embryotoxic and teratogenic if administered to pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause severe, dose-limiting, and potentially fatal diarrhea",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; early-onset and late-onset forms of severe diarrhea have been reported with irinotecan administration. Early diarrhea has occurred during or shortly after infusion and may be accompanied by symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and abdominal cramping. Atropine 0.01 mg/kg I.V. (maximum dose: 0.4 mg) may be used to prevent or treat symptoms of early diarrhea. Late diarrhea has occurred &gt;24 hours after irinotecan administration and can be prolonged leading to life-threatening dehydration and electrolyte imbalance. Late diarrhea should be promptly treated with loperamide until a normal pattern of bowel movements returns; fluid and electrolyte replacement may be needed for dehydration. Provide antibiotic support if patient develops persistent diarrhea (grade 3 or 4), ileus, fever, sepsis, or severe neutropenia; cefixime (8 mg/kg/day, maximum dose: 400 mg) has been used in children as prophylaxis for diarrhea beginning 5 days prior to irinotecan therapy and continued throughout course (Wagner, 2008); cefpodoxime (10 mg/kg/day divided twice daily, maximum dose: 200 mg) has also been used (McNall-Knapp, 2010; Wagner, 2010). Interrupt or reduce subsequent irinotecan doses if National Cancer Institute (NCI) grade 3 (increase of 7-9 stools daily, or incontinence, or severe cramping) or grade 4 (increase &ge;10 stools daily, grossly bloody stool, or need for parenteral support) late diarrhea occurs. Cases of colitis complicated by ulceration, bleeding, ileus, and infection have been reported; initiate antibiotics promptly in patients with ileus. Renal impairment and acute renal failure have been reported, possibly due to dehydration secondary to diarrhea; use with caution in patients with renal impairment; not recommended in patients on dialysis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause severe myelosuppression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; deaths due to sepsis following severe neutropenia have been reported with irinotecan administration; complications due to neutropenia should be promptly managed with antibiotics. Therapy should be temporarily discontinued if neutropenic fever occurs or if the absolute neutrophil count is &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . The dose of irinotecan should be reduced if there is a clinically significant decrease in total WBC (&lt;200/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), neutrophil count (&lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), or platelet count (&lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Fatal cases of interstitial pulmonary disease (IPD)-like events have been reported with single-agent and combination therapy. Promptly evaluate changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms; discontinue therapy if IPD is diagnosed.  Patients homozygous for the UGT1A1*28 allele are at increased risk of neutropenia; initial one-level dose reduction should be considered for both single-agent and combination regimens. Heterozygous carriers of the UGT1A1*28 allele may also be at increased risk; however, most patients have tolerated normal starting doses. Patients with abnormal glucuronidation of bilirubin, such as Gilbert's syndrome, may also be at greater risk of myelosuppression when receiving irinotecan. Severe hypersensitivity reactions (including anaphylaxis) have occurred. Thromboembolic events have been reported. Do not use in patients with hereditary fructose intolerance (product contains sorbitol).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP3A4 (major), P-glycoprotein, SLCO1B1, UGT1A1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Irinotecan. The metabolism (via glucuronidation) of the active SN-38 metabolite may be primarily impacted by this interaction.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with carbamazepine, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Irinotecan. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenobarbital, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: May increase serum concentrations of the active metabolite(s) of Irinotecan. Regorafenib may increase the serum concentration of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of Irinotecan. Sorafenib may also increase the concentration of the active metabolite of irinotecan, SN-38.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Irinotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of diarrhea and dehydration, serum electrolytes, serum BUN and creatinine; infusion site for signs of inflammation; CBC with differential and platelet count, hemoglobin, liver function tests, and serum bilirubin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A test is available for genotyping of UGT1A1; however, guidelines for use are not established and not recommended in patients who have experienced toxicity as a dose reduction is already recommended (NCCN Colon Cancer Guidelines v.1.2011)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prodrug undergoes de-esterification by cellular carboxylesterases to a potent active metabolite (SN-38) which is a topoisomerase I inhibitor. Binds to topoisomerase I-DNA complex preventing religation of single-strand DNA breaks, resulting in double-strand DNA breakage and cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: ~37 L/m",
"     <sup>",
"      2",
"     </sup>",
"     (range: 15.2-77 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ) (Ma, 2000); distributes to pleural fluid, sweat, and saliva",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 33-150 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Irinotecan: 30% to 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SN-38 (active metabolite): 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Median: 9%; increased in presence of gefitinib (median: 42%) (Furman, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents (Ma, 2000):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Irinotecan: 2.66 hours (range: 1.82-4.47 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SN-38 (active metabolite): 1.58 hours (range: 0.29-8.28 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Irinotecan: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SN-38 (active metabolite): 10-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Irinotecan: Oral: Children and Adolescents: 3 hours (Wagner, 2010a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SN-38: I.V.: ~1 hour following a 90-minute infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Irinotecan is converted to its active metabolite SN-38 by carboxylesterase-mediated cleavage of the carbamate bond. SN-38 undergoes conjugation by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to a glucuronide metabolite in the liver. Irinotecan also undergoes oxidation by cytochrome P450 3A4 to yield to 2 inactive metabolites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 11% to 20% of irinotecan and &lt;1% SN-38 is excreted in the urine; clearance in children comparable to adult rates although greater interpatient variability in pediatric patients has been reported (Ma, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/44/1733?source=see_link\">",
"      see \"Irinotecan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Advise women of childbearing potential to avoid becoming pregnant while receiving irinotecan. Report immediately any burning, pain, redness, or swelling at infusion site. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause severe diarrhea; initiate loperamide therapy at the first episode of poorly formed or loose stools after irinotecan administration. Report immediately if diarrhea persists or you experience signs of dehydration (eg, fainting, dizziness, lightheadedness; avoid the use of laxatives. Susceptibility to infection increased; may cause nausea, vomiting, or hair loss (will regrow after treatment is completed). Report immediately unresolved nausea or vomiting, alterations in urinary pattern (increased or decreased), opportunistic infection (fever, chills, unusual bruising or bleeding, fatigue, purulent vaginal discharge, unhealed mouth sores), chest pain, or respiratory difficulty.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Loperamide dosing for treatment of late diarrhea: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     8-10 kg: 1 mg after the first loose bowel movement followed by 0.5 mg every 3 hours until a normal pattern of bowel movement returns. Take 0.75 mg every 4 hours during the night rather than every 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     10.1-20 kg: 1 mg after the first loose bowel movement followed by 1 mg every 3 hours until a normal pattern of bowel movement returns. Take 1 mg every 4 hours during the night rather than every 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     20.1-30 kg: 2 mg after the first loose bowel movement followed by 1 mg every 3 hours until a normal pattern of bowel movement returns. Take 2 mg every 4 hours during the night rather than every 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     30.1-43 kg: 2 mg after the first loose bowel movement followed by 1 mg every 2 hours until a normal pattern of bowel movement returns. Take 2 mg every 4 hours during the night rather than every 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;43 kg: 4 mg after the first loose bowel movement followed by 2 mg every 2 hours until the patient is diarrhea free for 12 hours. Take 4 mg every 4 hours during the night rather than every 2 hours.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bagatell R, London WB, Wagner LM, et al, \"Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(2):208-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/21115869/pubmed\" id=\"21115869\" target=\"_blank\">",
"        21115869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bomgaars L, Kerr J, Berg S, et al, \"A Phase I Study of Irinotecan Administered on a Weekly Schedule in Pediatric Patients,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 46(1):50-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/15768380/pubmed\" id=\"15768380\" target=\"_blank\">",
"        15768380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bomgaars LR, Bernstein M, Krailo M, et al, \"Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(29):4622-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/17925558/pubmed\" id=\"17925558\" target=\"_blank\">",
"        17925558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casey DA, Wexler LH, Merchant MS, et al, &ldquo;Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1029-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/19637327/pubmed\" id=\"19637327\" target=\"_blank\">",
"        19637327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cosetti M, Wexler LH, Calleja E, et al, &ldquo;Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2002, 24(2):101-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/11990694/pubmed\" id=\"11990694\" target=\"_blank\">",
"        11990694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furman WL, Navid F, Daw NC, et al, \"Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(27):4599-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/19687340/pubmed\" id=\"19687340\" target=\"_blank\">",
"        19687340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gajjar A, Chintagumpala MM, Bowers DC, et al, &ldquo;Effect of Intrapatient Dosage Escalation of Irinotecan on Its Pharmacokinetics in Pediatric Patients Who Have High-Grade Gliomas and Receive Enzyme-Inducing Anticonvulsant Therapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 97(9 Suppl):2374-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/12712459/pubmed\" id=\"12712459\" target=\"_blank\">",
"        12712459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, \"Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, Kramer K, Modak S, et al, \"Five-Day Courses of Irinotecan as Palliative Therapy for Patients With Neuroblastoma,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 103(4):858-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/15637685/pubmed\" id=\"15637685\" target=\"_blank\">",
"        15637685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ma MK, Zamboni WC, Radomski KM, et al, \"Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children With Recurrent Solid Tumors After Protracted Low-Dose Irinotecan,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2000, 6(3):813-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/10741701/pubmed\" id=\"10741701\" target=\"_blank\">",
"        10741701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mascarenhas L, Lyden ER, Breitfeld PP, et al, \"Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(30):4658-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/20837952/pubmed\" id=\"20837952\" target=\"_blank\">",
"        20837952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGregor LM, Stewart CF, Crews KR, et al, \"Dose Escalation of Intravenous Irinotecan Using Oral Cefpodoxime: A Phase I Study in Pediatric Patients With Refractory Solid Tumors,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2012, 58(3):372-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/21509928/pubmed\" id=\"21509928\" target=\"_blank\">",
"        21509928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McNall-Knapp RY, Williams CN, Reeves EN, et al, \"Extended Phase I Evaluation of Vincristine, Irinotecan, Temozolomide, and Antibiotic in Children With Refractory Solid Tumors,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010, 54(7):909-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/20405511/pubmed\" id=\"20405511\" target=\"_blank\">",
"        20405511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappo AS, Lyden E, Breitfeld P, et al, \"Two Consecutive Phase II Window trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(4):362-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/17264331/pubmed\" id=\"17264331\" target=\"_blank\">",
"        17264331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vassal G, Couanet D, Stockdale E, et al, \"Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(4):356-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/17264330/pubmed\" id=\"17264330\" target=\"_blank\">",
"        17264330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner LM, Crews KR, Stewart CF, et al, \"Reducing Irinotecan-Associated Diarrhea in Children,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2008, 50(2):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/17570704/pubmed\" id=\"17570704\" target=\"_blank\">",
"        17570704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner LM, McAllister N, Goldsby RE, et al, \"Temozolomide and Intravenous Irinotecan for Treatment of Advanced Ewing Sarcoma,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2007, 48(2):132-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/16317751/pubmed\" id=\"16317751\" target=\"_blank\">",
"        16317751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner LM, \"Oral Irinotecan for Treatment of Pediatric Solid Tumors: Ready for Prime Time?\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010, 54(5):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/20108333/pubmed\" id=\"20108333\" target=\"_blank\">",
"        20108333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner LM, Perentesis JP, Reid JM, et al, \"Phase I Trial of Two Schedules of Vincristine, Oral irinotecan, and Temozolomide (VOIT) for Children With Relapsed or Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Study,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010a, 54(4):538-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/48/15113/abstract-text/20049936/pubmed\" id=\"20049936\" target=\"_blank\">",
"        20049936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13238 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15113=[""].join("\n");
var outline_f14_48_15113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708954\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184455\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048038\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048030\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184432\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184417\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048042\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184500\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048033\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048041\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401643\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184499\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048045\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048029\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048028\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184487\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184426\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184428\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184440\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048037\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048027\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048044\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048035\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048046\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=related_link\">",
"      Irinotecan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/44/1733?source=related_link\">",
"      Irinotecan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_48_15114="Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults";
var content_f14_48_15114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Abbas E Kitabchi, PhD, MD, FACP, FACE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15114/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/48/15114/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/48/15114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also called nonketotic hyperglycemia) are two of the most serious acute complications of diabetes. They are part of the spectrum of hyperglycemia and each represents an extreme in the spectrum.",
"   </p>",
"   <p>",
"    The treatment of DKA and HHS in adults will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DKA and HHS differ clinically according to the presence of ketoacidosis and the degree of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The definitions proposed by the American Diabetes Association for DKA and HHS are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef72111 \" href=\"UTD.htm?24/19/24892\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In DKA, metabolic acidosis is often the major finding, while the serum glucose concentration is generally below 800",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. However, serum glucose concentrations may exceed 900",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in patients with DKA who are comatose [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In HHS, there is little or no ketoacid accumulation, the serum glucose concentration frequently exceeds 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (56",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      the serum osmolality may reach 380",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      and neurologic abnormalities are frequently present (including coma in 25 to 50 percent of cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,2,5,6\">",
"       1,2,5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant overlap between DKA and HHS occurs in more than one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/7\">",
"     7",
"    </a>",
"    ]. The typical total body deficits of water and electrolytes in DKA and HHS are compared in the table (",
"    <a class=\"graphic graphic_table graphicRef76060 \" href=\"UTD.htm?35/3/35899\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment overview and protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of DKA and HHS is similar, including the administration of insulin and correction of the fluid and electrolyte abnormalities that are typically present, including hyperglycemia and hyperosmolality, hypovolemia, metabolic acidosis (in DKA), and potassium depletion (",
"    <a class=\"graphic graphic_table graphicRef57723 \" href=\"UTD.htm?23/42/24237\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,8-10\">",
"     1,8-10",
"    </a>",
"    ]. The factors responsible for these metabolic abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy also requires frequent patient monitoring and identification and treatment of precipitating events. Infection (most commonly pneumonia and urinary tract infection) is a common precipitating event. Thus, cultures should be obtained if there are suggestive clinical findings, recognizing that infection may be present in the absence of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An algorithmic approach developed for the ADA is shown in the flow diagrams for treating DKA (",
"    <a class=\"graphic graphic_algorithm graphicRef61747 \" href=\"UTD.htm?15/26/15782\">",
"     algorithm 1",
"    </a>",
"    ) and HHS (",
"    <a class=\"graphic graphic_algorithm graphicRef67368 \" href=\"UTD.htm?1/42/1700\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both DKA and HHS are medical emergencies that require prompt recognition and management. An initial history and rapid but careful physical examination should focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway, breathing, and circulation (ABC) status",
"     </li>",
"     <li>",
"      Mental status",
"     </li>",
"     <li>",
"      Possible precipitating events (eg, source of infection, myocardial infarction)",
"     </li>",
"     <li>",
"      Volume status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial laboratory evaluation of a patient with suspected DKA or HHS should include determination of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum glucose",
"     </li>",
"     <li>",
"      Serum electrolytes (with calculation of the anion gap), BUN, and plasma creatinine",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Urinalysis and urine ketones by dipstick",
"     </li>",
"     <li>",
"      Plasma osmolality",
"     </li>",
"     <li>",
"      Serum ketones (if urine ketones are present)",
"     </li>",
"     <li>",
"      Arterial blood gas if the serum bicarbonate is substantially reduced",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing, such as cultures of urine, sputum, and blood, serum lipase and amylase, and chest x-ray, should be performed on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum glucose should initially be measured every hour until stable, while serum electrolytes, blood urea nitrogen, creatinine, osmolality, and venous pH (for DKA) should be measured every two to four hours, depending upon disease severity and the clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat arterial blood gases are unnecessary during the treatment of DKA; venous pH, which is about 0.03 units lower than arterial pH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/11\">",
"     11",
"    </a>",
"    ], is adequate to assess the response to therapy and avoids the pain and potential complications associated with repeated arterial punctures (",
"    <a class=\"graphic graphic_form graphicRef62913 \" href=\"UTD.htm?27/55/28529\">",
"     form 1",
"    </a>",
"    ). Monitoring serum bicarbonate is another alternative if blood chemistries can be returned in a timely fashion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acidosis in DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct measurement of beta-hydroxybutyrate in the blood is the preferred method for monitoring the degree of ketonemia and has become more convenient with the development of bedside meters capable of measuring whole blood beta-hydroxybutyrate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/12\">",
"     12",
"    </a>",
"    ]. However, this approach is not available in many hospitals.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    tablets or reagent sticks react with acetoacetate and acetone (produced by the decarboxylation of acetoacetic acid), but do not identify beta-hydroxybutyrate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum ketones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During insulin therapy, beta-hydroxybutyrate is converted to acetoacetate. Thus, if the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    method is used for monitoring of ketones in the blood or urine, an increasingly positive test due to this conversion may erroneously lead the clinician to believe that ketosis has worsened (",
"    <a class=\"graphic graphic_figure graphicRef60366 \" href=\"UTD.htm?24/11/24767\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, assessments of urinary or serum ketone levels by the nitroprusside method should not be used as an indicator of response to therapy.",
"   </p>",
"   <p>",
"    If the results of blood chemistries can be returned in a timely fashion, an alternative to monitoring venous pH and serum beta-hydroxybutyrate is monitoring the serum bicarbonate concentration (to assess correction of the metabolic acidosis) and the serum anion gap (to assess correction of the ketoacidemia).",
"   </p>",
"   <p>",
"    The serum anion gap provides an estimate of the quantity of unmeasured anions in the plasma, such as albumin and, in DKA, ketoacid anions. It is calculated by subtracting the major measured anions (chloride and bicarbonate) from the major measured cation (sodium):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Serum anion gap &nbsp;= &nbsp;Serum sodium &nbsp;- &nbsp;(serum chloride + bicarbonate)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring the anion gap will give a good estimate of serum ketoacid anion levels in DKA. Normalization of the anion gap reflects disappearance of ketoacid anions in the serum and correction of the ketoacidosis. However, ketonemia and ketonuria may persist for more than 36 hours due to the slower removal of acetone, in part via the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Since acetone is biochemically neutral, such patients do not have persistent ketoacidosis.",
"   </p>",
"   <p>",
"    The factors that can affect the anion gap during the treatment of DKA are reviewed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Anion gap'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fluid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial fluid therapy in DKA and HHS is directed toward expansion of the intravascular volume and restoration of renal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/16\">",
"     16",
"    </a>",
"    ]. Adequate rehydration with subsequent correction of the hyperosmolar state may result in a more robust response to low dose insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average fluid loss is 3 to 6 liters in DKA and up to 8 to 10 liters in HHS, due largely to the glucose osmotic diuresis (",
"    <a class=\"graphic graphic_table graphicRef76060 \" href=\"UTD.htm?35/3/35899\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,2,8,10\">",
"     1,2,8,10",
"    </a>",
"    ]. In addition to inducing water loss, glucosuria results in the loss of approximately 70 meq of sodium and potassium for each liter of fluid lost. The aim of therapy is to replete the extracellular fluid volume without inducing cerebral edema due to too rapid reduction in the plasma osmolality. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Cerebral edema'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Cerebral edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid repletion is usually initiated with isotonic saline (0.9 percent sodium chloride). This solution will replace the fluid deficit, correct the extracellular volume depletion more rapidly than one-half isotonic saline, lower the plasma osmolality (since it is still hypoosmotic to the patient), and reduce the serum glucose concentration both by dilution and by increasing urinary losses as renal perfusion is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal rate at which isotonic saline is given is dependent upon the clinical state of the patient. Isotonic saline should be infused as quickly as possible in patients who are in shock. In the absence of cardiac compromise, isotonic saline is infused at a rate of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    lean body weight per hour (about 1000",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    in an average-sized person) during the first few hours, with a maximum of &lt;50",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in the first four hours (",
"    <a class=\"graphic graphic_algorithm graphicRef61747 \" href=\"UTD.htm?15/26/15782\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67368 \" href=\"UTD.htm?1/42/1700\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent choice for fluid replacement depends upon the state of hydration, serum electrolyte levels, and the urine output. Most patients are switched at some point to one-half isotonic saline to replace the free water loss induced by the glucose osmotic diuresis. When this should occur is uncertain, because of concern about the possible development of cerebral edema if the plasma osmolality is reduced too rapidly. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, one-half isotonic saline infused at 4 to 14",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour is appropriate if the corrected serum sodium is normal or elevated; isotonic saline at a similar rate is appropriate if the corrected serum sodium is low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"     1",
"    </a>",
"    ]. Concurrent potassium replacement may be another indication for the use of one-half isotonic saline. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum sodium'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Effect of potassium supplementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Successful progress with fluid replacement is judged by frequent hemodynamic and laboratory monitoring. Fluid replacement should correct estimated deficits within the first 24 hours. In patients with renal or cardiac compromise, more frequent monitoring must be performed during fluid resuscitation to avoid iatrogenic fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/9,10,16,18-21\">",
"     9,10,16,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective volume repletion will raise the glomerular filtration rate, resulting in reductions in the blood urea nitrogen (BUN) and serum creatinine concentration. The serum creatinine is initially elevated out of proportion to the fall in glomerular filtration rate, because acetoacetate artifactually raises measured creatinine in the standard colorimetric assay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/22\">",
"     22",
"    </a>",
"    ]. Metabolism of the acetoacetate following the administration of insulin will lower the measured serum creatinine concentration toward its true value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Effect of potassium supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of one-half isotonic saline therapy may be influenced by potassium balance. Almost all patients with DKA or HHS have a substantial potassium deficit due to urinary and, in some cases, gastrointestinal losses. However, because of a shift of potassium out of the cells due primarily to insulin deficiency and hyperosmolality, the serum potassium is often elevated at presentation. In such patients, potassium repletion is not begun until the serum potassium concentration falls below 5.3",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Potassium depletion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potassium repletion affects the saline solution that is given since potassium is as osmotically active as sodium. If 40 meq of potassium is added to each liter, one-half isotonic saline should be used if the patient is hemodynamically stable since this solution contains 117 meq of cation (77 meq of sodium and 40 meq of potassium) and is therefore equivalent to approximately three-quarters isotonic saline. In contrast, the addition of potassium to isotonic saline results in the generation of a hypertonic fluid that will not correct the hyperosmolality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Effect of potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin therapy lowers the serum glucose concentration (primarily by decreasing hepatic glucose production rather than enhancing peripheral utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/23\">",
"     23",
"    </a>",
"    ]), diminishes ketone production (by reducing both lipolysis and glucagon secretion), and may augment ketone utilization. The antilipolytic action of insulin requires a much lower dose than that required to reduce the serum glucose concentration. As a result, any dose of insulin that corrects the hyperglycemia will also normalize ketone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/9,13,23\">",
"     9,13,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Intravenous regular insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an initial infusion of isotonic saline to increase insulin responsiveness by lowering the plasma osmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], the only indication for delaying insulin therapy is a serum potassium below 3.3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    since insulin will worsen the hypokalemia by driving potassium into the cells. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Potassium depletion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A continuous intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    is the treatment of choice, unless the episode of DKA is uncomplicated and mild. In the past, a bolus dose of insulin was given before the low dose insulin infusion to more rapidly activate insulin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/9,24-27\">",
"     9,24-27",
"    </a>",
"    ]. However, a randomized trial showed that a bolus dose was not necessary if intravenous insulin was infused at a rate of 0.14",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour, which is equivalent to 10",
"    <span class=\"nowrap\">",
"     U/hour",
"    </span>",
"    in a 70 kg patient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/28\">",
"     28",
"    </a>",
"    ]. Based upon this trial, DKA can be treated either with an IV bolus (0.1",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    body weight), followed by a continuous infusion of regular insulin at a dose of 0.1",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour or with an intravenous infusion alone at a rate of at least 0.14",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    The insulin dosing is the same in DKA and HHS (",
"    <a class=\"graphic graphic_algorithm graphicRef61747 \" href=\"UTD.htm?15/26/15782\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67368 \" href=\"UTD.htm?1/42/1700\">",
"     algorithm 2",
"    </a>",
"    ). The possible role of other insulin preparations is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intravenous insulin analogs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Alternatives to intravenous insulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    usually decreases the serum glucose concentration by 50 to 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8 to 3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    per hour or more [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/23,25-27\">",
"     23,25-27",
"    </a>",
"    ]. Higher doses do not generally produce a more prominent hypoglycemic effect, possibly because the insulin receptors are already saturated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/24\">",
"     24",
"    </a>",
"    ]. If the serum glucose does not fall by 50 to 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8 to 3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    from the initial value in the first hour, the insulin infusion rate should be doubled every hour until a steady decline in serum glucose is achieved. If the serum glucose levels fail to fall, the intravenous access should be checked to make certain that the insulin is being delivered and that no filters are interposed that may bind insulin.",
"   </p>",
"   <p>",
"    The actual fall in serum glucose is greater than that produced by insulin alone. Fluid repletion can initially reduce the serum glucose by 35 to 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9 to 3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    per hour due to both hemodilution and increased urinary losses as renal perfusion is enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. The rate of fall in serum glucose may be more pronounced in patients with HHS who are typically more volume depleted.",
"   </p>",
"   <p>",
"    When the serum glucose reaches 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in DKA or 250 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9 to 16.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in HHS, the intravenous saline solution is switched to dextrose in saline, and it may be possible to decrease the insulin infusion rate to 0.02 to 0.05",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/10,18,24\">",
"     10,18,24",
"    </a>",
"    ]. Reducing the serum glucose at this time below 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in DKA or 250 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9 to 16.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in HHS may promote the development of cerebral edema. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Cerebral edema'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"     \"Cerebral edema in children with diabetic ketoacidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intravenous insulin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of other intravenous insulin preparations was evaluated in a trial of 74 patients with DKA who were randomly assigned to intravenous regular or glulisine insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/29\">",
"     29",
"    </a>",
"    ]. The initial dosing was the same (0.1",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    IV bolus, followed by an infusion at 0.1",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    per hour). Patients were otherwise treated similarly, according to ADA guidelines. After resolution of DKA, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    received subcutaneous NPH and regular insulin twice daily, whereas patients treated with IV glulisine insulin received glargine once daily and glulisine before meals.",
"   </p>",
"   <p>",
"    There were no differences between the two groups in the mean duration of treatment, amount of insulin administered, or total duration of insulin infusion until resolution of DKA. After transition to subcutaneous insulin, glycemic control was also similar. However, patients treated with NPH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    had a higher incidence of hypoglycemia. Thus, intravenous regular and glulisine insulins were equally effective in treating DKA. Choice of intravenous insulin should be based upon institutional preferences, clinician experience, and cost concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Human versus analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     DKA or HHS resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperglycemic crisis is considered to be resolved when the following goals are reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ketoacidosis has resolved, as evidenced by normalization of the serum anion gap (less than 12",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      As mentioned above, ketonemia and ketonuria may persist for more than 36 hours due to the slower removal of acetone, in part via the lungs [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Since acetone is biochemically neutral, such patients do not have persistent ketoacidosis.",
"     </li>",
"     <li>",
"      Patients with HHS are mentally alert and the plasma effective osmolality is below 315",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"     </li>",
"     <li>",
"      The patient is able to eat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ADA guidelines and one author (AK) suggest that the intravenous insulin infusion can be tapered, and a multiple-dose subcutaneous (SC) insulin schedule started, in patients who meet the following goals (the last three apply only to DKA):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum glucose below 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in DKA or 250 to 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in HHS",
"     </li>",
"     <li>",
"      Serum anion gap &lt;12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (or less than the upper limit of normal for the local laboratory)",
"     </li>",
"     <li>",
"      Serum bicarbonate &ge;18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Venous pH &gt;7.30",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second author (BR) notes that, in the absence of end-stage renal disease, all patients develop a normal anion gap acidosis (\"non-gap acidosis\") with resolution of the ketoacidosis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Anion gap'",
"    </a>",
"    below.) In this setting, insulin therapy will have no further effect on the acidosis. Thus, the intravenous insulin may be tapered and a multiple-dose subcutaneous insulin schedule started when the ketoacidosis is corrected (as evidenced by a normal anion gap or the absence of beta-hydroxybutyric acid with direct testing) and the serum glucose meets the above target.",
"   </p>",
"   <p>",
"    Regardless of when rapid or short-acting subcutaneous insulin is started, intravenous insulin infusion should be continued for an overlap of one to two hours. Abrupt discontinuation of intravenous insulin can lead to an acute fall in insulin levels, possibly resulting in recurrence of hyperglycemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ketoacidosis. If the patient is unable to take oral nutrition, it is preferable to continue the intravenous insulin infusion.",
"   </p>",
"   <p>",
"    Patients with known diabetes who were previously treated with insulin may be given insulin at the dose they were receiving before the onset of DKA or HHS. In insulin-naive patients, a multi-dose insulin regimen should be started at a dose of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per day, including bolus and basal insulin until an optimal dose is established. However, good clinical judgment and frequent glucose assessment is vital in initiating a new insulin regimen in insulin-naive patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Alternatives to intravenous insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both intramuscular and subcutaneous insulin therapy, although less often used, appear to be as effective as intravenous therapy if the patient is not in shock [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The efficacy and cost effectiveness of subcutaneous rapid-acting insulin analogs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    and aspart) in the management of uncomplicated DKA have been demonstrated in two randomized trials in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one trial, for example, 40 patients were assigned to one of two regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous rapid-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      given on the regular medicine wards or an intermediate care unit as an initial injection of 0.3",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      followed by 0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      every hour until the serum glucose was less than 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      the insulin dose was then decreased by half (to 0.05 or 0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      respectively) and administered every one or two hours until resolution of the ketoacidosis.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      given in the intensive care unit as an initial bolus of 0.1",
"      <span class=\"nowrap\">",
"       U/kg,",
"      </span>",
"      followed by an infusion of 0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per hour until the serum glucose was less than 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      the insulin dose was then decreased to 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per hour until resolution of the ketoacidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy until correction of hyperglycemia and resolution of ketoacidosis was the same with both regimens (7 and 10 to 11 hours, respectively) but there was a 39 percent reduction in cost with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , most likely related to less need for intensive care unit admission.",
"   </p>",
"   <p>",
"    We suggest subcutaneous administration of a rapid-acting insulin analog only in patients with mild DKA and administered on the general medical ward only when staffing is available for hourly monitoring of capillary blood glucose with a reliable standardized glucometer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Potassium depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both renal and gastrointestinal losses contribute to an often marked degree of potassium depletion. The increase in renal potassium excretion is primarily related to the glucose osmotic diuresis and to hypovolemia-induced hyperaldosteronism.",
"   </p>",
"   <p>",
"    Despite the total body potassium deficit, the serum potassium concentration is usually normal or, in about one-third of cases, elevated at presentation due primarily to insulin deficiency and hyperosmolality, both of which result in potassium movement out of the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, acidemia alone probably does not play a major role in the elevated serum potassium associated with DKA. The greater importance of insulin deficiency and hyperosmolality is illustrated by the observation that hyperkalemia also occurs in HHS despite the absence of ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link&amp;anchor=H3#H3\">",
"     \"Potassium balance in acid-base disorders\", section on 'Metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This change in potassium distribution is rapidly reversed with the administration of insulin, resulting in an often dramatic fall in the serum potassium concentration. As a result, careful monitoring of the serum potassium is an essential part of the management of both DKA and HHS.",
"   </p>",
"   <p>",
"    To prevent hypokalemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    is generally added to the replacement fluid once the serum potassium concentration falls below 5.3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    assuming an adequate urine output (&gt;50",
"    <span class=\"nowrap\">",
"     mL/hour).",
"    </span>",
"    If the patient is hemodynamically stable, one-half isotonic saline is preferred since the addition of potassium to isotonic saline will result in a hypertonic solution that will delay correction of the hyperosmolality. The serum potassium should be maintained between 4.0 and 5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Effect of potassium supplementation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Potassium repletion is more urgent in patients with massive potassium deficits who are hypokalemic prior to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Such patients require aggressive potassium replacement (20 to 30",
"    <span class=\"nowrap\">",
"     meq/hour),",
"    </span>",
"    which usually requires 40 to 60",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    added to one-half isotonic saline. Since insulin will worsen the hypokalemia, insulin therapy should be delayed until the serum potassium is above 3.3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to avoid possible arrhythmias, cardiac arrest, and respiratory muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia in uncontrolled diabetes mellitus has a variable effect on the serum sodium concentration, as factors are present that can both lower and raise the measured value [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By raising the serum osmolality, hyperglycemia results in osmotic water movement out of the cells, thereby lowering the serum sodium concentration by dilution.",
"     </li>",
"     <li>",
"      The direct effect of hyperglycemia is counteracted by the glucosuria-induced osmotic diuresis. The diuresis results in water loss in excess of sodium and potassium, which will tend to raise the serum sodium concentration and plasma osmolality unless there is a comparable increase in water intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum sodium concentration at presentation varies with the balance of these mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reversing the hyperglycemia with insulin will lower the plasma osmolality, which will cause water to move from the extracellular fluid into the cells, thereby raising the serum sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1,5,10,36,37\">",
"     1,5,10,36,37",
"    </a>",
"    ]. Thus, a patient with a normal initial serum sodium concentration will usually become hypernatremic during therapy with insulin and isotonic saline. The degree to which this is likely to occur can be estimated at presentation by calculation of the \"corrected\" serum sodium concentration, that is, the serum sodium concentration that should be present if the serum glucose concentration were lowered to normal with insulin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Corrected serum Na &nbsp;= &nbsp;Measured serum Na &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [&Delta;SG",
"    </span>",
"    &nbsp;&divide; &nbsp;42]",
"   </p>",
"   <p>",
"    Where",
"    <span class=\"nowrap\">",
"     &Delta;SG",
"    </span>",
"    is the increment above normal in the serum glucose concentration (in",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    The",
"    <span class=\"nowrap\">",
"     &Delta;SG",
"    </span>",
"    should be divided by 2.3 if measured in",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bicarbonate and metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for bicarbonate therapy in DKA are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/38\">",
"     38",
"    </a>",
"    ] and evidence of benefit is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In a randomized trial of 21 DKA patients with an admission arterial pH between 6.90 and 7.14 (mean 7.01), bicarbonate therapy did not change morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the study was small, limited to patients with an arterial pH 6.90 and above, and there was no difference in the rate of rise in the arterial pH and serum bicarbonate between the bicarbonate and placebo groups. No prospective randomized trials have been performed concerning the use of bicarbonate in DKA with pH values less than 6.90.",
"   </p>",
"   <p>",
"    The specific indications for bicarbonate administration are important because there are three potential concerns with such therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overzealous use of alkali can lead to a rise in pCO2 (since there is less of an acidemic stimulus to hyperventilation), resulting in a paradoxical fall in cerebral pH as the lipid-soluble CO2 rapidly crosses the blood-brain barrier. Neurologic deterioration has been reported in this setting, but is probably a rare event [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of alkali may slow the rate of recovery of the ketosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. In a study of seven patients, the three patients who were treated with bicarbonate had a rise in serum ketoacid levels during bicarbonate infusion, resulting in a six-hour delay in improvement of ketosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/43\">",
"       43",
"      </a>",
"      ]. Animal studies suggest that bicarbonate therapy increases hepatic ketogenesis. However, in the randomized trial cited above, bicarbonate therapy had no effect on the rate of decline in serum ketone levels [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alkali administration can lead to a posttreatment metabolic alkalosis, since metabolism of ketoacid anions with insulin results in the generation of bicarbonate and spontaneous correction of most of the metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anion gap'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, selected patients who may benefit from cautious alkali therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/42\">",
"     42",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an arterial pH less than 7.00 in whom decreased cardiac contractility and vasodilatation can further impair tissue perfusion. At an arterial pH above 7.00, most experts agree that bicarbonate therapy is not necessary, since insulin therapy alone will result in resolution of most of the metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with potentially life-threatening hyperkalemia, since bicarbonate administration in acidemic patients drives potassium into cells, thereby lowering the serum potassium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend administering bicarbonate if the arterial pH is less than 6.90. We give 100 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    in 400 mL sterile water with 20 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , if the serum potassium is less than 5.3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    administered over two hours.",
"   </p>",
"   <p>",
"    The venous pH should be monitored every two hours, and bicarbonate dosed as above, until the pH rises above 7.00.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variable relationship between the elevation in serum anion gap and the fall in serum bicarbonate concentration because of the excretion of ketoacid anions in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ketoacid anions have been called \"potential bicarbonate,\" since their metabolism following the administration of insulin results in the generation of bicarbonate and reversal of the acidosis. The effect of ketoacid anion excretion on the course of ketoacidosis varies with the accompanying cation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The excretion of ketoacid anions with hydrogen or ammonium is associated with an equivalent loss of protons, correcting both the anion gap and the acidemia. It has been estimated that approximately 30 percent of the ketoacids produced in DKA are excreted in the urine in patients with relatively normal renal function; the conversion of acetoacetic acid to acetone can neutralize another 15 to 25 percent of the acid load [",
"      <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The excretion of ketoacid anions with sodium or potassium represents the loss of bicarbonate precursors (ie, \"potential bicarbonate\") and is therefore equivalent to bicarbonate loss. The net effect is that the anion gap is reduced but the acidosis persists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of the urinary loss of \"potential bicarbonate,\" almost all patients with DKA (except those with advanced renal failure) develop a normal anion gap acidosis (also known as a \"non-gap acidosis\") during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/47,50,51\">",
"     47,50,51",
"    </a>",
"    ]. Suppose, for example, that a patient has a serum bicarbonate of 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and an anion gap of 24",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (approximately 16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above normal). Insulin therapy promotes correction of the ketoacidosis by inhibiting lipolysis, which decreases the supply of free fatty acids to the liver for ketogenesis, by inhibiting ketogenesis in the liver, and by promoting peripheral ketone metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=see_link&amp;anchor=H8#H8\">",
"     \"Insulin action\", section on 'Insulin and ketone body metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect is that the 16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of ketoacid anion will be metabolized, which will regenerate some of the HCO3 lost in the initial buffering reaction. However, the plasma HCO3 may only rise by about 8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (to 16",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    with the rest of the HCO3 replenishing the cell and bone buffer stores. At this point, the patient will have metabolic acidosis with a normal AG, due to the combination of the previous production of the intact ketoacid and the subsequent loss of the ketoacid anion in the urine. If no ketoacid anions had been excreted in the urine (as in a dialysis patient), then insulin therapy would have returned both the anion gap and serum bicarbonate concentration to baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link&amp;anchor=H6#H6\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Ketoacidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Phosphate depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole body phosphate depletion is common in uncontrolled diabetes mellitus, although the serum phosphate concentration may initially be normal or elevated due to movement of phosphate out of the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/8,52\">",
"     8,52",
"    </a>",
"    ]. As with potassium balance, phosphate depletion is rapidly unmasked following the institution of insulin therapy, frequently leading to hypophosphatemia that is usually asymptomatic.",
"   </p>",
"   <p>",
"    The fall in serum phosphate concentration during the treatment of DKA is acute, self-limited, and usually not associated with marked phosphate depletion or adverse effects. Clinically evident hemolysis as well as rhabdomyolysis with myoglobinuria are rare complications of the hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"     \"Signs and symptoms of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective randomized trials of patients with DKA have failed to show a beneficial effect of phosphate replacement on the duration of ketoacidosis, dose of insulin required, rate of fall of serum glucose, or morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In addition, phosphate replacement may have adverse effects such as hypocalcemia and hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/56,59-61\">",
"     56,59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, we do NOT recommend the routine use of phosphate in the treatment of DKA or HHS. However, to avoid cardiac and skeletal muscle weakness and respiratory depression due to hypophosphatemia, careful phosphate replacement may be indicated in patients who develop cardiac dysfunction, hemolytic anemia, or respiratory depression, and in those with a serum phosphate concentration below 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/62\">",
"     62",
"    </a>",
"    ]. When needed, 20 to 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    can be added to replacement fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of the treatment of DKA and HHS, hypoglycemia and hypokalemia, have been reduced significantly since the administration of low dose insulin and careful monitoring of serum potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/63\">",
"     63",
"    </a>",
"    ]. Hyperglycemia may result from interruption or discontinuation of intravenous insulin without prior coverage with subcutaneous insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema in uncontrolled diabetes mellitus (usually DKA, with occasional reports in HHS) is primarily a disease of children and almost all affected patients are below the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/64\">",
"     64",
"    </a>",
"    ]. Symptoms typically emerge with 12 to 24 hours of the initiation of treatment for DKA, but may be present prior to the onset of therapy. Issues related to cerebral edema in DKA, including pathogenesis, are discussed in detail separately in the pediatric section but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"     \"Cerebral edema in children with diabetic ketoacidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Headache is the earliest clinical manifestation, followed by lethargy, and decreased arousal. Neurologic deterioration may be rapid, with seizures, incontinence, pupillary changes, bradycardia, and respiratory arrest. These symptoms progress if brainstem herniation occurs, and the rate of progression may be so rapid that papilledema is not seen.",
"   </p>",
"   <p>",
"    Cerebral edema is associated with a mortality rate of 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, an essential part of therapy in DKA is careful monitoring for changes in mental or neurologic status that would permit early identification and therapy of cerebral edema.",
"   </p>",
"   <p>",
"    The 2009 ADA guidelines on hyperglycemic crises in diabetes in adults suggested that the following preventive measures may reduce the risk of cerebral edema in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gradual replacement of sodium and water deficits in patients who are hyperosmolar. The usual regimen for the first few hours is isotonic saline at a rate of 10 to 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      lean body weight per hour (about 1000",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      in an average-sized person) with a maximum of &lt;50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in the first four hours (",
"      <a class=\"graphic graphic_algorithm graphicRef61747 \" href=\"UTD.htm?15/26/15782\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67368 \" href=\"UTD.htm?1/42/1700\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The addition of dextrose to the saline solution once the serum glucose levels reach 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in DKA or 250 to 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in HHS. In HHS, the serum glucose should be maintained at 250 to 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      until the hyperosmolality and mental status improve and the patient is clinically stable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data evaluating the outcome and treatment of cerebral edema in adults are not available. Recommendations for treatment are based upon clinical judgment in the absence of scientific evidence. Case reports and small series in children suggest benefit from prompt administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    (0.25 to 1.0",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    and perhaps from hypertonic (3 percent) saline (5 to 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 30 min) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/64\">",
"     64",
"    </a>",
"    ]. These approaches raise the plasma osmolality, resulting in osmotic movement of water out of the brain and a reduction in cerebral edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Noncardiogenic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia and rarely noncardiogenic pulmonary edema can complicate the treatment of DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Hypoxemia is attributed to a reduction in colloid osmotic pressure that results in increased lung water content and decreased lung compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/48/15114/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with DKA who have a widened alveolar-arterial oxygen gradient noted on initial blood gas measurement or rales on physical examination appear to be at higher risk for the development of pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=see_link\">",
"       \"Patient information: Diabetic ketoacidosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=see_link\">",
"       \"Patient information: Hyperosmolar nonketotic coma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy for both diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) includes fluid replacement to correct both hypovolemia and hyperosmolality, insulin administration to correct hyperglycemia and, in DKA, metabolic acidosis, potassium repletion, and, in selected patients with DKA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      . Frequent monitoring is essential and underlying precipitating events should be identified and corrected. A table outlining the emergency management of DKA in adults is provided (",
"      <a class=\"graphic graphic_table graphicRef57723 \" href=\"UTD.htm?23/42/24237\">",
"       table 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Treatment algorithms for the management of DKA and HHS were included in the 2009 American Diabetes Association guidelines on hyperglycemic crises in adults (",
"      <a class=\"graphic graphic_algorithm graphicRef61747 \" href=\"UTD.htm?15/26/15782\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67368 \" href=\"UTD.htm?1/42/1700\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment overview and protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring involves hourly glucose measurement until stable, and basic chemistry profile, plasma osmolality, and venous pH every two to four hours. The course of ketoacidemia can be assessed by direct measurement of beta-hydroxybutyrate, the major circulating ketoacid,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      measurement of the serum anion gap. In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      tablets or reagent sticks should not be used because they react with acetoacetate and acetone, but not with beta-hydroxybutyrate. Acetone is biochemically neutral and does not contribute to the ketoacidosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend vigorous intravenous fluid replacement to correct both hypovolemia and hyperosmolality (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Fluid replacement should correct estimated deficits within the first 24 hours, with care to avoid an overly rapid reduction in the serum osmolality.",
"      <br/>",
"      <br/>",
"      We begin with isotonic (0.9 percent) saline infused at a rate of 15 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, in the absence of cardiac compromise, for the first few hours. This is followed by one-half isotonic (0.45 percent) saline at 4 to 14",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour if the serum sodium is normal or elevated; isotonic saline is continued if hyponatremia is present. We add dextrose to the saline solution when the serum glucose reaches 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in DKA or 250 to 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in HHS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fluid replacement'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The need for potassium repletion may influence the timing of one-half isotonic saline therapy, since the addition of potassium to isotonic saline creates a hypertonic solution that can worsen the underlying hyperosmolality. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Effect of potassium supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initial treatment with low-dose intravenous insulin in all patients with moderate to severe DKA who have a serum potassium &ge;3.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with an initial serum potassium below 3.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      should receive aggressive fluid and potassium replacement PRIOR to treatment with insulin. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Potassium depletion'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The insulin regimen is the same in DKA and HHS. If the serum potassium is &ge;3.3",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      we give a continuous intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      at 0.14",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per hour; at this dose, an initial intravenous bolus is not necessary. An alternative option is to administer an IV bolus (0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      body weight) of regular insulin, followed by a continuous infusion at a dose of 0.1",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per hour. The dose is doubled if the glucose does not fall by 50 to 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8 to 3.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the first hour. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insulin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A cost-effective alternative to intravenous insulin in the initial treatment of uncomplicated DKA is the use of subcutaneous rapid-acting insulin analogs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      and aspart) in selected patients in settings in which adequate monitoring can be assured. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Alternatives to intravenous insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We initiate a multiple-dose subcutaneous insulin schedule when the ketoacidosis has resolved and the patient is able to eat. The intravenous insulin infusion should be continued for one to two hours after initiating the subcutaneous insulin, to avoid recurrence of hyperglycemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'DKA or HHS resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DKA or HHS typically have a marked degree of potassium depletion due to both renal and, in some patients, gastrointestinal losses. However, because of potassium redistribution from the cells into the extracellular fluid, the initial serum potassium concentration is often normal or elevated, an effect that will be reversed by insulin therapy.",
"      <br/>",
"      <br/>",
"      We recommend that replacement with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) be initiated when the serum potassium concentration is &le;5.3",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Patients with an initial serum potassium below 3.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      should receive aggressive fluid and potassium replacement PRIOR to treatment with insulin to prevent initial worsening of the hypokalemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Potassium depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      therapy to help correct the metabolic acidosis are controversial. We suggest treatment with intravenous sodium bicarbonate in patients with an arterial pH less than 6.9 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bicarbonate and metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although whole body phosphate depletion is usually present, we recommend NOT administering phosphate routinely (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest phosphate replacement for patients with severe hypophosphatemia (&lt;1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.32",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      respiratory or cardiac failure, or severe anemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Phosphate depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral edema is rare in adults, but is associated with high rates of morbidity and mortality. Possible preventive measures in high-risk patients include gradual rather than rapid correction of fluid and sodium deficits (maximum reduction in plasma osmolality of 3",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      per hour), and maintenance of a slightly elevated serum glucose until the patient is stable. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Cerebral edema'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/1\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/2\">",
"      Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/3\">",
"      Kitabchi AE, Umpierrez GE, Fisher JN, et al. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008; 93:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/4\">",
"      Morris LR, Kitabchi AE. Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoacidosis. Diabetes Care 1980; 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/5\">",
"      Daugirdas JT, Kronfol NO, Tzamaloukas AH, Ing TS. Hyperosmolar coma: cellular dehydration and the serum sodium concentration. Ann Intern Med 1989; 110:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/6\">",
"      Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet 1973; 2:635.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM Press, New York 1981. p.95.",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.809-815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/9\">",
"      Barrett EJ, DeFronzo RA. Diabetic ketoacidosis: diagnosis and treatment. Hosp Pract (Off Ed) 1984; 19:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/10\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/11\">",
"      Middleton P, Kelly AM, Brown J, Robertson M. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J 2006; 23:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/12\">",
"      Wiggam MI, O'Kane MJ, Harper R, et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 1997; 20:1347.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Joslin's Diabetes Mellitus, 13th, Kahn CR, Weir GC (Eds), Lea &amp; Febiger, Philadelphia 1994. p.738.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/14\">",
"      Sulway MJ, Malins JM. Acetone in diabetic ketoacidosis. Lancet 1970; 2:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/15\">",
"      Reichard GA Jr, Skutches CL, Hoeldtke RD, Owen OE. Acetone metabolism in humans during diabetic ketoacidosis. Diabetes 1986; 35:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/16\">",
"      Hillman K. Fluid resuscitation in diabetic emergencies--a reappraisal. Intensive Care Med 1987; 13:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/17\">",
"      Bratusch-Marrain, PR, Komajati, M, Waldhausal, W. The effect of hyperosmolarity on glucose metabolism. Pract Cardiol 1985; 11:153.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Umpierrez GE, Murphy MB. Diabetic ketoacidosis and hyperglycemic hypersmolar state. In: International Textbook of Diabetes Mellitus, 3rd, DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley &amp; Sons, Chichester, UK 2004. p.1101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/19\">",
"      Waldh&auml;usl W, Kleinberger G, Korn A, et al. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. Diabetes 1979; 28:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/20\">",
"      Ennis, ED, Stahl, EJ, Kreisberg, RA. The hyperosmolar hyperglycemic syndrome. Diabetes Rev 1994; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/21\">",
"      Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990; 6:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/22\">",
"      Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/23\">",
"      Luzi L, Barrett EJ, Groop LC, et al. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 1988; 37:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/24\">",
"      Brown PM, Tompkins CV, Juul S, S&ouml;nksen PH. Mechanism of action of insulin in diabetic patients: a dose-related effect on glucose production and utilisation. Br Med J 1978; 1:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/25\">",
"      Rosenthal NR, Barrett EJ. An assessment of insulin action in hyperosmolar hyperglycemic nonketotic diabetic patients. J Clin Endocrinol Metab 1985; 60:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/26\">",
"      Page MM, Alberti KG, Greenwood R, et al. Treatment of diabetic coma with continuous low-dose infusion of insulin. Br Med J 1974; 2:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/27\">",
"      Padilla AJ, Loeb JN. \"Low-dose\" versus \"high-dose\" insulin regimens in the management of uncontrolled diabetes. A survey. Am J Med 1977; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/28\">",
"      Kitabchi AE, Murphy MB, Spencer J, et al. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care 2008; 31:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/29\">",
"      Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 2009; 32:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/30\">",
"      Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med 1977; 297:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/31\">",
"      Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med 2004; 117:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/32\">",
"      Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004; 27:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/33\">",
"      Adrogu&eacute; HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/34\">",
"      Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/35\">",
"      Beigelman PM. Potassium in severe diabetic ketoacidosis. Am J Med 1973; 54:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/36\">",
"      Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/37\">",
"      Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/38\">",
"      Viallon A, Zeni F, Lafond P, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care Med 1999; 27:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/39\">",
"      Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/40\">",
"      Lever E, Jaspan JB. Sodium bicarbonate therapy in severe diabetic ketoacidosis. Am J Med 1983; 75:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/41\">",
"      Latif KA, Freire AX, Kitabchi AE, et al. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 2002; 25:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/42\">",
"      Narins RG, Cohen JJ. Bicarbonate therapy for organic acidosis: the case for its continued use. Ann Intern Med 1987; 106:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/43\">",
"      Okuda Y, Adrogue HJ, Field JB, et al. Counterproductive effects of sodium bicarbonate in diabetic ketoacidosis. J Clin Endocrinol Metab 1996; 81:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/44\">",
"      Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J (Clin Res Ed) 1984; 289:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/45\">",
"      DeFronzo, RA, Matzuda, M, Barret, E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/46\">",
"      Fraley DS, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int 1977; 12:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/47\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/48\">",
"      Adrogu&eacute; HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/49\">",
"      Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/50\">",
"      Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978; 89:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/51\">",
"      Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. Nephron 1990; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/52\">",
"      Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/53\">",
"      RAINEY RL, ESTES PW, NEELY CL, AMICK LD. Myoglobinuria following diabetic acidosis with electromyographic evaluation. Arch Intern Med 1963; 111:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/54\">",
"      Casteels K, Beckers D, Wouters C, Van Geet C. Rhabdomyolysis in diabetic ketoacidosis. Pediatr Diabetes 2003; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/55\">",
"      Shilo S, Werner D, Hershko C. Acute hemolytic anemia caused by severe hypophosphatemia in diabetic ketoacidosis. Acta Haematol 1985; 73:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/56\">",
"      Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983; 57:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/57\">",
"      Keller U, Berger W. Prevention of hypophosphatemia by phosphate infusion during treatment of diabetic ketoacidosis and hyperosmolar coma. Diabetes 1980; 29:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/58\">",
"      Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med 1982; 142:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/59\">",
"      Barsotti MM. Potassium phosphate and potassium chloride in the treatment of DKA. Diabetes Care 1980; 3:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/60\">",
"      Winter RJ, Harris CJ, Phillips LS, Green OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med 1979; 67:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/61\">",
"      Zipf WB, Bacon GE, Spencer ML, et al. Hypocalcemia, hypomagnesemia, and transient hypoparathyroidism during therapy with potassium phosphate in diabetic ketoacidosis. Diabetes Care 1979; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/62\">",
"      Kreisberg RA. Phosphorus deficiency and hypophosphatemia. Hosp Pract 1977; 12:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/63\">",
"      Kitabchi AE, Ayyagari V, Guerra SM. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med 1976; 84:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/64\">",
"      Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/65\">",
"      Sprung CL, Rackow EC, Fein IA. Pulmonary edema; a complication of diabetic ketoacidosis. Chest 1980; 77:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/66\">",
"      Powner D, Snyder JV, Grenvik A. Altered pulmonary capillary permeability complicating recovery from diabetic ketoacidosis. Chest 1975; 68:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/48/15114/abstract/67\">",
"      Brun-Buisson CJ, Bonnet F, Bergeret S, et al. Recurrent high-permeability pulmonary edema associated with diabetic ketoacidosis. Crit Care Med 1985; 13:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1795 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15114=[""].join("\n");
var outline_f14_48_15114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment overview and protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acidosis in DKA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fluid replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Effect of potassium supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Intravenous regular insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intravenous insulin analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - DKA or HHS resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Alternatives to intravenous insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Potassium depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bicarbonate and metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anion gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Phosphate depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1795|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?15/26/15782\" title=\"algorithm 1\">",
"      ADA management patients DKA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/42/1700\" title=\"algorithm 2\">",
"      ADA management patients HHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1795|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/11/24767\" title=\"figure 1\">",
"      Ketone response to treatment DKA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1795|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?27/55/28529\" title=\"form 1\">",
"      Patient data flow sheet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1795|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/19/24892\" title=\"table 1\">",
"      ADA criteria DKA HHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/3/35899\" title=\"table 2\">",
"      ADA DKA HHS water deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/42/24237\" title=\"table 3\">",
"      DKA rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=related_link\">",
"      Cerebral edema in children with diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=related_link\">",
"      Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=related_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=related_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_48_15115="Anomalies associated with oligohydramnios";
var content_f14_48_15115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Type and frequency of congenital anomalies associated with oligohydramnios in a literature review",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        94 (65)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        17 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aneuploidy",
"       </td>",
"       <td>",
"        12 (8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        7 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal system",
"       </td>",
"       <td>",
"        5 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular system",
"       </td>",
"       <td>",
"        4 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        6 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        145",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hill, LM. Clin Obstet Gynecol 1997; 40:314.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15115=[""].join("\n");
var outline_f14_48_15115=null;
var title_f14_48_15116="Cutaneous nonspec lesions";
var content_f14_48_15116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cutaneous non-specific lesions that suggest systemic lupus erythematosus:",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Nonscarring alopecia (\"lupus hair, telogen effluvium, alopecia areata)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Sclerodactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Rheumatoid nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Sj&ouml;gren's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Calcinosis cutis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        6. Bullous diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Autoimmune blister diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Erythema multiforme (Rowell syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Porphyria cutanea tarda",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Papular and nodular mucinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Cutis laxa/anetoderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        10. Cutaneous vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        i. Leukocytoclastic (palpable purpura, urticarial vasculitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        ii. Periarteritis nodosa like",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        iii. Thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Vasculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        i. Degos-like lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        ii. Livedoid vasculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        iii. Atrophy blanche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        iv. Raynaud's phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        v. Periungual telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        vi. Palmar erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        vii. Erythromelalgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        viii. Acrocyanosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel L Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15116=[""].join("\n");
var outline_f14_48_15116=null;
var title_f14_48_15117="ACEI vs other drugs in DM rats";
var content_f14_48_15117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor is more effective than triple therapy in protecting against experimental diabetic nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 225px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Efficacy of antihypertensive therapy in diabetic rats in reducing the number of sclerotic glomeruli at 70 weeks. Triple therapy with hydrochlorothiazide, hydralazine, and reserpine was partially protective, but captopril was completely protective, with the degree of glomerulosclerosis being less than that in control (normal) rats (left column). Captopril also normalized the intraglomerular pressure (46 mmHg) versus 64 mmHg in untreated diabetic animals and 56 mmHg with triple therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Anderson S, Rennke HG, Garcia DL, et al. Kidney Int 1989; 36:526.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15117=[""].join("\n");
var outline_f14_48_15117=null;
var title_f14_48_15118="Recirculation and HD delivery";
var content_f14_48_15118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output and recirculation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of increasing dialyzer blood flow (Qb) on total body urea clearance (Ktb) during hemodialysis. The top curve (Kd) represents the ideal curve in which all of the dialysis prescription is delivered. The lower curves reflect the progressive decrease in Ktb induced by the sequential addition of a low cardiac output (Qco = 5 L/min); plus a high access blood flow (Qac = 50% Qco); plus 15 percent access recirculation.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15118=[""].join("\n");
var outline_f14_48_15118=null;
var title_f14_48_15119="Analyte MoMs in the second trimester";
var content_f14_48_15119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Analyte Multiples of the Median (MoMs): Second trimester",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each blue line refers to unaffected pregnancies and each red line refers to Down syndrome pregnancies.",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein; DIA: dimetric inhibin A; uE3: unconjugated estriol; HCG: human chorionic gonadotropin.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn E Palomaki, BS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_48_15119=[""].join("\n");
var outline_f14_48_15119=null;
